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Abstract  The work described in this thesis involves developing synthetic methods to produce a range of drug-like small molecules that can be used as chemical tools to understand and modulate disease pathophysiology. There are two types of such tools investigated in this thesis: diagnostic tools for imaging experiments, and inhibitory tools for modulating biochemical pathways.   The imaging tools are designed to target apoptosis, accumulating in cells undergoing early-stage apoptotic events, and contain a fluorescent tag, thus providing a real-time technique for observing and monitoring these events and even to modulate them from inside the cell. The imaging agent would then be used to guide the design of a radiolabelled small molecule that can be used alongside traditional cancer therapies, to preferentially enter cells going through apoptosis, ensuring that these cells commit to cell death and do not recover.   The inhibitory tools are designed to study the molecular mechanisms of MK2, a protein that has been implicated in disease progression and cellular ageing events.  
This worked used the premature ageing syndrome, Werner’s Syndrome as a model for normal human ageing.  In Chapter 2, several fluorescent markers are considered for the development of a real-time imaging tool to target apoptosis. The structures of the fluorescent agents are based on two structures known to preferentially enter cells going through the early stages of apoptosis; didansyl cystine and ML10. The conclusion of this investigation led to ML10 being used as the basis for further development of fluorescent agents. The formation of several novel BODIPY compounds is described, with one compound tested in a cell line for its ability to preferentially enter cells going through the early stages of apoptosis. The results of this test led to an investigation into the lipophilicity of BODIPY compounds versus ML10. This investigation involved the use of software to generate cLogP values as a guide for potential designs of further BODIPY structures. The development of a drug-like 
iv  structure that can mimic the action of the BODIPY compound is also explored, with the inclusion of a step to insert iodine-131 at a later stage in the development.  In Chapter 3, microwave-assisted organic synthesis was used to develop novel routes toward benzothiophene derivatives, which formed part of a new route towards the Pfizer developed MK2 inhibitor PF-3644022. This work was published in Organic and Biomolecular Chemistry. The full route was proposed in the doctoral thesis of Dr. Jessica Dwyer, and the latter part of this thesis set out to improve the yield of the final step. A collaboration with the Kostakis group led to an investigation into the use of the catalyst Zn2Y2(C21H25NO3)4 for its applicability to the Doebner-type multi-component reaction that would lead to the formation of PF-3644022. Although no conclusive results were obtained from the reactions trialled, the work opened up new channels of collaboration for the Bagley group and potential for further exploration of the use of isoskeletal coordination cluster catalysts in organic multi-component reactions.   Overall, the aim of this work was to deliver rapid routes to these chemical tools so that, through in vivo and in vitro biological studies, we can better understand the role of kinase targets during disease progression and therapy in healthy and diseased cells. In this context, this work establishes novel routes to new chemical tools, validates their identity and action, and explores their application in providing new insights into biochemical processes and new opportunities for chemical intervention in pathophysiological events.    
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Chapter 1 – Introduction  This chapter will discuss the background and premise for the projects described in this thesis. First there will be a discussion on the different forms of cell death and cellular ageing and the implication in human health. The scope for therapeutic intervention will also be explored. The second half of this chapter will include a discussion on the scope for development of kinase inhibitors, specifically p38 and MK2, in order to investigate their roles in human ageing and age-related diseases. The rare autosomal disorder, Werner’s Syndrome, will also be discussed as a model for normal ageing.  
1.1. Cell death Death is an inevitable part of life for all living organisms including cells. Without cell death, an average 80 year old human would be in possession of a 16 km intestine and carry around approximately two tons of bone marrow and lymph nodes.1 As such, “programmed cell death” is a normal part of a cell’s lifecycle, usually at the end of its replicative lifespan, but can be triggered by external factors (described later in 
Chapter 1). It is worth noting at this point that programmed cell death is not a term that can be used synonymously with apoptosis, which is a common misconception.   In 2009, the Nomenclature Committee on Cell Death (NCCD) published a set of guidelines to classify and define different types of cell death and the associated morphological changes.2 The NCCD described four distinct modes of cell death; apoptosis, autophagy, cornification and necrosis, with apoptosis and necrosis being the most widely used classifications of mammalian cell death.2 Each mode of cell death will now be described in sections 1.1.1-1.1.5. In section 1.1.5, cellular senescence will be discussed, though not as a form of cell death but in respect to cellular ageing. This is an important process to consider when discussing human 
ageing and Werner’s Syndrome (WS) in section 1.3.  As a genetically controlled process, programmed cell death has been linked to several diseases such as cancers, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome).3 
2  Therefore it can be postulated that by altering the course of programmed cell death, there is a potential to create new therapies for a range of diseases. These will be discussed in section 1.2.  
1.1.1. Apoptosis Apoptosis is a form of programmed cell death and is a natural part of a cell’s lifecycle. It is a very important process which controls the regulation and maintenance of cell populations in tissues, as part of homeostasis. It is also a defence mechanism that is employed by cells that are damaged or diseased in order to stop replication of mutations in new cells, therefore protecting the organism from further damage.4 According to a review by Ulukaya, Acilan and Yilmaz in 2011, abnormal rates of apoptosis have been linked to several disorders.5  Increased rates of apoptosis are linked to disorders such as AIDS, neurodegenerative disorders, insulin-dependent diabetes, hepatitis C infection, myocardial infarction and atherosclerosis and decreased rates of apoptosis are linked to autoimmune diseases and cancer.   The term "apoptosis" was proposed in 1972 by Kerr, Wyllie and Currie and was derived from a Greek word, meaning “dropping off”.6 Prior to their publication, cell death was assumed to take place but no study had considered the mechanisms behind it, and therefore no classification of the different types of cell death had been proposed. Using electron microscopy to visualize cells, the authors described two distinct stages taking place during the newly described apoptosis; the first was the formation of apoptotic bodies and the second was phagocytosis. Since then many studies have been carried out to try and understand the mechanisms underlying apoptosis and we now know that there is in fact several stages.   Apoptosis is characterised by distinct, observable morphological changes; an apoptotic cell appears to shrink, chromatin aggregates and condenses around the nuclear membrane and the cellular membrane remains intact whilst undergoing a process called blebbing (the membrane starts to pinch in and detach from the main cell as an apoptotic body). Apoptotic bodies containing condensed cell organelles are then cleared away by phagocytes; this process is controlled and highly regulated and as such does not trigger an inflammatory response (Figure 1).  
3   
 
Figure 1: Diagram depicting a cell undergoing apoptosis. Cell and organelles undergo shrinkage and blebbing, followed by the formation of apoptotic bodies.  For apoptosis to occur, cysteine proteases of the caspase family need to be activated sequentially. This can be done via one of three pathways; the death receptor mediated pathway (extrinsic pathway), the mitochondrial mediated pathway (intrinsic pathway) or the endoplasmic reticulum (ER) stress pathway. The death receptor and mitochondrial mediated pathways both rely on caspase-3 to initiate apoptosis (Figure 2). The death receptor pathway requires a member of the tumour necrosis factor (TNF) kinase family to bind to the death receptors on the surface of the cell. This recruits the protein Fas-associated death domain (FADD) which in turn recruits caspase-8, leading to the activation of caspase-3. The mitochondrial mediated pathway employs proapoptotic and antiapoptotic members of the BCL2 protein family and is initiated by oxygen radicals, γ radiation or DNA injury.7 These stimuli activate proapoptotic BH3 (BCL2 homology 3 domain) proteins which inhibit the antiapoptotic BCL2 proteins, thereby allowing proapoptotic BAX and BAK proteins to increase the permeability of the mitochondria, releasing cytochrome c which activates caspase-9 which in turn activates caspase-3.7–9  
4  
 
Figure 2: Pathways leading to the activation of caspase-3, known as an executioner caspase, triggering apoptosis. Left: Death receptor mediated pathway. Right: Mitochondrial mediated pathway. Adapted from Swanson et al. 2009.9  The ER stress pathway occurs when the main functions of the ER are disturbed; the main functions of the ER are folding, modification and the sorting of newly synthesized proteins, Ca2+ storage and signalling.10 Overloading or depleting the Ca2+ stocks leads to changes in protein folding and subsequently ER stress. If the stress is prolonged this leads to accumulation of procaspase-12 in the ER membrane, which is then activated and cleaved by m-calpain. This can also be brought on by mobilization of intracellular Ca2+ stores. Activated procaspase-12 goes on to activate caspases that lead to apoptosis.11   
1.1.1.1. Disorders associated with apoptosis As mentioned previously, apoptosis has been found to play a role in many disorders. Disorders such as AIDS, neurodegenerative disorders, insulin-dependent diabetes, hepatitis C infection, myocardial infarction and atherosclerosis have been linked to increased rates of apoptosis whilst decreased rates of apoptosis are linked to 
5  autoimmune diseases and cancer.5 As such many therapeutics have been developed with the aim to either induce or prevent apoptosis.   
Cancer If the process leading to the initiation of apoptosis is defective, then this can lead to potentially cancerous growths known as neoplasms, increased expression of prosurvival BCL2 family proteins and mutations of the tumour suppressor gene TP53. TP53 is also the encoder of the protein p53 which suppresses tumour growth by initiating apoptosis in response to DNA damage. Therefore, by mutating TP53, apoptosis is not induced when DNA damage occurs, leading to the formation of abnormal growths.7,9,12,13 The development of cancers and therapeutic interventions will be discussed in more detail in section 1.2.  
Immune system The proapoptotic BH3-only protein BIM is relied upon for the deletion of clones of B and T cells that express autoreactive antigen receptors.  Both BIM and the death receptor FAS mediate the killing of mature, antigen activated B and T cells during the shut-down of immune responses. Defects in the FAS ligand or receptor appear in patients suffering with autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disorder which causes lymphocytes to accumulate in the lymph nodes, liver and spleen causing them to enlarge.11  It is also thought that the FAS death receptor is involved in type 1 diabetes by CD8 T cells expressing the FAS ligand interacting with FAS receptors on insulin secreting cells, thereby inducing cell death and leading to the loss of beta cells from pancreatic islets.9  
Neurological disorders There is evidence to suggest that, whilst neurons are in the development stage, they are particularly susceptible to apoptosis being triggered by noxious stimuli which leads to the development of neonatal brain disorders.14 For example, foetal alcohol syndrome, a disorder brought on by the consumption of alcohol during pregnancy that can lead to both physical and mental impairments in the child, is caused by ethanol induced blockage of the N-methyl-D-aspartate (NMDA) receptor and 
activation of γ-aminobutyric acid (GABA) receptor leading to neurodegeneration via 
6  apoptosis.15 These same receptors are also modulated by general anaesthetics and animal models have shown that use of general anaesthetics during pregnancy could also cause defects in brain development.16  
Cardiovascular diseases Apoptosis can be triggered prematurely by lack of oxygen due to decreased blood flow, otherwise known as hypoxia, during events such as a myocardial infarction.9 This can lead to an increase in the size of an infarction. Therefore, it could be hypothesized that if apoptosis could be inhibited then this would prevent cell loss. For example, the use of  cyclosporine (1, Figure 3) as an apoptosis inhibitor has been trialled in patients suffering with an acute myocardial infarction before undergoing a percutaneous coronary intervention and the results showed a significant reduction in the size of the infarcted tissue when imaged by MRI (magnetic resonance imaging) in comparison to a control group of patients.17 1 works as an apoptosis inhibitor by blocking mitochondrial permeability-transition pores, which as discussed in section 1.1.1., leads to release of cytochrome c and induction of apoptosis.  
 
Figure 3: Cyclosporine.  
Sepsis Sepsis is a serious condition with a high mortality rate that is brought on by the immune system overreacting to a severe infection, causing inflammation 
7  throughout the body which ends in immunosuppression.18–20 The immunosuppression means that the body loses its ability to fight the primary infection as well becoming susceptible to new infections.9 Animal studies have shown that there is an increase in apoptosis of lymphoid organs and parenchymal tissues, leading to the conclusion that apoptosis plays a role in organ failure in severe cases.18,20 The increase of lymphocyte apoptosis has been shown to be a cause of sepsis lethality in experiments where apoptosis of lymphocytes was  inhibited which resulted in improved survival.21 There is also evidence to suggest that the septic response may be accelerated by a combination of overactivation of neutrophils and macrophages as well as poorly regulated cell death; delayed apoptosis of neutrophils and necrosis in tissues.20 Therefore targeting cell death for therapeutic intervention in the treatment of sepsis is an attractive prospect.  
1.1.1.2. Reversal of apoptosis  For a long time, apoptosis was considered as an irreversible process; once it had been induced the cell would die. However, there is now evidence to suggest that this is not the case. Though the “point of no return” is still debated, it is generally accepted that apoptosis is irreversible after caspase activation and once DNA damage had occurred.  In 1996, Look et al. demonstrated that the E2A-HLF fusion gene, the chimeric oncogene responsible for the transformation of B-cells into leukaemic cells, was able to extend cell survival as well as reverse IL-3 (interleukin-3) dependent and p53-mediated apoptosis.22 During the study cells were treated with ZnSO4 and the growth factor, IL-3, was removed. Cells that did not express E2A-HLF went through the process of apoptosis, whereas cells that did express E2A-HLF survived and went on to resume their normal cell cycle upon the return of IL-3.22 The study also provided evidence that cells that overexpressed E2A-HLF were protected from p53 mediated apoptosis when exposed to ionized radiation, thus leading the authors to conclude that E2A-HLF positive leukaemic cells were protected against both radiation and drug-induced apoptosis. Though this study did not provide evidence that the process of apoptosis could be reversed once initiated, it did provide significant evidence to prove that cancerous cells were able employ mechanisms to 
8  evade apoptosis-inducing agents, surviving in their presence and carrying on with normal cellular functions once the agent had been removed.  A report by Fung et. al. in 2009 showed that cancer cells that had an apoptosis-inducing agent applied to them were able to recover once the agent was removed and could even go on to continue to proliferate.23 The group first tested HeLa cells by exposing them to the apoptosis-inducer jasplakinolide (2, Figure 4) and observed the morphological changes using real-time living cell microscopy after 3 hours of exposure.   
 
Figure 4: Jasplakinolide.  Aside from visual confirmation of apoptosis, further confirmation was acquired using colorimetric caspase assays to monitor the activation of apoptotic protease caspases and cleavage of pro-caspase-3 and an MTT assay to confirm the dysfunction of mitochondria. Cell counting revealed that 96% of the cells displayed characteristic hallmarks of apoptosis. The cells were then washed and cultured in fresh medium. After 14.5 hours, it was observed using living cell microscopy that the cells regained their normal morphology, with a cell count confirming 92% of the cells had regained their normal morphology after 24 hours (Figure 5).  
 
9  
 
Figure 5: Images taken to show the application of apoptosis-inducing agents causing cells to go through the early stages of apoptosis (images ii – viii) followed by removal of the apoptosis-inducing agent by washing, leading to the cells regaining their normal morphology (images ix – xii). Image used with permission from Nature Publishing Group.23 
 
10  Survival was further proven by the cells going on to proliferate with no significant difference in percentage proliferation compared to the control cells. The study included testing HeLa cells with different apoptosis-inducing agents such as ethanol and staurosporine (3, Figure 6). Other cancer cell lines were also tested; human skin cancer A375, liver cancer HepG2, breast cancer MCF7 and prostate cancer PC3. The authors were able to demonstrate the ability of cancer cells to potentially escape the culling process during treatments such as chemotherapy. Therefore, recurrence of cancer in patients undergoing chemotherapy was proposed to be due to the proliferation of surviving cancer cells in the intervals between treatments, as well as the deficiency of apoptotic pathways in cancer cells, anticancer drug resistance of the tumorigenic stem cells and the inefficiency of drug penetration into solid tumours.   
 
Figure 6: Staurosporine.  
The study also suggested that the “point of no return” was in proportion with the amount of nuclear fragmentation that had taken place: the more nuclear fragmentation that had occurred, the less likely it was that the cell would survive.23    In 2012, the same group published another report, this time proposing the term 
“anastasis” (derived from a Greek word meaning “rise to life”) to refer to the phenomenon of cells recovering from apoptosis.24 This study presented evidence that cells can recover even once the “executioner caspase”, caspase-3, has been activated. This was found to be true in several different cell lines. Liver and heart cells, embryonic fibroblast NIH 3T3 cells and HeLa cells were all exposed to an 
11  apoptosis-inducing agent (ethanol, DMSO or jasplakinolide (2, Figure 4), morphological and biochemical hallmarks of apoptosis were observed (cell shrinkage, blebbing, etc.) and then the apoptosis-inducing agent was washed away, after which point a reversal of apoptosis and subsequent proliferation was observed. Gel electrophoresis assays carried out once the apoptotic-inducing agent had been applied, then again after the agent had been removed, detected that DNA damage had occurred during apoptosis, but that the damage had been repaired after removal of the agent. Despite this apparent repair, micronuclei (fragments of unrepaired DNA) were found to be present and even formed in daughter cells during the first cell division after reversal of apoptosis. Due to the genetic alteration of these cells, the authors suggested that the reversal of apoptosis could be carcinogenic. This mechanism for survival could be the reason why repeated injury leads to increased susceptibility for developing cancer; for example, alcoholics are at an increased risk of developing liver cancer. This mechanism for survival after a crisis leads to genomic rearrangements that could explain cancer cells’ ability to survive treatments such as chemo- and radiotherapy and then go on to become resistant. Mutations that occur in cells that were healthy before chemo- or radiotherapy may also explain the development of new tumours.   This apparent escape mechanism from apoptosis has been the driving force behind one of the research topics discussed in this thesis.  The hypothesis is that by developing chemical tools that can preferentially enter cells going through apoptosis, those tools could then be used to deliver a molecular cargo into the cells. This molecular cargo could then be used to ensure that the cell does indeed die, therefore substantially reducing the risk of cancers returning post-treatment and developing resistance to chemo- and radiotherapeutics.  
1.1.2. Autophagy This term is derived from the Greek words “auto” meaning self and “phagy” meaning to eat. This is a process by which a cell will “eat” organelles that are deemed non-essential in an effort to survive when exposed to certain stress conditions, either environmentally or developmentally.9,25  For instance, these stress conditions can include deprivation of nutrients, misfolding of proteins or damage to the 
12  mitochondria. Autophagy has been linked to many diseases and has led to the development of many drug candidates, many of which specifically target various forms of cancer.26,27   
1.1.3. Cornification Cornification is a type of programmed cell death that is responsible for the formation of skin, hair and nails.2,28 The process involves removal of organelles from the cell followed by the accumulation of keratin in the cytoplasm to provide strength. Cross-linking of transglutaminase proteins and the covalent attachment of lipids, excreted into the extracellular space, to the cornified envelope proteins leads to the formation of a waterproof barrier (Figure 7).28   
 
Figure 7: Process of cornification. Image used with permission from Elsevier.28  
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1.1.4. Necrosis Derived from the Greek word “nekros” meaning corpse, necrosis is characterized by the swelling of a cell and its organelles, eventually leading to the rupture of the cell membrane and the spilling of the cell contents outside of the cell (Figure 8). This traumatic type of cell death triggers an immune response in the form of inflammation. As such, the process is not considered as programmed cell death, but an accidental cell death that is in response to some kind of trauma. However, there is evidence to suggest that in certain instances necrosis can be triggered, therefore making it a controlled form of cell death known as “necroptosis”.29,30   
 
Figure 8: Diagram depicting a cell undergoing necrosis. The cell and organelles swell until the cell membrane ruptures, spilling the contents outside of the cell, which then triggers an inflammatory response.  
1.1.4.1. Necroptosis Necroptosis, otherwise known as regulated necrosis, is initiated by the binding of TNF to the receptor TNFR1 and subsequent activation of RIP1 and RIP3 kinases.2,28–30 Like necrosis, it is characterised by cellular and organelle swelling culminating in a ruptured cell membrane and leakage of the cell’s contents. The controlled nature of this form of necrosis was discovered when a small molecule known as necrostatin-1 (4, Figure 9) was shown to suppress necrosis by inhibiting RIPK1 thereby blocking the effect of TNF.29 This showed that, since necrosis could be regulated, there was scope to investigate its therapeutic potential. Necroptosis has been linked to inflammatory disorders such as Crohn’s disease and multiple sclerosis but it is not known whether necroptosis is a causative factor of these conditions or whether it is a consequence of them.29   
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Figure 9: Necrostatin-1.  
1.1.5. Senescence The term senescence is derived from the Latin word “senex” which means old age and as such the term senescence is often used interchangeably with the terms 
“cellular ageing” or “replicative senescence”. Cellular senescence was an idea first put forward by Hayflick in 1965 in a report that proved that cells did indeed have a limited replicative lifespan and can therefore be thought of as going through an ageing or senescence process; this was the opposite view to that held within the scientific community at the time.31 Characteristic hallmarks of senescence are growth arrest, resistance to apoptosis and altered gene expression, though these characteristics are not unique to senescent cells. Instead, the tumour suppressor gene p16 is used as a marker to indicate apoptosis, though this can also be somewhat unreliable as not all senescent cells express p16 and tumour cells that have pRB function also express p16.32 Other markers that can identify senescent cells include DEC1 (differentiated embryo-chondrocyte expressed-1), p15 (a CDKI), DCR2 (decoy death receptor-2), SAHFs (senescence associated heterochromatic foci) and SDFs (senescence associated DNA-damage foci).   There are a few factors that can cause cells to senesce. Telomere-dependent senescence occurs when telomeres become critically short, rendering proliferation impossible. This is due to a phenomenon known as the end-replication problem where, during DNA replication, DNA polymerase is unable to completely replicate DNA ends, proteins which cap the ends of telomeres as protection from degradation.33 Each time the cell replicates, the telomeres are slightly shortened until eventually they become critically short. If DNA becomes damaged this can induce DNA-damage-initiated senescence, leading to the expression of p16. Chromatin perturbance, specifically euchromatin formation promoted by chemical 
15  histone deacetylase inhibition (HDAi), appears to induce senescence, though the mechanism for this process is poorly understood. Oncogene-induced senescence has been observed when an oncogenic form of RAS was expressed in normal human fibroblasts.32 Senescence can be induced by chronic stimulation of interferon-β which increases the concentration of intracellular oxygen radicals leading to a p53-dependent DDR (DNA damage response) and senescence. Stress has also been suggested to induce senescence by inducing p16-dependent, telomere-independent senescence, often referred to as cell-culture stress or culture shock.32  Cellular senescence has been linked to both cancer and ageing. For cancer progression, senescence can act as a barrier, suppressing tumorigenesis due to the requirement of cell proliferation. The link between ageing and senescence is not clear cut, as though it appears that the number of senescent cells increases with age, it is not clear whether they actually play a contributory part in the ageing process.  Recently there has been progress made in this field that suggests that by inducing senescent cells to go through apoptosis they can be cleared from the body and reverse the signs of ageing.34,35 The FOXO (foxhead box O) family of proteins was identified as being a potential therapeutic target for this process due to their involvement in cell cycle arrest, survival and stem cell signalling. FOXOs interact with p53 to induce cell cycle arrest and senescence. FOXO4 was identified as the factor responsible for interacting with p53 to prevent apoptosis. A cell-permeable-peptide was synthesized that interfered with the FOXO4-p53 interaction which induced apoptosis. In mouse models, fitness, fur density and renal function were restored.35  
1.1.5.1. p53 p53 is a tumour suppression protein that responds to cellular stresses to stop the proliferation of cells that have developed mutations. The role of p53 is to bind to DNA where it recognizes damage. It can then initiate growth arrest, DNA repair or apoptosis. During growth arrest, the cdk inhibitor p21 is activated and the cell is stopped from proliferating until its DNA is repaired.36 If repair is not possible, cell death by apoptosis is initiated via the activation of proapoptotic factors, such as BAX.36 Mutation of p53 can therefore lead to the formation of neoplasms.  
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1.2. Cancer In order for cells to form tumours that go on to become malignant, they require a succession of the six hallmarks of cancer, the proposition of which was introduced by Hanahan and Weinberg in 2000, an update of which was published in 2011 to 
include the potential of two hallmarks and two “enabling characteristics”.37,38 The originally reported six hallmarks are sustaining proliferative signalling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis and activating invasion and metastasis. Each of these hallmarks relies upon genome instability to generate genetic diversity that advances acquisition and inflammation and fosters multiple hallmark functions, the details of which will now be described.  
Sustaining proliferative signalling Homeostasis, i.e. the careful balance between cell proliferation and cell death, is thrown into upset by cancer cells which can continue proliferating.  They are able to do this in a number of ways. While normal cells rely on other cells to produce mitotic growth signals to become proliferative, cancer cells have developed the ability to be proliferatively autonomous by producing and responding to their own growth factors in a positive feedback loop, also known as autocrine stimulation. They do this either by producing growth factor ligands or the cancer cells may send signals to recruited healthy cells within the tumour to provide them with various growth factors.39,40   
Evading growth suppressors As well as being able to sustain proliferation, cancer cells must also evade growth suppressors.  Two key proteins involved in tumour growth suppression are RB (retinoblastoma-associated) and TP53 proteins. Cancer cells that are deficient in these pathways lack the ability to process intra- and extracellular signals that would signal that a cell should not go through the growth and division cycle.41–43   
Resisting cell death  The process of apoptosis has been described in section 1.1.1. It is thought that cancer cells can employ various strategies to avoid triggering apoptosis. Most 
17  commonly the tumour suppressor TP53 is missing from cancer cells, meaning that the upregulation of BH3-only proteins cannot occur. Apoptosis can also be avoided by the increased expression of anti-apoptotic regulators and survival signals, such as BCL-2 and Igf1/2, respectively, via the downregulation of pro-apoptotic factors such as BAX and BIM.7,8,12,27    
Enabling replicative immortality During the proliferation of healthy cells, telomeres become shortened until eventually they are no longer able to perform the duty of protecting the ends of chromosomal DNA from end-to-end fusion. Once telomeres are too short, apoptosis is induced. Cancer cells express telomerase, a DNA polymerase that adds segments to telomeres, circumventing any shortening of the telomeres during proliferative cycles. This essentially leads to cancerous cells becoming immortal.44,45   
Inducing angiogenesis For tumours to grow they must meet the same set of requirements as normal tissues, including access to nutrients and oxygen and the removal of carbon dioxide and waste. Angiogenesis is the process by which new blood vessels are produced and is normally only active in adults during wound healing or the female reproductive cycle. However, during tumour growth, angiogenesis is activated and causes existing vessels to grow new vessels to supply neoplastic growths.46–48  
 
Activating invasion and metastasis Cancer cells are able to escape the tumour mass and colonize other tissues. This can be achieved in two ways. The first is through the loss or downregulation of cell-to-cell and cell-to-matrix adhesion molecules, a family of proteins known as cadherins. The second is through the upregulation of adhesion molecules that are normally expressed during embryogenesis and organogenesis, such as N-cadherin.49–51  
1.2.1. Traditional cancer therapy There are many options for treating cancer and it is common to use several different treatment options at once to maximise the chances of treatment working. Once cancer is detected it will be treated as aggressively as possible (limitations of the 
18  treatment will depend on the type/stage of cancer and the tolerance of the patient). Due to the toxicity of therapeutics, treatment needs to be delivered in cycles, killing cancer cells and shrinking the tumour size a little bit at a time, allowing the patient to recover in between cycles. Obviously, this can only be true if treatment is given with a curative intent. Sadly, that is not always possible and all that can be offered is treatment for palliative care, i.e. treatment would be provided either to extend the 
patient’s life expectancy or to ease pain and suffering. In this case, treatments need to be carefully monitored to ensure that the side effects are not worse than the effects of the disease itself.   Chemotherapy and radiotherapy will be discussed here as these therapies focus on damaging cancer cells to induce cell death. However, these are not the only two forms of cancer treatment. There is also hormone therapy and targeted therapies such as use of protein kinase inhibitors, differentiating agents and immunotherapy.   
1.2.1.1. Chemotherapy Chemotherapy as a cancer treatment has a rather interesting history. During World War II, an attack on a cargo of mustard gas (6, Figure 10) led to a town being engulfed by the mustard gas (6), killing or severely burning more than 1000 of the 
town’s inhabitants.52 Autopsies of the victims led to the discovery that 6 had destroyed most of their white blood cells, suggesting a preferential attack of the chemicals on the bone marrow. Subsequently, a hypothesis was put forward that 6 could target cancer cells due to their similar nature of fast proliferation. Eventually this led to the development of mechlorethamine (7), a derivative of 6 which is still 
in use as a chemotherapeutic agent today against Hodgkin’s disease, leukaemia and brain tumors.52 Since then, a plethora of drugs have been developed that are derived from 6, all working by targeting DNA and preventing it from replicating and dividing.   
 
Figure 10: Mustard gas.  
19  These chemotherapeutic drugs target proliferative cells indiscriminately, meaning that healthy cells that proliferate quickly are targeted as well as cancer cells, such as the digestive tract, skin and hair follicles and bone marrow.53 This leads to many unpleasant side effects, including vomiting, diarrhoea, depression, hair loss and susceptibility to infections. As such, other drugs have been developed in order to combat these debilitating side effects, some examples of which will now be discussed.  
Alkylating agents This class of drugs work by reacting with DNA, forming covalent bonds that cause DNA breaks.54–56 Examples of alkylating agents are derivatives of mustard gas (6) some of which are shown in Figure 11, though these are not the only class of alkylating agents used as chemotherapeutics.57  
 
Figure 11: Examples of alkylating agents. Left: Mustard gas (6). Middle: Mechlorethamine (7). 
Right: Cyclophosphamide (8).  Platinum containing compounds are another form of alkylating agent. The three main platinum compounds currently used as chemotherapeutic agents are Cisplatin (9), Carboplatin (10) and Oxaliplatin (11) (Figure 12). All three work intracellularly, forming covalent bonds with nucleotides.57–59  
 
Figure 12: Examples of platinum containing alkylating agents: cisplatin (9), carboplatin (10) and oxiplatin (11).   
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Antimetabolites Antimetabolites can work in two ways, either they inhibit the proteins needed for DNA synthesis or they become incorporated into DNA and RNA causing damage to or termination of the chain.54,55,57,59 These modes of action are a consequence of the antimetabolites closely resembling the naturally occurring purines and pyrimidines (Figure 13).  
 
Figure 13: Examples of antimetabolites. Top row pyrimidine analogues: 5-fluorouracil (11), floxuridine (12) and gemcitabine (13). Bottom row purine analogues: mercaptopurine (14), azaguanine (15) and fludarabine (16).  
Topoisomerase inhibitors Topoisomerase is a class of proteins that help DNA strands separate for replication. By inhibiting this process, DNA damage is induced followed by cell death.57,59 Examples of topoisomerase inhibitors are seen in Figure 14.  
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Figure 14: Examples of topoisomerase inhibitors. Top: topotecan (17), irinotecan (18). Bottom: etopside (19).  
Antitumor antibiotics/anthracyclines Originally produced by microorganisms as a class of antibiotics, these chemotherapeutics work in several different ways. They can cause DNA damage, generate free radicals to cause oxidative stress and also act as topoisomerase inhibitors.57,59 Some examples of antitumor antibiotics/anthracyclines can be seen in Figure 15.  
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Figure 15: Examples of anti-tumour antibiotics: daunorubicin (20), doxorubicin (21).  
Corticosteroids These can be natural or synthetic hormones and work by inducing apoptosis through binding to receptors inside the cells.59 Examples of cortico steroids can be seen in Figure 16.  
 
Figure 16: Examples of corticosteroids: prednisone (22), dexamethasone (23).  
1.2.1.2. Radiotherapy Radiation therapy uses ionizing radiation to kill and control the growth of cancer cells that are localized to one area. It works by damaging DNA which induces cell death. Radiation beams must pass through other organs to reach the tumour, and so to spare the surrounding healthy tissues from damage, the beams are delivered from several different angles and intersect the tumour to provide the highest dose of radiation at the tumour site.59 How the surrounding tissues respond to the radiation beams limits the dosage that can be used. The aim of treatment is to deliver the highest dose possible to the tumour whilst maintaining the health and functionality of the surrounding tissues. Due to the retention of functionality in the surrounding 
23  tissues, radiation therapy is ideal for targeting cancers that have grown around critical structures such as the spinal cord or large vessels.56,60,61   
1.2.2. Apoptotic pathway targeted cancer therapies As discussed above in section 1.2., one of the hallmarks of cancer is evasion of apoptosis by cancer cells.37,38 This means that malignant cells are not cleared from the body, and can go on to replicate, forming neoplasms. Therefore, the apoptosis pathways present an interesting target for therapeutic intervention. Development of therapeutic agents include those that target both the extrinsic and intrinsic pathways, described in greater detail in sections 1.2.2.1 and 1.2.2.2. respectively.    
1.2.2.1. Extrinsic pathway intervention The extrinsic pathway requires extracellular signals to induce apoptosis, which are referred to as death ligands. Death ligands bind to death receptors (DR) which leads to the recruitment Fas-associated death domain (FADD) which in turn recruits caspase-8, leading to the activation of caspase-3, -6, and -7. This triggers the cleavage of proteins and the cytoskeleton leading to cell death (Figure 17).9,62 DR’s are therefore a target for therapeutic intervention, with TNF and Fas showing extensive in vitro anti-tumour activity.63 However, in vivo tests using animal models have shown that TNF and Fas activate non-specific TNF receptors, which resulted in damage to several tissues leading to septic shock and hepatic failure.64,65 Therefore, there is a need for agents which are able to induce the extrinsic pathway without associated toxicity or serious adverse events. Development of other DR extrinsic pathway inducers with improved tolerability are detailed below.  
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Figure 17: Extrinsic apoptosis pathway. Adapted from Swanson et al. 2009 and Pfeffer and Singh 2018.9,62  
TRAIL/APO2L Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L), is a member of the TNF superfamily and has been found to be an effective extrinsic pathway inducer that is not associated with the toxicities of Fas and TNF.63,66 TRAIL/APO2L induces apoptosis in many tumour cell types by binding the TRAIL trimer to the TRAIL-Receptor (TRAIL-R) 1 or TRAIL-R2 (also known as death receptors DR4 and DR5), resulting in TRAIL trimerisation. This leads to the recruitment of FADD, eventually leading to cell death.67–69 Promisingly, in preclinical testing, when TRAIL was used in combination with chemotherapy or radiotherapy, a significant reduction in tumour growth was observed.70–72  
25  The two main therapeutic strategies that have been tested clinically are a recombinant form of human TRAIL (Apo2L.0 or AMG-951/Dulanermin) and antibodies that specifically target TRAIL-R1 or TRAIL-R2.67 Although these two strategies have been shown to be safe and well tolerated in patients, the clinical studies showed that the tumour cells will either become resistant during the course of treatment, or were already resistant at initiation of treatment.68,73–79 To try to overcome this apparent TRAIL resistance, recent studies have been focussed on the development of second generation TRAIL-based therapies that have a greater cytotoxic effect on cancer cells.67  Current methods to stabilise TRAIL and increase its elimination half-life involves the single-chain TRAIL (sc-TRAIL) approach, and linking TRAIL with molecules that exhibit better pharmacokinetic properties such as human serum albumin (HAS) or polyethylene glycol (PEG).80–82 For the sc-TRAIL approach, the molecule is expressed as a trimer, in which the three molecules are interlinked head-to-tail, preventing errors being introduced during expression whilst also preventing off-target interactions.80 The TRAIL-linking approach, with HSA or PEG, has been shown to increase the elimination half-life, stability and solubility in in vivo studies.81  
Monoclonal antibodies  Monoclonal antibodies have demonstrated the ability to induce apoptosis and be effective in tumour regression by activating TRAIL-R1 and TRAIL-R2.63,82 in preclinical trials, TRAIL-R1 and TRAIL-R2 antibodies such as mapatumamab and conatumumab have been shown to be quite efficacious whilst also demonstrating a favourable safety and stability profile.82–84 Both of these antibodies, as well as many others, have been studied as both a monotherapy and in combination with traditional cancer therapies. Whilst both mapatumumab and conatumumab proved effective as monotherapy, only conatumumab demonstrated efficacy as a combination therapy.82 Monoclonal antibodies have a much longer half-life than TRAIL/APO2 which provides the potential advantage of a less frequent dosing regimen.63  
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Adoptive cell transfer (ACT) In order to try to overcome the issue of resistance development observed when using certain extrinsic pathway inducers, treatment could be tailored to each patient, whereby specific biomarkers of resistance are identified in order to characterise cells with high expression levels of death receptors which would be sensitive to antibodies.82,85 One exciting new development that takes this approach is a type of immunotherapy called adoptive cell transfer (ACT), in which a patient’s own immune cells are modified in order to improve their ability to target tumour cells.86   One such ACT therapy that has gained a lot of attention recently is CAR-T, which uses genetically modified T cells. This therapy has been dubbed “the living drug” since it works by drawing the patients’ blood, separating out the T cells then employing a disarmed virus to genetically engineer the T cells to produce receptors on their surface called chimeric antigen receptors (CAR). The patient would then go through a round of chemotherapy to deplete their lymphocytes, before receiving an infusion of their CAR-T cells.86   These modified CAR-T cells have demonstrated an ability to induce apoptosis specifically in tumour cells by triggering the TRAIL receptor DR4, as well as trigger the mechanisms of T cell cytotoxicity.87,88  So far, two CAR-T therapies have been approved by the Food and Drug Administration (FDA), one, Kymriah (tisagenlecleucel),  indicated for the treatment of children with acute lymphoblastic leukemia (ALL) and the other, Yescarta (axicabtagene ciloleucel),  indicated for adults with advanced lymphomas. Research is still currently ongoing into the use of CART-T and ACT-type therapies for use against other types of cancer and solid tumours.86  
1.2.2.2. Intrinsic pathway intervention The intrinsic apoptosis pathway is stimulated by proapoptotic and antiapoptotic members of the BCL2 protein family and is initiated by oxygen radicals, γ radiation or DNA injury.7 These stimuli result in the upregulation of pro-apoptotic BH3-only (BCL2 homology 3 domain) proteins which inhibit the antiapoptotic BCL2 
27  proteins, leading to the activation of proapoptotic BAX and BAK proteins. BAX is regulated by the tumour suppressor gene p53, and once activated BAX and BAK oligomerise which increases the permeability of the mitochondria.89 This leads to the release of cytochrome c which activates caspase-9 and in turn activates the executioner caspase-3, -6, and -7. The executioner caspases then go on to break down proteins, which leads to cell death. (Figure 18).7–9,62,68   
 
Figure 18: Intrinsic apoptosis pathway. Adapted from Swanson et al. 2009 and Pfeffer and Singh 2018.9,62  Since BH3-only proteins play a key role in regulating and promoting apoptosis they are an appealing target for therapeutic intervention.90–93 It has been found that over expression of prosurvival BCL-2 proteins is present in various tumours and as such, many lines of enquiry have been explored attempting to  inhibit BCL-2, a few of which are discussed briefly below.68,94,95  
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Antisense oligonucleotides Antisense oligonucleotides are short, single-stranded pieces of DNA that have been synthetically sequenced to target mRNA, enhancing the effects of cytotoxic drugs. Though not a complex procedure, use of oligonucletides has been constricted by their susceptibility to intracellular degradation.96–99 However, a new generation of antisense oligonucleotides are currently being tested in clinical settings which are proving to have a greater stability than their predecessors, and have a favourable safety profile.100–102 One of the most promising candidates is oblimersen (also known as G3139 and Genasense) which has been tested in clinical trials as a monotherapy as well as in combination with many anticancer agents against several cancer types.95,103–106 Oblimersen is of special interest as it is the first oligonucleotide that has been proven to downregulate BCL-2 in human tumours within 3-5 days of starting treatment.68,102  
BH3 mimetics BH3-only proteins can initiate apoptosis by either neutralising antiapoptotic BCL-2 proteins, or by activating BAK and BAX.93,107–109 The former mode of action works by the BH3-only proteins binding to the hydrophobic pocket via four hydrophobic residues.110,111 This mode of action is very well understood and as such has been exploited by drug developers leading to the development of many small-molecule BH3-mimetics.112–116   
Targeting inhibitors of apoptosis proteins (IAPs) Inhibitors of apoptosis proteins (IAPs) are a family of proteins that inhibit apoptosis by blocking caspase function, which prevents signalling the extrinsic apoptotic pathway, thereby inhibiting cell death.117,118 It has been found that overexpression of IAPs in tumour cells is linked to an overall poor survival rate and is associated with the development of resistance to chemotherapeutics.119–121 Therefore, targeting IAPs for the development of anticancer therapies has proven a popular strategy. Small-molecule inhibitors of IAPs have been developed which act by either binding to the IAPs itself, or by interfering with IAP mRNA and protein expression.117,122  
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1.3. Imaging cells In this project, before molecules could be developed that could potentially carry a molecular cargo into a cell going through apoptosis and ensuring that the cell dies, it was important to ensure that we were indeed only targeting apoptotic cells. Therefore, a model to test where the cargo was being delivered had to be developed. By attaching a fluorescent marker to the drug-delivering molecule, visualisation of the targeted cells would be possible. Different fluorophores were investigated (Chapter 2) and eventually a series of BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) derivatives were developed.   
1.3.1. Fluorescence Fluorescence, was first described in 1565 by the Spanish physician and botanist Nicolás Monardes, who noted that when wood from the Lignum nephriticum tree was soaked in water the water took on a blue colour.123 The Aztecs had been using the water for its medicinal properties as a diuretic. According to Rodriguez et al. the chemical responsible for the blue colour was matlaline (25, named after the Aztec 
word for blue, “matlali”) which is not actually present in the plant but is produced when one of the tree’s flavonoids, coatline B (24), undergoes spontaneous oxidation upon exposure to slightly alkaline water (Scheme 1).124 
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Scheme 1: Mechanism proposed by Rodriguez et al. for the formation of matlaline via the spontaneous oxidation of coatline B.124  Edward D. Clarke and Rene-Just Hauy separately reported in 1819 and 1822 respectively about the dichroic nature of calcium fluoride; it appeared blue under reflected light and green under transmitted light.123 In 1833 Sir David Brewster reported that sunlight passing through a solution containing chlorophyll fluoresced red  and in 1845 Sir John Herschel reported that an acidic solution of quinine sulfate appeared blue in certain lights.123 However it was not until 1852 that the phenomenon was fully investigated by Sir George Stokes, who observed that the wavelengths of the emitted light were longer than the wavelength of the dispersed light; this later became known as Stokes Law. Though Stokes referred to the 
phenomenon as “dispersive reflection”, in a footnote he proposed that the term fluorescence should be used instead.123   Fluorescence occurs when light of a certain wavelength (specific to the fluorophore 
being observed) promotes a π-electron to a singlet excited state, meaning that the spin of the electron is opposite to its pair in the ground state. As such the transition 
31  from the excited state back to the ground state is spin-allowed and occurs quickly, emitting a photon in the process (Figure 19).125  This process is different to phosphorescence which occurs when electrons are promoted to the triplet state and are no longer spin-paired to the electron in the ground state. In this situation the process of the electron returning to the ground state takes a lot longer and the emission of light continues long after the incident light source is removed.125 
 
Figure 19: Jablonski diagram depicting a S-electron being promoted to a singlet excited state followed by its return to ground state, emitting a photon in the process.    
1.3.2. Aposense – Small molecule detectors of apoptosis An aposense is an umbrella term for a family of small, non-peptidic molecules that can preferentially enter apoptotic or necrotic cells during the early stages of cell death and accumulate in them for identification via fluorescence imaging. This method was originally reported by Shirvan et al. as a non-invasive method for imaging renal tubular cell injury in renal ischemia.126 In their report the authors described the binding method of N,N’-didansyl-L-cystine (DDC, 26, Figure 20) to apoptotic cells and used its fluorescent characteristics and its radiolabelled (3H) derivative for identification and quantification purposes.  
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Figure 20: Left: Image of an apoptotic cell with DDC (26) accumulated in the cytoplasm and annexin V bound to the membrane.126 Right: 3,3'-disulfanediylbis(2-(5-(dimethylamino)naphthalene-1-sulfonamido)propanoic acid) aka N,N’-didansyl-L-cystine (DDC, 26).  The studies were carried out using adult T-cell leukemia Jurkat cells and cervical carcinoma HeLa cells, in which apoptosis was induced and then imaged by staining with DDC and annexin V and viewed using fluorescence microscopy and flow cytometry. Visualization showed that the DDC accumulated in the cytoplasm and annexin V attached to the cell membrane, as shown in Figure 20.  This method was then transferred to animal models where renal ischemia was induced in rats in one kidney, using the other as a control to try and image the induced cell death. It was subsequently found that annexin V, a well-known apoptosis marker that had already been investigated in animal models and clinical trials, had a high affinity for the intact renal cortex and so proved unusable for this study.127 The authors clearly demonstrated the successful application of fluorescent chemical tools as a non-invasive, real-time technique for the diagnosis and monitoring of conditions like renal ischemia.  We were particularly interested in this behaviour as apoptotic cells share many characteristic hallmarks with senescent cells, the build-up of which is the 
mechanistic basis for triggering accelerated ageing in Werner’s syndrome (section 
1.4.1.). Senescence has been linked to both cancer and ageing. Cancerous cells need mutations, which occur in the p53 and p16-pRB pathways, to avoid telomere-
33  dependent and oncogene-induced senescence. Studies have also shown that markers for senescence are more abundant in aged organisms than younger ones. Furthermore, currently there are no small or large molecule detectors of senescence.32 
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1.4. Ageing Ageing is often accompanied by a number of age-related diseases such as 
Alzheimer’s and Parkinson’s disease, arthritis and various forms of cancer.128 The build-up of senescent cells has been linked to both ageing and cancer (section 
1.1.5.). By using the premature ageing syndrome Werner’s Syndrome (WS) as a model for normal ageing phenotypes, this project aimed to increase our understanding of the underlying causes of ageing and the role senescence plays in the ageing process; ultimately to use that knowledge in order to improve the quality of life for a population that is living longer than ever before.  
1.4.1. Werner’s Syndrome 
 
Figure 21: Different stages of the life of a patient with Werner’s Syndrome, illustrating how the disease presents itself as premature ageing.129  The rare autosomal recessive disorder known as Werner’s Syndrome (WS) is caused by a mutation of the WRN gene, which encodes for RecQ helicase. RecQ helicase is involved in DNA replication, recombination and repair. Sufferers of WS exhibit premature ageing, as shown in Figure 21,129 and as a result have a reduced median life expectancy of around 47 years. Due to these factors WS is often used to study the mechanisms of normal human ageing. The premature ageing is thought to be caused by a stress–induced growth arrest mediated by p38 MAPK. The mitogen activated protein kinases (MAPKs) are a family of enzymes essential for inflammatory cell signalling and so have long been investigated as targets in drug 
development for diseases such as rheumatoid arthritis and Crohn’s disease and are thought to be involved in accelerated cellular ageing in WS.  
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Figure 22: BIRB 796 interactions with p38 as summarised by Regan et al.130   The most promising advancement in developing a drug for people living with WS has been BIRB 796 (27, Figure 22) which was developed by the German pharmaceutical company, Boehringer Ingelheim. It is a N-pyrazolyl-N’-naphthyl urea that inhibits p38 MAPK130 and JNK. BIRB 796 and other compounds of the same class are of special interest due to their different binding mode to p38 MAPK when compared to other ATP site kinase inhibitors. Torcellini et al. reported the mode of binding of N-pyrazolyl and N-aryl urea based inhibitors of p38 MAPK, including BIRB 796.131 It was found that when p38 was exposed to the ureas investigated during the study, they occupied a binding domain not previously seen in other Ser/Thr kinases, the DFG-motif (Asp168-Phe169-Gly170 motif) which exhibits a DFG-out conformation, which the ureas can occupy. This unique binding mode is facilitated by movement of a phenylalanine side chain found in the DFG-motif of the activation loop. P38 is one component of the MAPK intracellular enzyme cascade that is responsible for regulating key signalling pathways, which lead to the production of some pro-inflammatory cytokines such as TNF-α and IL-1β.   
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Figure 23: SB 203580 (28) and SB 242235 (29).  Torcellini et al. described the process by which BIRB 796 was selected for clinical trials.131 The study began with the pyrinidinyl imidazole SB 203580 (28, Figure 23), which had been identified as an orally active, potent and selective inhibitor of p38 MAPK during animal testing. SB 242235 (29, Figure 23), an analogue of SB 203580, was also tested in human clinical trials after it was shown to inhibit endotoxin-induced ex vivo production of TNF-α and IL-1β. Unfortunately, during clinical trials 
of BIRB 796 involving patients with Crohn’s disease, Schreiber et al. found elevated levels of alanine transaminase (ALT), a biomarker for hepatic toxicity in clinical pathology.132 This led Miyamoto et al. to propose a possible mechanism for the hepatotoxicity of BIRB 796.133 This effectively ended the trial.    
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1.5. P38 and MK2  The p38 MAPKs are a family of proteins that consists of four isoforms; α, β, γ and δ with each isoform triggering a different response. P38α and β are found throughout 
the body, whereas p38γ is found exclusively in skeletal muscle and p38δ is predominantly found in the testes, pancreas and small intestine.134,135 Only p38α 
and β activate MK2.135 The role of p38 is to activate downstream kinase targets or to directly activate other targets inside the nucleus to trigger an immunological response, such as inflammation. However, if p38α is over-activated this can lead to a feedback loop that leads to production of pro-inflammatory cytokines such as TNF-
α and ILs which exacerbates diseases such as rheumatoid arthritis and inflammatory bowel disease.134–136 Due to the role of p38 in numerous disease pathophysiologies it is an obvious target for therapeutic intervention and, as such, inhibitors have been studied extensively for their use as anti-inflammatory agents.130,137–139   MK2 belongs to a family of mitogen activated protein kinases and is a phosphorylation target for p38. MAPKs are important for cellular functions such as proliferation, apoptosis, gene regulation, differentiation and motility and also co-transport p38 MAPKs to the cytoplasm.140,141 MK2 is a Ser/Thr protein kinase of the calcium/calmodulin-dependent protein kinase family that is a direct downstream substrate of p38 kinases that regulates lipo-polysaccharide stimulated TNF-D.142 Since p38 knockout mice have been found to be lethal,143 MK2 is a potential alternative target for inhibition as MK2 knockout mice are viable, display a reduced expression of TNF-α when stimulated with lipopolysaccharides and are resistant to developing arthritis in disease models.144,145   Previously, p38α MAPK, the upstream activator of MK2, has been targeted for inhibition by the small molecule inhibitor SB 203580 (28) which blocked the synthesis of pro-inflammatory cytokines at the post-transcriptional level, but showed relatively poor kinase selectivity.141,146 However, it was observed that the inhibitor worked by preventing activation of MK2. This was evidence that corroborated observations made in MK2-deficient animal models, which also showed that p38 MAPK activity was unaffected by a deficiency in MK2. 
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Figure 24: The p38 signalling pathway, adapted from Bagley et al. 2010. 147  
1.5.1. The p38 MAPK cascade The p38 MAPK cascade is activated when extracellular factors such as UV light, stress or pro-inflammatory cytokines such as TNF-α and IL-β135,148 activate cell surface receptors and induce the three step pathway to p38 activation; MAPKKK (mitogen activated protein kinase kinase kinase) activates MKK3/4/6 (mitogen activated protein kinase kinase) which activates p38 (Figure 24).136 From this point, p38 can either directly activate transcription factors or activate MK2 or MSK1/2 (Figure 25).136,149 Activation of MK2 leads to the production of pro-inflammatory cytokines whereas activation of MSK1/2 leads to the production of anti-inflammatory cytokines.136 
 
Oxidative stress, osmotic shock, heat, UV light, inflammatory cytokines, growth factors MLK3 MKK3/6 P38 MAPK MK2/3
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Figure 25: Overview of the p38 cascade. Extracellular factors activate a cell surface receptor which activates MAPKKK which then activates M KK3/4/6 which activates p38α. P38α can then directly activate transcription factors or the protein kinase targets MK2 or MSK1/2.  
1.5.2. P38 inhibitors Due to the role of p38 in the overproduction of pro-inflammatory cytokines involved in the pathogenesis of many inflammatory diseases, it is quite an attractive target for inhibition.  BIRB 796 has already been discussed in section 1.4.1. but some other examples of p38 inhibitors will be briefly discussed here to demonstrate the work that has gone into trying to develop a novel inhibitor of p38 that can be used as a therapeutic agent for the treatment of inflammatory diseases.  
40  Vertex Pharmaceuticals proceeded to phase II clinical trials with their pyrimido-pyridazinone-based candidate, VX-745 (30, Figure 26), and found the inhibitor was well tolerated by RA sufferers. It selectively inhibited p38α with an IC50 of 5 nM. However, the clinical trials were suspended due to adverse neurological effects in dogs.150,151 The company followed-up with a new inhibitor, VX-702 (31, Figure 26), which was not able to cross the blood-brain barrier.152 This new inhibitor progressed to phase II clinical trials; however, the therapeutic effect was not much greater than in the placebo group, and so the trials ended.150  
 
Figure 26: Examples of p38 inhibitors: VX-745 (30, phase II), VX-702 (31, phase II).  Roche developed RO-4402257 (32, Figure 27) as a selective inhibitor of the p38α isoform which had an IC50 of 14 nM.153 This inhibitor progressed to phase II clinical trials involving RA sufferers, where it failed to show efficacy and was responsible for several undesirable side effects, such as infections, skin disorders and dizziness in patients.148,154  
 
Figure 27: P38 inhibitor RO-4402257.  From the examples presented here it is obvious that while selectively targeting p38 is not too much of an issue, developing an efficacious therapeutic without off-target effects is and this has led to the failure of many p38 inhibitors that have progressed to clinical trials.155 These effects could be due to the fact that p38 controls feedback 
41  loops that block upstream kinases that can activate other pro-inflammatory pathways, thus inhibition of p38 could lead to over activation of these other kinases.155,156 Therefore, it has been suggested that p38 should no longer be targeted for therapeutic intervention, and therapies should instead be targeted upstream or downstream of p38.148,157,158  
1.5.3. MK2 inhibitors As mentioned previously, the p38 inhibitor SB 203580 worked by preventing activation of the downstream kinase MK2, making MK2 an interesting potential target for inhibition.141,146 As further evidence of MK2’s suitability for inhibition, it was found that p38 knockout mice were lethal whereas MK2 knockout mice were not only viable but had reduced levels of TNF-α.157,159,160 MK2 also mediates the phosphorylation of HSP27, a protein that is involved with cell migration and actin remodelling. The MK2/HSP27 pathway has been implicated in F-actin stress fibre formation in WS cells. The build-up of these fibres is thought to be involved in the premature ageing of WS cells, and also the cell migration of cancer cells. Hence therapeutic intervention may be beneficial for a range of disorders including cancers.155,161 Using high throughput screening (HTS), many ATP-competitive small molecules targeting MK2 have been identified as potential candidates for further derivatization and development into potential therapeutics.  Pfizer investigated derivatives of benzopyranopyridines, pyrrolopyridinones, carbolines and benzothiophenes (Figure 28).160,162–164 Derivatives of carbolines were also investigated by Boehringer-Ingelheim (Figure 29).165       
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Figure 28: Pfizer developed a range of pharmacophores into MK2 inhibitors. R, R1 and X = points of derivatization.  
 
Figure 29: Boehringer-Ingleheim developed a series of carbolines as MK2 inhibitors. R, R1 and R2 = points of derivatization.   
43  Anderson et al. at Pfizer determined from the SAR analysis of pyrrolopyridinone compounds that conformationally constrained moieties were able to occupy the hinge region of MK2 and could gain good selectivity.160 This observation eventually led to the development of a fused heterocyclic benzo[b]thiophene derivative, PF-3644022 (33, Figure 30), which is a highly potent inhibitor of MK2.142 Unfortunately, through animal testing it was found that PF-3644022 caused acute hepatoxicity.166   
 
Figure 30: PF-3644022.  However, it has been used as a tool to investigate the role of MK2 in WS, and the link between MK2/p38 and the Sonic Hedgehog (Shh) pathways in breast cancer development. A recent study presented evidence that Shh, a protein that plays a pivotal role in cancer progression, could activate p38 and MK2 which would go on to activate PFKFB3, a protein responsible for promoting glycolysis and proliferation in breast cancer cells. The direct involvement of MK2 was proven by treatment of the cells with 33 and a decrease in the levels of PFKFB3 was observed.167 Thus, the development of MK2 inhibitors presents an intriguing possibility for the development of anti-cancer therapies. Efforts to develop new synthetic routes towards 33 will be discussed in Chapter 3.  A wealth of pharmacophores have been investigated by many different companies and it has been determined that ATP-competitive inhibitors suffer from poor solubility, poor cell permeation and poor selectivity since the MK2 binding site is structurally very similar to other kinases.155 As such, future work in this area is being focused on non-ATP-competitive inhibitors.    
44  Through a combination of HTS and ALIS (automated ligand identification system, an integrated system of sequential rapid size-exclusion chromatography, reverse-phase chromatography, and electrospray ionization mass spectrometry, used for identification of non-covalent small molecule ligands from combinatorial libraries) techniques Merck identified that derivatives of furan-2-carboxamides as potential non-ATP competitive MK2 inhibitors (Figure 31).168,169 Further derivatization created more rigid structures in the form of dihydrooxadiazole, imidazole, and tricyclic azepinone derivatives.170–173   
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Figure 31: Merck developed non-ATP competitive MK2 inhibitors: furan-2-carboxamide derivative (A) which was further derivatized to create more rigid structures in the form of dihydrooxadiazole and imidazole derivatives (B) and tricyclic azepinone derivatives (C). Addition of a fourth condensed ring (D) further restricted conformational flexibility.  Finally, a fourth condensed ring was added to further restrict conformational flexibility.173 These analogues showed promising results; they did not suffer from solubility issues and presented good affinity and activity. This study demonstrates the great promise for the future development of non-ATP competitive inhibitors.  
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1.6. Project Aims The aim of this project was to develop two types of chemical tools; diagnostic tools and inhibitory tools.   To develop diagnostic tools for imaging, we have expanded on work originally reported by Shirvan et al. on the use of the aposense molecule N,N’-didansyl-L-cystine (DDC, 26), who investigated it as part of a non-invasive method for imaging renal tubular cell injury in renal ischemia.126 In order for us to create novel aposense molecules, a series of BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) based molecules have been designed and synthesized. BODIPYs were chosen due to their favourable fluorescence emission and excitation wavelength and the relatively simple and cost-effective methods by which they could be synthesized. Fluorophores are typically difficult to make and expensive to buy, hence not ideal in a medicinal chemistry setting. By tagging small molecules with fluorophores we hoped to be able to visualise cellular events, in order that we could better design molecules that could target cells undergoing morphological changes and deliver molecular cargos to the cell interior. The hope was that this would lead to new opportunities for developing therapeutic regimes for accelerated ageing disorders and in cancer treatments (both chemo- and radiotherapy).  Inhibitors being developed as part of this thesis have a common motif in the form of benzothiophenes. The synthetic goal for the first stage of this project was to develop a rapid route to this core motif. This was established in collaboration with Dr. Jessica Dwyer, whose goal it was to introduce functionality suitable for subsequent elaboration to target inhibitors. Using microwave irradiation and our established conditions and reagents, excellent results were achieved. The methods developed appeared to be superior to other routes which relied upon halogenation. Leading on from this, a new synthetic route towards the MK2 inhibitor, PF-3644022 (33), has been developed in collaboration with Dr. Dwyer. To conclude, a rapid, microwave-assisted method for the preparation of benzothiophenes for further derivatization to synthesize chemical tools has been developed for the formation of LIMK, PIM and MK2 inhibitor scaffolds. This work has been published in Organic & Biomolecular Chemistry.174 
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1.6.1. Microwave-assisted organic synthesis Microwave-assisted organic synthesis was first implemented in the mid-1980s but development of microwave-assisted methods was rather slow due to a lack of controllability and issues with safety, though mostly due to a lack of understanding of microwave dielectric heating.175 The mid-1990s saw the introduction of microwave equipment developed specifically for organic chemistry reactions, thus the technique became incredibly popular due to increased safety precautions, the potential for solvent-free reactions to be carried out and the possibility of drastically reducing reaction times whilst achieving high yields. Microwave reaction times are usually reduced compared with conventional heating, for example via an oil bath or aluminium heating block, because conventional heating heats the sample slowly allowing a temperature gradient to develop and create local hotspots, which can lead to the production of side products or even reagent decomposition. During microwave dielectric heating, the microwave radiation can pass straight through the walls of the vessel, quickly and uniformly heating the reactants and solvent, which reduces the formation of unwanted side products and decomposition. By using sealed vessels to create pressurized systems, solvents can be heated above their atmospheric boiling point thus creating energy profiles which normally cannot be achieved safely by conventional heating.    
 
Figure 32: Diagram depicting the oscillating field and its effects on molecules in solution. Polar molecules rotate to align themselves with the alternating electric field whilst ions rapidly move along with the applied field. 
48  As a form of electromagnetic radiation, microwave radiation can be split into two components, the magnetic field component and the electric field component, the latter of which is responsible for the dielectric heating and causes the dipolar polarization mechanism and the conduction mechanism. It is through a combination of these two mechanisms that rapid temperature gradients can be achieved (Figure 
32).  The dipolar polarization mechanism is the process by which the microwave radiation causes a polar molecule to rotate to align itself with the alternating electric field. The frequency of irradiation chosen in a microwave reactor is sufficiently low to stop the molecule from precisely following the oscillating field, so that a phase difference between the dipole and the orientation of the field causes energy to be lost as heat during friction and collisions with other molecules.   The conduction mechanism occurs through addition of ions to the solution and is a much stronger method of generating heat than the dipolar polarisation mechanism. Ions align with the oscillating electric field and follow the applied field rapidly, colliding with other molecules resulting in the conversion of kinetic energy to heat energy. Therefore, adding ions to a non-polar solution will permit the solution to be heated via microwave irradiation.  The use of microwave technology has been become widely recognised as a reliable and highly efficient technique. The scope of microwave-assisted organic synthesis is incredibly wide with few limitations to the types of reactions that can be carried out. As such, it is now extensively employed in research and development176,177 as well as being relied upon throughout this project to specifically conduct heterocyclic synthesis and metal-mediated reactions efficiently.        
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Chapter 2: Diagnostic tools 
 
2.1. Background and aims The aim of this project was to create a fluorescent chemical tool that would selectively accumulate in cells going through the early stages of apoptosis. This molecule would then be used as a proof-of-concept to design further chemical tools through substitution at the position of the fluorophore with a molecular cargo, while still maintaining selectivity towards accumulation in apoptotic cells. There are several examples of apoptosis imaging agents and several molecular imaging techniques, however this project was only concerned with fluorescent probes to be used in in vitro testing. Figure 33 depicts a flow diagram outlining each planned stage of this project in sequence.  
 
Figure 33: Stages of development of chemical tools that are selective towards cells going through the early stages of apoptosis.  
2.2. Introduction Using fluorophores to observe biological events in cells and organisms has been of interest to the scientific community since the first report of an organic fluorescent molecule, quinine sulfate, written in 1845 by Sir John Herschel (34, Figure 
34).178,179 The term fluorescence did not find use until 1852 when George Stokes made the suggestion in a report on the discovery of fluorescent molecules.180   
Development of fluorophore labelled molecule Visualisation of intracellular activity
Development of molecule without fluorophore Inclusion of molecular cargo (i.e. radiolabel) 
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Figure 34: Quinine sulfate, discovered by Sir John Herschel in 1845.179  Since then, a huge array of fluorescent probes and indicators have been developed that are able to target biological events such as pH changes, the presence of metal ions, protein activities and signalling events, allowing these behaviours to be observed by an investigator. Fluorescence imaging techniques are not only useful for biological research but can be used as a non-invasive technique for the diagnosis and treatment of diseases through being able to detect biological events in cells or tissue. The first report of fluorescent probes that could bind to cells in order for them to be observed was in 1914 by von Prowazek181, previous studies into imaging biological samples involved plants, bacteria and animal tissues that could spontaneously fluoresce.178   Some of the more popular small-molecule fluorophores, and ones that feature in this report, are fluorescein, rhodamine and BODIPY dyes (Figure 35). Fluorescein and rhodamine dyes have been in use since the late nineteenth century.178,182,183 Since then, many derivatives of these probes have been developed, with investigations into structural modifications still being continued.   
 
Figure 35: General structures of fluorescein (35), rhodamine (36) and BODIPY (37). 
51  One of the most useful developments in fluorescence imaging has been structural 
modification to include an “on/off” functionality. This is the altering of the optical properties of a molecule in response to its environment that allows an investigator 
to “see” these changes. This can be achieved through photoinduced electron transfer 
(PeT) or Fӧster (or fluorescence) resonance energy transfer (FRET). PeT-based probes work by transferring an electron to or from the fluorophore in the excited state, from or to an electron donor or acceptor that is introduced to the vicinity, resulting in a change in the intensity of fluorescence observed (Figure 36).   
 
Figure 36: Schematic representation of PeT-based fluorescent probes, modified from Terai and Nagano 2012.178  FRET-based probes work via a non-radiative transfer of energy between two linked fluorophores, one acting as a donor and one as an acceptor. As a result of this exchange, fluorescence observed from this system is very weak, but when the linker that attaches the two fluorophores is broken, FRET is cancelled and a strong fluorescence is observed from the donor molecule (Figure 37).  
 
Figure 37: Schematic representation of FRET-based fluorescent probes, modified from Terai and Nagano 2012.178  
2.2.1. Investigation into small-molecule fluorescent probes 
52  The fluorophores developed during this project were designed as a model to guide the development of a drug-like structure that would carry a molecular cargo into apoptotic cells. Since the molecular cargo in question would be a radiopharmaceutical, which would require specialist training and equipment to handle, as well as specialist storage, the fluorophore model was deemed easier, safer and a more efficient approach to guide the process of drug development.   Two reports on existing apoptosis detectors were taken into consideration at the start of this project. The first was a report by Shirvan et al. on the development of a fluorescent probe, didansyl cystine (26, Figure 38) that could preferentially enter and accumulate inside apoptotic cells (section 2.2.1.1).126 The second was a report by Ziv et al. on the development of a PET (positron emission tomography) imaging agent known as ML10 (38, Figure 38), that could preferentially detect and enter apoptotic cells (section 2.2.1.2).184   
 
Figure 38: Didansyl cystine (26) and ML10 (38) both contain a di-carboxylic acid, a linker unit of 5/6 atoms.  Interestingly, both structures featured a dicarboxylic acid, a linker and small fluorescent unit (although ML10 features a radiolabel, the authors had briefly investigated an analogue containing a fluorophore). This project oversaw the modification of these structures to achieve the goal of developing new properties. 
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2.2.1.1. Didansyl Cystine based fluorophores The first probe to be investigated as part of this project was didansyl cystine ((2R,2'R)-3,3'-disulfanediylbis(2-(5-(dimethylamino)naphthalene-1-sulfonamido) propanoic acid, DDC, 26). As has already been discussed in Chapter 1.3.2 this probe was originally reported by Shirvan et al. as a non-invasive method for imaging renal tubular cell injury in renal ischemia.126 
 DDC (26) was particularly attractive as it was reported to be able to pass through the cell membrane and accumulate intracellularly with a high specificity for cells undergoing apoptosis. The cell lines used by Shirvan et al. were human adult T-cell leukemia Jurkat cells and cervical carcinoma HeLa cells. Apoptosis was induced in the Jurkat cells either by treatment with IgM anti-Fas (CD95) antibody or with the caspase inhibitor Z-VAD-FMK in DMSO before the cells were incubated with the IgM anti-Fas antibody, whereas the HeLa cells were treated with staurosporine. Since our tests would involve different cell lines it was decided to synthesise DDC and observe its capabilities in vitro before considering what modifications should be carried out in order for the molecule to deliver a molecular cargo intracellularly.   As will be discussed in section 2.3.1. there was a need to find other fluorophores to incorporate onto the cystine unit linker. After an investigation into appropriate 
fluorescent units using the Thermo Fisher Scientific’s Fluorescence SpectraViewer, available via the Thermo Fisher Scientific website, fluoroscein isothiocyanate (FITC) and rhodamine B isothiocyanate were chosen as candidates for further investigation.  Fluorescein and its derivatives are some of the most widely used set of fluorophores for biological research due to their exceptional fluorescence quantum yield, their high absorptivity and good solubility in water. FITC (39, Figure 39) is a small molecule with wide-ranging applications in biology. Its most common use is to label and track cells in fluorescence microscopy.   
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Figure 39: Fluoroscein isothiocyanate (FITC) (39). λex 492 nm, λem 518 nm.  Rhodamine B isothiocyanate (40, Figure 40) is also a small molecule that has found widespread use in biology, mainly as a protein labelling probe.  
 
Figure 40: Rhodamine B isothicyanate (40). λex 543 nm, λem 580 nm.  
2.2.1.2. ML10 based fluorophores ML10 (2-(5-fluoropentyl)-2-methylmalonic acid, 38, see Figure 41) was developed as a PET (positron emission tomography) imaging agent of apoptosis by Ziv et al.184  Since there is considerable evidence to support the hypothesis that apoptosis plays a significant role in the pathophysiology of many diseases (Chapter 1.1.1.), Ziv et 
al. set out to develop a PET tracer that could be made available for clinical diagnosis.   
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Figure 41: ML10 (38).  The group took inspiration from a class of proteins that bind to the membrane of cells undergoing apoptosis, which undergoes a loss of membrane potential and becomes permanently acidified due to the externalization of phosphatidylserine (PS).  Though it was known that the γ-carboxyglutamic-acid (Gla, 41, Figure 42) domain proteins, the anticoagulant proteins C and S, and the anti-apoptotic protein gas6 could bind to apoptotic cells, they had not been investigated for their potential use as apoptosis probes. All of these proteins had in common domains rich in the 
uncommon amino acid Gla, which is formed in the liver by the γ-carboxylation of glutamate.   
 
Figure 42: The uncommon amino acid DL-γ-carboxyglutamic acid (Gla).  Gla contains an alkyl malonate group which seems to be responsible for enabling the binding of the proteins to the acidic membranes. It was therefore hypothesised that the small molecule apoptosis probe should contain an alkyl malonate building block. The proposed mechanism of the uptake of ML10 into apoptotic cells is shown in 
Figure 43.  
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Figure 43: Proposed mechanism for ML10 uptake in apoptotic cells, modified from Ziv et al.184 A: Protonation states of the malonate moiety of ML10, where X is favoured in aqueous conditions. B: Proposed mechanism for the transit of ML10 through a cell membrane of a cell going through the early stages of apoptosis, as such the membrane would be intact, externalization of PS leads to acidified external membrane which allows ML10 to capture a proton. This results in increased hydrophobicity and charge dispersion of ML10 which allows ML10 to enter the membrane. Passage through the membrane and delivery into the cytosol facilitated by depolarisation of ML10 and reacidification upon entrance to an acidic cytosol, characteristic of an apoptotic cell.  However, there is a slight flaw with this theory of passive diffusion of ML10 across the cell membrane. Permeability is usually governed by polarity and size, and as such, passive diffusion is usually limited to very small, moderately polar molecules or nonpolar gases. In fact, the cell membrane is almost impossible to cross for larger, uncharged polar molecules as well as all charged molecules. Therefore, these types of molecules require active transport to carry them across the membrane and into the cell.185 Amino acids fall into the category of larger molecules that require active transport, and they make use of secondary active transporters that harness the 
57  stored energy from the electrochemical gradient of another solute.185,186 Since the structure of ML10 was based on the uncommon amino acid DL-γ-carboxyglutamic acid (Gla), and it would also carry a charge in aqueous conditions, it is therefore possible that it would also require the use of an active transporter to cross the cell membrane.  Modifications were made to the malonate unit: adding an alkyl chain to make the molecule amphipathic for better interaction with the cell membrane, optimised to 
include five carbon atoms, and addition of a methyl group at the α-position to prevent in vivo metabolism.  To test the viability of the newly designed probe, a number of easily observable derivatives were examined: a tritium labelled derivative (3H-ML10) and a fluorescent derivative where the fluorine had been swapped with a dansyl group (ML10-dansyl). Apoptosis was induced in Jurkat cells by treatment with anti-Fas antibody. 3H-ML10 and ML10-dansyl were tested alongside propidium iodide (PI, a marker of membrane disruption i.e. late stage apoptosis) and Annexin-V (an early stage apoptosis probe that adheres to the cell membrane upon the externalisation of PS (phosphatidylserine)). The results showed that both 3H-ML10 and ML10-dansyl accumulated inside cells shortly after the apoptosis was induced, indicated by the fact that there was no PI uptake in the cells. 3H-ML10 uptake appeared to coincide with the uptake of Annexin-V.  The method Ziv et al. used to prepare ML10-dansyl is described in Scheme 2. This involved first the preparation of 3-(5-bromo-pentyloxy)tetrahydropyran (44) by the protection of 5-bromopentanol (42) with dihydropyran (43), catalysed by pyridinium p-toluene sulfonate (PPTS). (44) was coupled with α-methyl di-tert-butyl-malonate (45) in the presence of potassium bis(trimethylsilyl)amide 
(KHMDS), forming the α-methyl, THP pentyl substituted malonate (46). The protecting groups were then removed with PPTS in ethanol to provide 2-(5-hydroxypentyl)-2-methyl-malonic-acid di-tert-butyl ester (47). The Boc-protected dansyl group (49) was prepared by reacting 5-dimethylamino-1-naphthalenesulfonamide (48), di-tert-butyl-dicarbonate and small amounts of 4-
58  dimethylaminopyridine in the presence of triethylamine. A Mitsonubo reaction was carried out to couple the Boc-dansyl amide (49) to 2-(5-hydroxy-pentyl)-2-methyl-malonic-acid di-tert-butyl (47), which involved reacting with triphenylphosphine and diisopropyl azodicarboxylate (DIAD). Removal of the tert-butyl protecting groups by hydrolysis using TFA at low temperature resulted in the final product, ML10-dansyl (51).  
 
Scheme 2: Preparation of ML10-dansyl as reported by Ziv et al.184 Reagents and conditions: i) Pyridinium p-toluenesulfonate (PPTS); ii) Potassium bis(trimethylsilyl)amide (KHMDS); iii) EtOH, PPTS; iv) di-t-butyl-dicarbonate, NEt3, 4-dimethylaminopyridine; v) Mitsunobo conditions, PPh3, DIAD; vi) TFA, low temp. 
59  This study confirmed that an alkyl malonate derivative could successfully target apoptotic cells, and more importantly could do so with a fluorophore attached to the alkyl chain. We already knew that the dansyl group used in this case would not be suitable to observe with our equipment and so a new fluorophore was sought.   
Mitsunobo reaction The Mitsunobo reaction was first described in 1967 by Mitsunobo and Yamada for the preparation of esters from carboxylic acids using quaternary phosphonium salts.187  Since its inception, the process has been developed and is now much more widely applied as a dehydrative coupling of alcohols (usually primary and secondary alcohols, though tertiary alcohols have been used on occasion) to a pronucleophile, mediated by a reaction between a trialkyl- or triarylphosphine and a dialkyl azodicarboxylate (Scheme 3). When reactions are carried out using secondary alcohols, a complete inversion of stereochemistry is observed.  
 
Scheme 3: General scheme of the Mitsunobo reaction.  Generally, in order for the Mitsunobu reaction to proceed it is widely accepted that the pKa of the pronucleophile must be at least 11 or lower to be compatible with the dialkyl azodicarboxylate. This is because the acidic proton of the betaine, formed as a result of the reaction between triphenylphosphine and DEAD, needs to be removed to prevent alkylation of DEAD. Standard reaction conditions are usually 
60  fairly mild, typically carried out between room temperature and 0 °C and tolerated solvents include THF, diethyl ether, dichloromethane, toluene, and in some instances more polar solvents such as ethyl acetate, acetonitrile and DMF can be used.188  The Mitsunobo reaction can form both C-C bonds and C-heteroatom bonds depending on the type of pronucleophile employed. (Thio)carboxylic acids, (thio)phenols, imides and sulfonamides form C-O, C-S and C-N bonds. Using the example presented above in Scheme 2 a C-N bond is formed. The first stage involves the triphenyl phosphine reacting with the DIAD or DEAD via a nucleophilic attack which forms the betaine intermediate. The betaine intermediate then deprotonates the alcohol, forming an ion pair. The phosphonium ion binds to the oxygen, activating it as a leaving group and allowing nucleophilic substitution by the amine of the dansyl group (Scheme 4).  
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Scheme 4: Proposed mechanism for the formation of ML10-dansyl via Mitsunobo conditions, as described by Ziv et al.184  Currently there are limited instances of the Mitsunobo reaction being used for C-C bond forming reactions due to the relatively high pKa of carbon acids. The first C-C bond forming example was reported in 1985 by Falck and Manna and involved using 
62  lithium cyanide to displace an activated alcohol to produce the corresponding organic nitrile.189 Meldrum’s acid has also been used successfully as a pronucleophile due to having a pKa of 4.97, though the presence of two acidic protons makes control during the alkylation step difficult resulting in double C-alkylation. Shing et al. overcame the controllability problem by simply using a mono-substituted Meldrum’s acid for coupling with primary alcohols; coupling with secondary alcohols was problematic and required catalytic amounts of Pd(0) to promote C- alkylation over O-alylation.190  
2.2.1.2.1. BODIPYs The class of dyes known as BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) dyes was chosen as the most suitable (52, Figure 44).   
 
Figure 44: BODIPY core structure.  The BODIPY scaffold has been incredibly useful as a functional fluorescent probe due to its relatively high photostability, overall neutral charge, high fluorescence quantum yield and sharp excitation and emission spectra.191–194 BODIPY-based probes can be applied to both cell and in vivo imaging, with the latter possible due 
to the tunability of the BODIPY dye’s fluorescence via chemical modifications194–196 to the near infra-red (NIR) region of the spectrum. NIR fluorescence is very useful as NIR light can penetrate deep into tissues without causing significant damage or light scattering, allowing observations of targets in vivo.197   Though the BODIPY scaffold is highly hydrophobic, which would usually be problematic for the visualization of biological samples, the BODIPY scaffold can be modified easily to incorporate hydrophilic groups. Without the hydrophilic groups, the dyes tend to accumulate within subcellular membranes but with the incorporation of solubilizing groups such as tetraethylene glycol, and alkoxy and carboxylate groups, BODIPYs can instead accumulate in the cytosol. However, 
63  membrane permeability depends on the entire structure, thus when designing BODIPY based probes it is necessary to consider the pKa, logP and logD.  
BODIPYs also have the advantage of possessing an “on/off” functionality whereby 
the fluorescent property can be controlled by Fӧrster resonance energy transfer (FRET)198 or photo-induced electron transfer (PeT)199–201 in response to target molecules using the FRET or the PeT process as a quenching mechanism. By considering changes of the molecular structure and the effects on the frontier orbital energy level, the molecules can be designed to signal in response to changes in pH, protein activity, interactions between biomolecules and cells, and the presence of cations. There are several examples of this type of BODIPY structure that are commercially available.   BODIPYs are considered as a neutral molecule since the charge is spread throughout the conjugated ring system. It is therefore usually depicted in an uncharged form.   
 
Scheme 5: Resonance forms of the BODIPY core structure resulting in depiction as an uncharged molecule.   The first BODIPY was reported in 1968 by Treibs and Kreuzer.202 Whilst trying to form acylated pyrroles by using 2,4-dimethylpyrrole (53), acetic acid and boron trifluoride as a Lewis acid catalyst, a highly fluorescent compound was formed instead. This was due to the acid catalysed condensation of the pyrrole to form a dipyrrin which was complexed with the boron trifluoride diethyl etherate (Scheme 
6).  
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Scheme 6: Fist example of BODIPY synthesis carried out by Treibs and Kreuzer in 1968.202 Reagents and conditions: i) Ac2O, BF3.Et2O; ii) H+; iii) Ac2O, BF3.Et2O.  BODIPYs can be easily and cheaply synthesized from readily available materials and can also be easily modified making them a very attractive group of fluorophores to use for this study. The reaction proceeds via a Vilsmeier type reaction. BODIPYs are 
easily prepared by reacting a pyrrole with at least one free α-position, with an acid chloride and boron trifluoride diethyl etherate in the presence of a tertiary amine (Scheme 7).    
 
Scheme 7: General reaction scheme for the formation of the core BODIPY structure. i) Tertiary amine, BF3.Et2O.   It is worth mentioning that the IUPAC numbering of dipyrrins and dipyrromethene is different to BODIPY numbering (Figure 45), however the central carbon is always referred to as the meso position in line with porphyrin nomenclature.203  
 
Figure 45: IUPAC numbering of dipyrrin, dipyrromethene and BODIPY.203   Though the BODIPY core structure requires a relatively straightforward synthetic procedure, extra care must be taken when working with pyrroles due to their highly reactive nature.  
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Pyrrole polymerisation Pyrroles are exceptionally good at electrophilic substitution reactions. The delocalization from the N lone pair is spread evenly around the ring and since it is a five-membered ring, the delocalization can be drawn easily anywhere around the ring (Scheme 8). A consequence of the delocalisation of the N lone pair is the ring becomes electron rich, raising the energy level of the HOMO and therefore making the ring more nucleophilic and more readily attacked by electrophiles.    
 
Scheme 8: Resonance forms of pyrrole.  The stabilization of regioisomeric transition states during electrophilic aromatic substitution through pyrrole resonance means that pyrrole can be easily attacked at any carbon. This can pose a problem for reactions where only mono-substitution is required, such as the reaction required for BODIPY synthesis. Protonation can also occur at any of the carbons around the ring which leads to polymerisation of pyrroles (Scheme 9) especially under strongly acidic conditions i.e. acids with a pKa <-4, such as HCl which is generated during the formation of the BODIPY core.   
 
Scheme 9: Polymerisation of pyrroles. 
66   In the absence of strong acids, it is possible to control the substitution of pyrroles and achieve only mono-substituted products using either the Vilsmeier reaction or the Mannich reaction. This is because most reagents will attack first at the 2- or 5-positions and will only attack the 3- or 4-positions if 2- and 5- are unavailable. Although it was mentioned earlier that delocalization is evenly spread around the pyrrole, intermediate products of reactions at the 2- and 5-positions are slightly more stable due to having a linear conjugated system i.e. both double bonds are conjugated with N+, as opposed to the cross-conjugated intermediate products from reactions at the 3- and 4-positions (Scheme 10).   
 
Scheme 10: Comparison of stability of intermediates of reactions with pyrroles. A: Reaction with electrophile at 2-position. B: Reaction with electrophile at 3-position.   
Vilsmeier reaction The Vilsmeier reaction is an acylation type reaction which involves reacting phosphorus oxychloride (POCl3) with N,N-dimethylamide to create a carbon electrophile in the absence of a strong or Lewis acid. The amide reacts with POCl3 forming an iminium cation which reacts with the pyrrole via a nucleophilic substitution reaction which provides the much more stable iminium salt. The salt is then hydrolysed with sodium carbonate and water which removes any acid formed and attaches the formyl group (Scheme 11).  
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Scheme 11: Vilsmeier reaction mechanism.  
Mannich reaction The reaction is initiated with the protonation of formaldehyde which goes on to react with an amine, forming an iminium cation. The iminium cation reacts with the pyrrole via an electrophilic substitution reaction (Scheme 12).  
 
Scheme 12: Mannich reaction meachanism.  
2.3. Results  
2.3.1. Didansyl cystine based fluorophores The synthetic route towards DDC (26) was quite straightforward. A mixture of cystine (55, 1 equiv.) and potassium carbonate was dissolved in equal quantities of acetone and water. Dansyl chloride (48, 2 equiv.) was then added and the mixture was allowed to stir at room temperature for 1.5 h. After this time, the acetone was 
68  removed and the solution acidified with citric acid (2 M), causing the product to precipitate out of solution as a yellow solid, to be collected by vacuum filtration in near quantitative yield (Scheme 13).  
 
Scheme 13: Formation of DDC (26). Reagents and conditions: i) K2CO3, water/acetone (1:1), 1.5 h, RT; (ii) acidify with citric acid (2 M), 99%.126  The biological properties of DDC (26) were imaged in vitro by Dr. Karen Marshall. It was found that the wavelength for excitation of DDC (26) lay outside of the range of 
the fluorescence microscopes (λex 365 nm, λem 420 nm). Therefore, it was decided to incorporate alternative fluorophores that could be imaged on site. The new fluorophores had to meet certain criteria to be considered; 1) commercially available and inexpensive, 2) relatively small molecule preferably non-charged in order to pass through a cell membrane, 3) wavelength of excitation no lower than 
λex 405 nm, 4) accessible using an isothiocyanate group for easy addition onto a 
cystine unit. This task was carried out using the Thermo Fisher Scientific’s Fluorescence SpectraViewer, available via the Thermo Fisher Scientific website. Using this method, two fluorophores were identified as being ideal candidates; fluoroscein isothiocyanate (39, FITC) and rhodamine B isothiocyanate (40).  The same reaction conditions employed for the formation of DDC (26) were used since the thiourea bond is usually one that forms easily under mild, aqueous conditions in the presence of base. However, upon addition of citric acid (2 M), no 
69  precipitate was seen to form. An extraction was attempted but no product was ever isolated.   
 
Scheme 14: Proposed reaction scheme for the formation of a cystine-fluorescein derivative.  Again, the same reactions conditions used for the formation of DDC (26) were employed to prepare the rhodamine derivative but without success (Scheme 15).  
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Scheme 15: Proposed reaction scheme for the formation of the cystine-rhodamine derivative.  Since it was now apparent that the using a cystine unit as a tether to the fluorophores was not going to be achieved easily it was decided to abandon this approach and take inspiration instead from another small molecule that had been proven to preferentially enter apoptotic cells.  
2.3.2. Development of BODIPY library Since it was already known that an alkyl malonate with a five-carbon tether was necessary, it was decided to aim to synthesize a compound with the general structure as seen in Figure 46.  
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Figure 46: General structure of ML10-BODIPY derivative.  
2.3.2.1. Unsubstituted Pyrrole  The first BODIPY attempted was the simplest using an unsubstituted pyrrole (56) and a method developed by Jiao et al.204 (Scheme 16). The pyrrole (56) needed to be freshly distilled for use in this reaction and the reaction carried out under an inert atmosphere. The first step required mixing the pyrrole with 6-bromohexanoyl chloride (57), allowing the mixture to stir at room temperature for 12 h. To counteract the effects of pyrrole polymerization, a large amount of dry solvent was required as well as a 10:1 ratio of pyrrole (56) to 6-bromohexanoyl chloride (57). Argon was allowed to flow through the vessel slowly to purge the flask of HCl gas generated during the reaction. A colour change was observed to take place over this time from a pale yellow to a dark red. After this time, triethylamine was added followed by the slow dropwise addition of boron trifluoride diethyletherate. During this stage HF gas released as a by-product so again the argon was fed through the vessel. The temperature was then increased to 50 °C and the mixture allowed to stir overnight.  
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Scheme 16: Formation of 58. Reagents and conditions: i) Inert atmosphere, 1,2-dichloroethane, RT, 12 h; ii) NEt3, BF3.Et2O, 50 °C, overnight, 43%.  Purification was carried out using flash chromatography using a gradient elution solvent system of 100% hexane to 10% ethyl acetate in hexane. During this stage, it was noted that a black substance, assumed to be a product of pyrrole polymerization, was unable to pass through the frit of the column.  This substance was found to block the column following a scale up attempt. A silica plug was employed in an attempt to remove the substance before carrying out flash chromatography, however it was found that a lot of the substance still eluted, making scale up of the process problematic.   Whilst a reasonable yield was achieved (43%), it was observed by TLC analysis that other fluorescent side products had formed during the reaction that were not removed by column chromatographic purification. An attempt was made to purify the product further by recrystallization but with little success. 1H NMR spectroscopic analysis also showed prominent peaks not belonging to the product.  Upon further analysis, the peaks were attributed to 58, 58 without BF2 coordination, and acyl chloride starting material (57) in a 1:1:3 ratio (Figure 47). This meant that the actual yield of 58 was 9%. 
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Figure 47: Analysis of 58. A: Mass spectrum showing m/z of 58 and starting material. B: 1H NMR spectrum showing the presence of product 58, 58 with uncoordinated BF2, and starting material 57 in a 1:1:3 ratio respectively.  
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74  The synthesis of two additional unsubstituted pyrrole-based BODIPY analogues was attempted bearing a shorter alkyl linking chain (Scheme 17) using the same conditions laid out above.   
 
Scheme 17: BODIPY analogues with shorter alkyl chains. Reagents and conditions: i) Inert atmosphere, 1,2-dichloroethane, RT, 12 h; ii) NEt3, BF3.Et2O, 50 °C, overnight, 18% (60), 15% (62).  Step 1 was successfully carried out for both examples, however yields achieved for 
60 and 62 were very low, 18% and 15% respectively. Interestingly there appeared to be no other products present in either of these samples. The 1H NMR spectrum for 60 suggested that 60 might be present without coordinated BF2, however the peak did not integrate to anything substantial, the other peaks integrated correctly for 60 and the mass spectrum only showed the presence of 60 (Figure 48). In contrast, the 1H NMR spectrum for 62 only showed peaks consistent with 62 (Figure 
49). 
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Figure 48: Analysis of 60. A: Mass spectrum showing m/z of 60. B: NMR spectroscopic analysis showing peaks consistent with the presence of product 60. 
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Figure 49: Analysis of 62. 1H NMR spectroscopic analysis showing peaks consistent with the presence of product 62.  In the case of 62, it was found that a side product, 63, had formed that could be isolated in almost the same yield as the main product (Scheme 18).   
 
Scheme 18: Formation of 62 and side product 63. Reagents and conditions: i) Inert atmosphere, 1,2-dichloroethane, RT, 12 h; ii) NEt3, BF3.Et2O, 50 °C, overnight, 15% (62), 11% (63).  Product 63 was isolated in an 11% yield and quite interestingly had completely different visual characteristics to product 62. Whilst product 62 was isolated as an orange solid which fluoresced yellow/green in solution, product 63 was isolated as a dark purple solid and bright pink in solution. Product 63 melted over a range of 
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77  124.6 – 130.9°C, indicating that the sample was impure. This was confirmed by 1H NMR spectroscopic analysis which showed peaks in the allylic region that did not belong to the product (Figure 50).  
 
Figure 50: Analysis of 63. 1H NMR spectrum showing peaks consistent with the presence of product 
63.  A proposed mechanism for the generation of products 62 and 63 is shown in 
Scheme 19. It is thought that the extra pyrrole addition occurred during the first stage of the reaction whilst the acyl chloride was reacting with half of the pyrrole present, generating HCl in the process (step A), which would help the remaining pyrrole start polymerising (step B). Both forms of pyrrole will then go on to form the backbone of the BODIPY core (step C). During the work-up stage, the mixture would be exposed to air causing the oxidation and rearomatisation of the substituted pyrrole (step D).  
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Scheme 19: Proposed mechanism for the formation of 62 and 63. A: Acyl chloride reacts with pyrrole generating HCl in the process. B: HCl catalyses pyrrole polymerization. C: Both unsubstituted and newly substituted pyrrole go on to form the backbone of the BODIPY core. D: Oxidation causes rearomatisation of pyrrole.  Attempts were made to carry out step 2 (Scheme 20) but the desired products could not be isolated.  
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Scheme 20: Proposed routes to unsubstituted pyrrole based BODIPY dyes with shorter carbon chain lengths.   Due to the difficulties encountered with polymerization using an unsubstituted pyrrole, the low yielding reactions and difficulty in obtaining pure products, it was decided to attempt to access a BODIPY derivative starting from a trisubstituted pyrrole.  
2.3.2.2. Trisubstituted Pyrrole  It was decided that for a trisubstitued pyrrole to be considered for investigation for this project, it should to be commercially available, inexpensive and contain small 
“R” groups, such as methyl or ethyl groups. The pyrrole that fell into this category was 3-ethyl-2,4-dimethyl-1H-pyrrole (68, Figure 51).  
 
Figure 51: 3-ethyl-2,4-dimethyl-1H-pyrrole (68). 
80  Again the reactions conditions developed by Jiao et al.204 were employed and 69 was achieved in a 54% yield (Scheme 21). The product was obtained as red, iridescent crystals.  
 
Scheme 21: Formation of 69. Reagents and conditions: i) Inert atmosphere, 1,2-dichloroethane, 12 h, RT; ii) NEt3, BF3.Et2O, 50 °C, overnight, 54%.  Purification was carried out with flash chromatography using a solvent gradient 100% hexane to 40% ethyl acetate in hexane. A black substance, assumed to be the same as described in section 2.3.2.1., was formed during this reaction and was unable to pass through the frit, therefore a one-pot scale up was not attempted. It was also notable that an NH peak was not present in the 1H NMR spectrum leading to the conclusion that the only product present was 69 and not 69 without coordinated BF2. A mass spectrometric analysis confirmed that the only product consistent with the analytical data was 69 (with Na+). A melting point of 150.5-151.3 °C indicated a high level of purity (Figure 52).           
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Figure 52: Analysis of 69. A: Mass spectrum showing m/z of 69. B: 1H NMR spectrum showing peaks consistent with the presence of product 69. 
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82  In order to scale up the synthesis of 69, for the sake of efficiency it was decided to attempt several reactions in parallel using a carousel. For this to be feasible, the amount of solvent had to be significantly reduced. Since the pyrrole being used only 
had one α-position free, it was postulated that polymerization would be less of a risk, therefore the requirement for a large amount of solvent might not be as necessary as for the reaction involving the unsubstituted pyrrole. A test reaction was set up in a round bottomed flask using a much smaller quantity of solvent and a yield of 40% was achieved. The same reaction conditions and scale were then used for a reaction in a carousel tube. However, after a few minutes of stirring the reaction mixture appeared to undergo a rapid and violent reaction, resulting in the formation of a black solid. It was postulated that this was due to the formation of HCl, which in the tall carousel tube could condense before being expelled by the flow of argon, thus returning to the reaction mixture, setting off a very quick chain reaction of pyrrole polymerization. It was therefore decided that a scale up using this method would be too unsafe and unreliable and scale up attempts were abandoned.  For the next stage, it was necessary to replace the bromine with the malonate group. There were two ways that this could be achieved. The first method that was considered involved synthesizing the malonate then attaching it to the alkyl chain via a substitution process. This would involve methylation of the commercially available di-tert-butyl malonate (70) by treating it with sodium hydride to deprotonate the central carbon, followed by reaction with methyl iodide to access 
71. C-C bond formation using 71 and 69 could then be achieved using potassium iodide to swap the bromine for iodine, followed by the addition of 71 and potassium carbonate. A simple deprotection of the tert-butyl groups using TFA would give access to 73 (Scheme 22).   
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Scheme 22: Proposed route for the synthesis of 73. Reagents and conditions: i) Under argon, NaH, THF, MeI, 3 h, RT; ii) KI, K2CO3, DMF, RT; iii) TFA.  An attempt to synthesize 71 was unsuccessful. The second method that was considered involved substitution of the bromine with the commercially available 
methylated Meldrum’s acid (74) which could later be ring opened to form the malonate.    This was achieved by first stirring 69 with potassium iodide in DMF at RT for 1 h. This would allow halogen exchange to take place; Br on 69 needed to be swapped with I in order to increase reactivity. A test reaction with no potassium iodide was carried out and resulted in no product being formed. A mass spectrum of the reaction mixture proved that a halogen exchange had indeed taken place (Figure 
53). 
84  
 
Figure 53: Mass spectrum proving that halogen exchange had occurred.  
Separately, methylated Meldrum’s acid (74) was treated with potassium carbonate in DMF at room temperature, allowing for a deprotonation of 74 to take place. The mixture containing 69, having undergone halogen exchange, was added to the mixture containing 74 and the combined reaction mixture was then heated to 50 °C and stirred for 48 h. The progress of the reaction was determined by TLC analysis. After aqueous work up, the product was purified by flash chromatography on silica gel using a solvent gradient of 100% hexane to 40% ethyl acetate in hexane. The product was achieved in a good yield of 59% (Scheme 23).  
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Scheme 23: Formation of 75. Reagents and conditions: i) Under argon, 69 and K2CO3 in DMF added to 74 and KI in DMF, 50 °C, 48 h, 59%.   
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Figure 54: Analysis of 75. A: Mass spectrum showing m/z of 75. B: 1H NMR spectrum showing peaks consistent with the presence of product 75. 
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87  The sharp melting point, 187.4 – 189.2°C, indicated a relatively high degree of purity and the 1H NMR spectrum showed there were negligible impurities present (Figure 
54).   
The ring opening of the methylated Meldrum’s acid was achieved by dissolving 75 and lithium hydroxide in a 1:1 mixture of THF and water. The mixture was stirred at room temperature and the reaction monitored by TLC analysis until reaction completion was indicated after 72 h. The solvent was removed and the aqueous reaction mixture was acidified to pH 2 using HCl (1 M). The product could then be extracted. The product was obtained in 25% yield (Scheme 24).  
 
Scheme 24: Formation of 73. Reagents and conditions: i) LiOH, THF-H2O (1:1), 72 h, RT, 25%.   1H NMR spectroscopic analysis showed peaks consistent with the presence of 73 and a mass spectrum confirmed that the m/z of 73 was present (Figure 55).  
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Figure 55: Analysis of 73. A: Mass spectrum showing m/z of 73. B: 1H NMR spectrum showing peaks consistent with the presence of product 73. 
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89  Once the product was obtained it could be tested in cells for its ability to preferentially enter apoptotic cells. At this point it was found that 73 seemed to be fairly stable in solution and could be stored for long periods of time without showing signs of degradation such as discolouration. Dr. Karen Marshall and Professor Louise Serpell investigated the behaviour of 73 using neurons from the hippocampus of a 1-day old rat that were cultured on a layer of astrocytes. The cells 
were treated with a dose of staurosporine (STS) at either 1 μM or 0.5 μM concentration for 5 hours for apoptosis to be induced. 73 was added at 50 μM concentration and the cells were incubated for 30 minutes then observed under a fluorescence microscope.i  
 
Figure 56: Cartoon representation of well plate containing cells treated with STS and/or a fluorescent dye.  To observe how 73 was acting, a picture of the well was taken under normal lighting 
conditions referred to as “brightfield”, then another picture was taken of the same 
                                                        i Experiments and analysis of results completed by K. Marshall, L. Serpell, University of Sussex, 2015, unpublished.  
90  well under UV light. The two pictures were merged and a clear picture of healthy, apoptotic and dead cells along with the fluorescent stain was visible (Figure 57). Annexin was used as a control as a commonly used apoptosis imaging agent.   
 
Figure 57: A composite image showing healthy, apoptotic and dead cells along with the fluorescent apoptotic imaging agent, in this case annexin. The healthy cells are seen as light grey and have taken up none of the annexin. The apoptotic cells have been stained green by annexin. The dead cells appear dark grey and have taken up none of the annexin.   The first wells to be imaged were the positive controls. These wells contained cells that had been treated with STS (1 or 0.5 μM) and stained with annexin to ensure that 
apoptosis had taken place in order to compare the difference between the different 
concentrations of STS. As observed in Figure 58 apoptosis had been induced and it 
appeared that the wells that received the higher dose of STS had a higher proportion 
of cells undergoing apoptosis, as would be expected.   The next set of wells to be imaged were the wells that had been treated with STS and stained using 73 (Figure 59). The wells that received the higher dose of STS again appeared to contain a higher proportion of cells stained with the BODIPY dye than the wells that received a lower dose. However, it also appeared that 73 had started to stain the media which is made up of astrocytes, leading to the conclusion that 73 may not be able to specifically enter cells going through apoptosis. 
91   Lastly, the negative control wells were imaged (Figure 60). These wells contained cells that were not treated with STS. One set of wells was treated with annexin and one set was treated with 73. The cells treated with annexin showed almost no cells undergoing apoptosis, whereas the wells treated with 73 showed some staining. 
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Results of positive controls 
 
Figure 58: Positive control images. Top: cells treated with 1 μM STS; bottom: cells treated with 0.5 
μM STS.  
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Results of treatment with 73 
 
Figure 59: Images of cells treat with 73. Top: cells treated with 1 μM STS; bottom: cells treated with 
0.5 μM STS. 
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Results of negative controls 
  
Figure 60: Negative control images. Top: cells treated with 1 μM STS; bottom: cells treated with 0.5 
μM STS. 
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95  The results from the negative controls led to the conclusion that 73 was not the specific apoptosis imaging agent it was designed to be. However, the apparent differences in the amount of staining in each of the resultant images provided some hope that perhaps there was some degree of specificity and so perhaps the structure could be altered to improve the results. It was therefore hypothesized that the addition of the fluorophore to the ML10 core structure had increased the lipophilicity, which had led to 73 staining the membranes of both healthy and apoptotic cells indiscriminately.  The hypothesis was explored further with the use of Marvin Sketch to calculate the logP of 73 and logP of ML10. It should be noted that when using predictive software that the values obtained are purely an estimation and are taken to be a general guide and not an accurate representation of the true values. When generating a clogP, it is also necessary to take into account the pKa of 73 and the pH of the cell culture medium which was around pH 7. At this pH, the malonate group would likely only be half protonated, which meant analyzing the conjugate base of 73. This provided a space filling diagram along with an evaluation of approximate values for each 
group’s contribution to the overall clogP. In Figure 61 it is shown that the clogP for 
73 had been calculated as 2.17. This was then compared with the clog P of ML10 which was determined by the software to be -1.57 (Figure 62).  
 
Figure 61: Marvin Sketch generated images of 73 for deducing the clogP.    
96  
 
Figure 62: Marvin Sketch generated images of ML10 for deducing the clogP.  Since a lower number indicates a lower degree of lipophilicity this would indicate that there is quite a large discrepancy between the lipophilicity of ML10 and 73. Therefore, structural modifications of 73 were considered in order to lower the clogP and thus optimize the properties of a new series of derivatives. The most obvious way to lower the clogP would be to reduce the carbon chain length.  
 
Figure 63: Marvin Sketch generated clogPs of potential BODIPY-ML10 structures.  From Figure 63 it was apparent that with a trisubstituted pyrrole for the formation of the BODIPY core, the clogP would not be reduced low enough to match that of ML10. These values were compared with comparative structures derived from an unsubstituted pyrrole-based BODIPY core. From Figure 64 it was apparent that pyrrole substituents contribute significantly to the lipophilicity of the structure. Investigations into unsubstituted pyrrole based BODIPY dyes were carried out but hit a dead end (section 2.1.2.3.1.) and so it was decided to investigate commercially available monosubstituted pyrroles (section 2.1.2.3.3.).    
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Figure 64: Marvin Sketch generated clogPs of potential BODIPY-ML10 structures.  Since reducing the carbon chain length would be an easy modification, and since bromoacyl chlorides of varying carbon chain length are commercially available, it was decided to apply the conditions already established for the formation of 73 to developing a small library of BODIPY derivatives using the trisubstituted pyrrole (68). This decision was made as it was unconfirmed how much of an effect, if any, the lipophilicity of a structure would have on the structure’s ability to specifically stain apoptotic cells.   
 
Scheme 25: BODIPY analogues with shorter alkyl chains. Reagents and conditions: i) Inert atmosphere, 1,2-dichloroethane, RT, 12 h; ii) NEt3, BF3.Et2O, 50 °C, overnight, 34% (76). 
98  Bromide 76 was successfully produced in a 34% yield, whilst 77 could not be isolated from the crude reaction mixture (Scheme 25). Attempts to attach the 
methylated Meldrum’s acid (74) to 76 failed (Scheme 26).  
 
Scheme 26: Proposed routes to trisubstituted pyrrole based BODIPY dyes with shorter carbon chain lengths.  
Considering the bulk of the trisubstituted pyrrole and the Meldrum’s acid, it is not unreasonable to assume that a steric clash between the groups could be the reason for the reaction not proceeding. Therefore, it was decided that a less hindered pyrrole should be sought.  
2.3.2.3. Monosubstituted Pyrrole  To overcome the steric hindrance problem, it was decided to investigate the synthesis of an alternative BODIPY series starting from a commercially available monosubstitued pyrrole, 2-methylpyrrole (82, Figure 65).   
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Figure 65: 2-methylpyrrole.  The lipophilicity of the final structures was analyzed by Marvin Sketch to determine their clogP values with varying carbon chain lengths. This indicated that the clogP of the 3,5-dimethyl-BODIPY derivative 85 was almost identical to the clogP of ML10 (Figure 66).  
 
Figure 66: Comparison of clogPs of 85 and ML10.  Based upon these findings, it was decided to proceed with the formation of this BODIPY derivative 85 with a one carbon linking chain (Scheme 27).    
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Scheme 27: Formation of 85. Reagents and conditions: i) Inert atmosphere, 1,2-dichloroethane, RT, 12 h; ii) NEt3, BF3.Et2O, 50 °C, overnight, 20%; iii) Inert atmosphere, 74 and K2CO3 in DMF added to 
83 and KI in DMF, 50 °C, 48 h, 17%; iv) LiOH, THF-H2O (1:1), 72 h, RT.  For step 1 the yield was comparable to the yields achieved when using the unsubstituted pyrrole as a starting material. The melting point of 83, 175.3 – 177.2 °C, suggested a reasonable level of purity, however 1H NMR spectroscopic analysis suggested the presence of some minor impurities (Figure 67).  
 
Figure 67: Analysis of 83. 1H NMR spectrum showing peaks consistent with the presence of product 
83, as well as some minor impurities.  
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101  The yield from step 2 at 17% was much lower than the only other successful 
example of Meldrum’s acid-BODIPY attachment, which proceeded in 59% yield. This could mean that steric interactions between the Meldrum’s acid and the BODIPY core were still affecting the reaction. With a melting point of 210.2 – 213.0°C, the degree of purity seemed to be reasonable, whereas the 1H NMR spectrum of the product indicated the presence of minor impurities (Figure 68).     
 
 
Figure 68: Analysis of 84. 1H NMR spectrum showing peaks consistent with the presence of product 
84, as well as some minor impurities.  
Unfortunately, an attempt to carry out the final step and ring open the Meldrum’s acid resulted in no final product being isolated. This could be due to the fact that this reaction was carried out on a small-scale due to the small yield achieved from step 2, and since the final step might also be a low yielding reaction, any final product made could have been lost during purification.  
2.3.3. Towards a drug-like structure Once tests have been completed using the BODIPY-ML10 fluorescent model, then it would be time to move onto testing small drug-like molecules needed to deliver a 
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102  molecular cargo into apoptotic cells. The molecular cargo in question would contain iodine-131 (131I) due to its ability to destroy tissue by short range beta radiation.   Since the C-I bond is quite a weak bond, it would be necessary to incorporate a ring to provide metabolic stability. Keeping to the theory that lipophilicity plays a role in 
the structure’s ability to preferentially enter apoptotic cells, the clogP of varying chain lengths was considered (Figure 69). Reducing the carbon chain length would not lower the clogP sufficiently to match that of ML10 but the addition of a H-bond acceptor to the ring would result in clogP values that approximate ML10 (Figure 
69).  
 
Figure 69: Results of investigation into clogP of potential structures for drug development.   A method for the synthesis of a similar structure had been developed by Zhu et al. in 2005 to access an intermediate towards the formation of an insecticidal N-substituted sulfoximine.205 Following a similar method in a two-step process, the first step proceeded by the addition of a dimethylated malonate group to 3-chloromethyl-6-chloropyridine by stirring at RT overnight in the presence of potassium tert-butoxide in THF. The solvent was removed from the mixture and the residue triturated with boiling hexane to give the alkylated product 88 as a colourless solid in 41% yield (Scheme 28). 
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Scheme 28: Preparation of 88. Reagents and conditions: i) Under argon, potassium tert-butoxide, THF, RT, overnight, purification by trituration with boiling hexane, 41%.  The second step involved the hydrolysis of the ester groups by adding lithium hydroxide monohydrate in water to 88 in THF. The mixture was left to stir overnight at RT then acidified with HCl to give the product as a colourless solid in 85% yield with no further purification required (Scheme 29).  
 
Scheme 29: Preparation of 89: i) LiOH·H2O in water, THF, RT, overnight, acidify with HCl, 85%.   The final step required halogen exchange to be carried out (Scheme 30). However, since the halogen that needed to be substituted was attached to a pyridine ring, a simple Finklestein reaction was not appropriate. Therefore, another method was sought.   
 
Scheme 30: Attempted halogen exchange of Cl to I using a method developed by Bissember and Banwell.206 A plausible method was found that had been developed by Bissember and Banwell in 2009.206 This method required the addition of acetyl chloride to a stirred mixture 
104  of 89 and sodium iodide in acetonitrile. The mixture was then subjected to microwave irradiation in a microwave reactor and heated for 3 hours at 80 °C. After this time, the mixture was treated with potassium carbonate (10% w/v aqueous solution), sodium sulphite (5% w/v aqueous solution), sodium thiosulfate (saturated aqueous solution) and the aqueous solutions washed with dichloromethane. Unfortunately, no product was recovered by this method, potentially due to the solubilizing effect of the dicarboxylic acid allowing the product to be water soluble. Thus, it was considered that the methyl protecting groups should not be removed until after the halogen exchange.     
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2.4. Future perspectives To finish the library of BODIPY fluorophores it would be necessary to complete the formation of 85 (Scheme 31).   
 
Scheme 31: Proposed reaction scheme for the formation of 85. Reagents and conditions: i) LiOH, THF-H2O (1:1), 72 h, RT.  Once 85 had been made it would be necessary to test it in a cell line, thus proving 
whether or not logP is a factor in the structure’s ability to preferentially enter apoptotic cells. If it was found that 85 was unable to do this then it may well be necessary to abandon this fluorophore project in favour of continuing work on 
developing the radiolabelled “drug-like” molecule, since the fluorophore development was only meant to be a model of how the radiolabelled molecule might behave.   The development of 90 was also not completed during this project. This could be achieved using a procedure developed by Bissember and Banwell (Scheme 32).206  
106  
 
Scheme 32: Proposed scheme for the formation of 90. Reagents and conditions: i) Under argon, potassium tert-butoxide, THF, RT, overnight, purification by trituration with boiling hexane; ii) acetyl chloride, NaI, irradiation at 80 °C for 3 h in a pressure-rated glass vial using a CEM Discover microwave synthesiser; iii) LiOH·H2O in water, THF, RT, overnight, acidify with HCl.  Since mono- and dialkylpyridines do display a weak fluorescence at about 300 nm207, it may be possible to observe 90 under a fluorescence microscope, though since that lies below the range of the on-site fluorescence microscope (section 
2.2.1.), it would be necessary to outsource that part of the project.   As part of future work, it would be prudent to investigate further development of 
90. There are many ways in which the structure could be altered in the event that the molecule didn’t quite do the job it had been designed for. For example, the pyridine ring could easily be swapped for a benzene ring and a variety of solubilizing groups added to the ring to adjust the clogP. In short, a whole library of compounds could be designed to be tested.  
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2.5. Conclusion Due to time constraints, it was not possible to finish all lines of enquiry within this project. There is still plenty of work that could be done to see the project through to completion, including developing a library of small molecules to be tested for their ability to accumulate in apoptotic cells. A lack of a biological collaborator meant that testing of the BODIPY fluorophores would not be possible. It was also found towards the end of the project that a contaminated argon cylinder may have played a role in the low yielding BODIPY reactions, the various side reactions and may explain the difficulty in reproducing results of earlier experiments. It may also be the reason behind the violent reaction described in section 2.2.2.3.2., though this cannot be proven and it is not recommended to try this particular method again.  Briefly, novel BODIPY structures were synthesized with varying levels of success. Through a continued investigation, and perhaps ignoring the goals set out by this thesis, many more novel BODIPYs could be made through the simple variation of starting materials used i.e. pyrroles with varying R groups and different acyl chlorides forming the meso position. Though not novel, 89 is a small molecule with lots of potential to be further developed into, hopefully one day, a therapeutic to assist existing cancer therapies.     
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Chapter 3: Inhibitory tools  
3.1. Background and aims The aim of this project was to further investigate synthetic routes already developed in the Bagley group for the synthesis of the MK2 inhibitor PF-3644022 (33; Figure 
70). This involved testing a new catalyst that it was hoped would aid the formation of the quinoline ring within the molecule and so establish a rapid efficient route to the inhibitor.   
 
Figure 70: PF-3644022.  Studies carried out by the Bagley group and others into the effects of p38 inhibitors in WS cells revealed a reversal of the accelerated ageing phenotype, suggesting the possibility of therapeutic intervention.147,208 However, p38 inhibitors have exhibited poor kinase selectivity and high toxicity.148,209,210 Therefore, as discussed in Chapter 1, it was necessary to consider targeting the downstream kinase MK2. The MK2 inhibitor PF-3644022 (33), which was first developed by Anderson et al. at Pfizer142, exhibited good selectivity for MK2 and nanomolar potency (IC50 5 nM)142,166, though it was found to induce hepatotoxicity in dogs.142,166,174 However, the encouraging preliminary data indicating use of 33 could correct the stressed morphology and increase the  replicative lifespan of WS cells, made a compelling case to improve the synthetic route towards 33 and so facilitate further biological study.211  
3.1.1. Background of PF-3644022 (33) PF-3644022 (33) was first described by Anderson et al. in 2010 as an ATP-competitive MK2 inhibitor and was developed at Pfizer for therapeutic intervention 
109  of rheumatoid arthritis. This was because MK2 knockout mice were shown to be resistant to developing arthritis.160  The authors declared PF-3644022 (33) to be 
“the first MK2 inhibitor described with oral efficacy in both acute and chronic 
models of inflammation”.142 As previously mentioned, 33 was shown to potently inhibit and have good selectivity for MK2 and in streptococcal cell wall induced arthritic mouse models, 33 exhibited good pharmacokinetic properties and efficacy.142  The hit-to-lead investigation into the development of an MK2 inhibitor was started in 2007212, with a high-throughput screen identifying a hit that was then modified to create a series of 2-arylpyridyl pyrroles. Crystallographic analysis of the inhibitors when complexed with both MK2 and CDK2 allowed the researchers to identify areas for modification that would provide the inhibitor with greater selectivity towards MK2, most notably by placing a rigid aryl group at the 2-postion of the quinoline ring. Around the same time, other groups had also been working on developing MK2 inhibitors and had identified carbolines with a fused lactam ring as potentially potent compounds160,165,212,213, leading to a scaffold Pfizer had modified during SAR studies in 2009 to fuse benzothiophene and lactam moieties (Figure 
71).163 The hypothesis was that the 7-methoxy group would form a hydrogen bond to the hinge region (Leu141 backbone NH) and the lactam portion would bind to the conserved catalytic Lys93 and Asp207 in the active site of MK2. During studies to try and improve the kinase selectivity and cell potency, a series of lactam-fused benzothiophenes was produced with an extra aryl group in order to provide a rigid attachment for selectivity in the hinge-binding region.163 This study led to the development of PF-3644022 (33).163  
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Figure 71: Anderson et al.’s combination of MK2 inhibitors which later led to the formation of PF-3644022 (33).163  Anderson et al.’s total synthesis (Scheme 33) started from a commercially-available nitroquinoline 94 that was converted to aminocyanoquinoline 95 by treatment with ethyl cyanoacetate and KOH in DMF. Diazotization converted the amino group to a bromide to provide 96. The bromide was treated with methyl thioglycolate to produce 97 via nucleophilic aromatic substitution and subsequent aminothiophene formation. Diazotization and subsequent substitution converted the amino group of 
97 to bromide 98. The bromide then underwent a Buchwald coupling with (R)-propane-1,2-diamine to produce diazapene 99.  Boc protecting groups were used to doubly protect 99 and the pyridine was oxidized to form N-oxide 100. Treatment with oxalyl chloride and removal of the Boc protecting groups produced intermediate 101, which provided a late stage intermediate for convenient analogue synthesis via Suzuki coupling. The proposal by the Bagley group was to streamline this total synthesis.  
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Scheme 33: Anderson et al. total synthesis of PF-3644022 (33).163 Reagents and conditions: i) ethyl cyanoacetate, KOH, DMF then HCl, ii) NaNO2 then HBr; iii) methyl mercaptoacetate, NaOMe, MeOH; iv) t-BuONO, CuBr2; v) (R)-propane-1,2-diamine, Pd2(dba)3 (5 mol%), (±)-BINAP (10 mol%), Cs2CO3 (2 equiv.) toluene, 110 °C, 24 h, then TFA/CH2Cl2, then NaOMe/MeOH; vi) Boc2O, DMAP, TEA; then 
m-CPBA, vii) (COCl)2, DMF, then HCl; viii) PhB(OH)2, Pd(PPh3)4, Na2CO3, 80 °C.    
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3.2. Synthetic routes  The total synthesis of PF-3644022 (33) was investigated by previous members of the Bagley group with varying degrees of success. Almost all steps in an alternative 8-step process were optimized to give 75–100% yield but the very last step proved to be difficult, with only a 6% yield obtained. Sections 3.2.1–3.2.5 describe the processes developed within the group and section 3.2.6 will discuss efforts made as part of this thesis to improve the yield of the final step for quinoline formation.  
3.2.1. Formation of 5-nitrobenzo[b]thiophene-2-carboxylic acid (106) Bagley et al. hypothesised that PF-3644022 (33) could be prepared from a benzothiophene core motif that could be further functionalized to produce a range of MK2 inhibitors, rather than starting from 6-nitroquiloline as reported by Anderson et al.163,214  
 
Scheme 34: Formation of benzothiophene 106. Reagents and conditions: i) K2CO3, DMF, irradiated at 90 °C for 15 min in a pressure-rated glass vial using a CEM Discover microwave synthesizer; ii) NaOH (1 M), MeOH, irradiated at 100 °C for 3 min in a pressure-rated glass vial (35 mL) using a CEM Discover microwave synthesizer; H2O; HCl (aq).  This rapid route towards a benzothiophene scaffold was developed by Bagley et al. and has been used towards the synthesis of the thieno[2,3-b]pyridine core motif of LIMK1 inhibitors, the benzo[4,5]thieno[3,2-e][1,4]diazepin-5(2H)-one scaffold of MK2 inhibitors and a benzo[4,5]thieno[3,2-d]-pyrimidin-4-one inhibitor of the PIM kinases.174 The annulation based method allowed the highly efficient preparation of 3-halo- and 3-amino-2-substituted benzo[b]thiophenes using microwave irradiation, producing the products in relatively high (>58%) yields.   Previous synthetic routes towards 3-halobenzo[b]thiophenes employed before this study were deemed problematic. For example, direct ring halogenation suffers from the low reactivity of heteroaryl units as well as poor compatibility with functional 
113  groups,215–218 and methods involving the 5-endo-dig halocyclization of ortho-alkynylaryl thiophenol derivatives,219–223 which requires installation of an alkyne by metal-catalyzed cross-coupling followed by cyclization mediated by a halogen-containing electrophile, have a number of inherent disadvantages.   The Bagley et al. method was applied to step (i) and (ii) and yields of 79% and 95% were achieved, respectively (Scheme 34).  
3.2.1.1. Methyl 3-Aminobenzo[b]thiophene-2-carboxylate (107) A method for the rapid synthesis of this core motif was developed in collaboration with Dr. Dwyer, whose goal it was to introduce functionality suitable for subsequent elaboration to the target inhibitor. Using a microwave synthesizer and the conditions and reagents listed in Scheme 35, the results listed in Table 1 were achieved. This method appears to be superior to other routes which rely upon halogenations.  
 
Scheme 35: Formation of benzothiophene 107. Reagents and conditions: i) DMSO, NEt3, microwave irradiation 15 min at 130 °C using a CEM discover microwave synthesizer. Yields: X = F, 65%; X = Br, 23%; X = I, 47%.  
114  
 
Scheme 36: Proposed mechanism for the formation of benzothiophene 107.  
Table 1: Optimization of microwave conditions for synthesis of 107 Entry Methoda X Temp. °C Time (min)b Yield (%)c 1 A F 130 11 56 
2 A F 130 15 65 3 A F 130 30 56 4 B I 130 15 47 5 C Br 130 15 23 
 From Table 1 it is evident that entry 2, using the fluorinated benzonitrile as the starting material, provided the best yield. Therefore, this method was used to test other halogenated benzonitriles with varying degrees of success. This result is to be expected due to the fact it is an SNAr reaction. Due to the electronegativity of fluorine and its ortho postion on the aromatic ring, the transition state is stabilized during 
aSee experimental section for method details. bHold time at the given temperature, as measured by the in-built IR sensor, by modulation of the initial microwave power. cIsolated yield of product 107 after reaction according to Scheme 35, cooling in a stream of compressed air and pouring the reaction mixture into iced water. 
115  the addition stage (the rate determining step), allowing acceptance of electrons followed by elimination of fluoride.224  
3.2.1.2. Methyl 3-Aminothieno[2,3-b]pyridine-2-carboxylate (108) Due to the success of the reaction in Scheme 35 in forming the benzothiophene derivatives for the MK2 inhibitor, the method was applied to a pyridine analogue, which is the core motif of a series of LIMK inhibitors (Scheme 37).   
 
Scheme 37: Formation of thienopyridine 108. Reagents and conditions: i) DMSO, NEt3, microwave irradiation 15 min at 130 °C using a CEM discover microwave synthesizer. Yields: X = F, 66%; X = Br, 51%; X = Cl, 69%   
 
Table 2 shows better yields than the benzothiophene derivatives. This is presumably due to the electronegative nitrogen and delocalization around the ring 
stabilizing the intermediate anion, so the leaving group doesn’t have to be such a good leaving group.224 However, the chloropyridine produced the best yield, though the yields of all three substrates are similar.  
Table 2: Results of microwave method applied to pyridine analogue, 108 Entry Method X Temp. °C Time (min) Yield (%) 1 A F 130 15 66 2 B Br 130 15 51 
3 C Cl 130 15 69 
aSee experimental section for method details. bHold time at the given temperature, as measured by the in-built IR sensor, by modulation of the initial microwave power. cIsolated yield of product 107 after reaction according to Scheme 35, cooling in a stream of compressed air and pouring the reaction mixture into iced water. 
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3.2.2. Formation of 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylate (110)  
 
Scheme 38: Formation of 110. Reagents and conditions: i) anhydrous NaOAc, glacial AcOH, Br2, 55 °C, 27 h; ii) MeI, K2CO3, DMF, 3 h, RT, then NH4Cl (aq.), 87%.  For the synthesis of 110 a procedure originally developed by Mbere et al. was modified.174,225 Mbere et al. described a method for the synthesis of a new ring fused benzo[b]thieno derivative with an embedded nine-membered ring system which was achieved by a ring closing metathesis methodology and catalyzed by a palladium mediated oxidative cyclisation. The modified method, published by Bagley et al. does not require the use of a palladium catalyst.174 The modified method was employed in this project and produced a product yield of 87% (Scheme 38).  
3.2.3. Formation of (R)-methyl 3((2-((tert-butoxycarbonyl)amino)propyl-
amino-5-nitrobenzo[b]thiophene-2-carboxylate (112) 
 
Scheme 39: Formation of 112. Reagents and conditions: i) Cs2CO3, (±)-BINAP, Pd(OAc)2, dry toluene, irradiated at 150 °C, 75 min in a pressure-rated glass vial using a CEM Discover microwave synthesizer by moderating the initial power (200 W); ii) EDCI·HCl, HOBt·H2O, DCM, 0 °C; RT, 30 min; 
117  aq. NH3 (18 M), 0°C; RT, 30 min; iii) BH3•SMe2, THF, Ar, 0 °C; 18 h, RT; ion exchange, SCX-2, MeOH; NH3, MeOH.  The reaction conditions used for the formation of (R)-methyl 3((2-((tert-butoxycarbonyl)amino)propyl-amino-5-nitrobenzo[b]thiophene-2-carboxylate (112) were adapted from the Buchwald-Hartwig N-arylation studies carried out by Queiroz et al. for the coupling of aryl amines and electron-rich and electron-poor 3-halogenated benzo[b]thiophenes. Queiroz et al. developed the palladium catalyzed amination of benzothiphenes.226 Bagley et al. modified the procedure to include microwave irradiation, shortening the reaction times to 1-1.25 h from the 24 h necessary with the conventional heating employed by Queiroz et al.174 whilst achieving similar yields. The amount of base required was also reduced when using microwave irradiation, which reduced the amount of transesterification side products. 112 was achieved in a 70% yield (Scheme 39).   For the formation of (R)-tert-butyl (2-aminopropyl)carbamate (111), there were two possible methods that could be used. The first method for conversion of the carboxylic acid to the amide used a mixed anhydride method and reaction with ethyl chloroformate under basic conditions followed by substitution with ammonia to give amide (111), which when carried out produced a yield of 40% (Scheme 39).227   The second method was based on peptide coupling using EDCI·HCl and HOBt·H2O with DIEA and ammonia followed by a reduction of the amide group using the Lewis acidic borane dimethylsulfide (BH3•SMe2) at 0 °C under an inert atmosphere, which was then allowed to warm to room temperature overnight. Reaction completion was determined by TLC analysis, and the excess BH3•SMe2 was removed under reduced pressure and the residues washed with MeOH to decomplex borane.228 The product (111) was purified by SCX-2 chromatography to give a high yield of 82% (Scheme 
39).   
3.2.3.1. Buchwald-Hartwig N-arylation – palladium catalysis and cyclisation During the mid-1990s, Buchwald and Hartwig simultaneously conducted studies into the use of palladium in forming carbon-heteroatom bonds. Palladium had 
118  already been widely investigated as a successful catalyst for a range of C-C bond forming reactions. The studies conducted by Buchwald and Hartwig showed successful application of palladium catalysts to promote nucleophilic substitution reactions at a vinylic or aromatic centre. Before these studies, it had been necessary to use harsh reaction conditions such as copper-mediated nucleophilic displacement reactions of aryl halides using various nitrogen nucleophiles,229 strongly acidic nitration and subsequent reduction to the aniline, and radical nucleophilic aromatic substitution (SRN1) using alkali metals and ammonia, which could return a mixture of products through benzyne formation.230   However, Buchwald and Hartwig were not the first to carry out studies into using palladium as a catalyst for carbon-heteroatom bond forming reactions; in 1983 Migita et al. used catalytic amounts of PdCl2[P(o-tolyl)3]2 to mediate aryl C-N bond formation and in 1984 Boger and Panek published an intramolecular palladium(0) mediated aryl C-N bond formation in the synthesis of the natural product lavendamycin.231,232 Migita et al. coupled aryl bromides and diethylaminotributyltin and screened a number of palladium complexes and found that catalytic amounts of PdCl2[P(o-tolyl)3]2 was much more efficient than Pd(PPh3)4 or PdCl2(PPh3)2.231 Boger and Panek used stoichiometric amounts of Pd(PPh3)4 in THF for the coupling and cyclisation of a linked aryl amine and aryl bromide, proposing the formation of a 6-membered σ-bonded palladacycle intermediate that resulted in the formation of 
a β-carboline.232  
 
Scheme 40: Migita et al.231 Reagents and conditions: i) PdCl2[P(o-tolyl)3]2 (1 mol%), toluene, 100 °C, Ar, 33-79%.  
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Scheme 41: Boger and Panek.232 Reagents and conditions: i) Pd(PPh3)4 (1.5 equiv.), THF, 80 °C, 21 h, 84%.  The simultaneous publication in 1994 of studies conducted by Buchwald and Hartwig extended the scope of carbon-heteroatom coupling using palladium catalysts. Hartwig et al. noted the similarity between Migita et al.’s studies and Stille coupling; both coupling reactions involving stannanes and halides, the former for C-N bond formation, the latter for C-C bond formation. Hartwig et al. continued with the study of coupling stannanes to halides but set out to identify the active species in the catalytic cycle by isolating intermediates from several stages of the cycle and conducted crystallographic characterization of these intermediates in order to gain insight to the mechanistic pathway. Through these studies, the group was able to isolate and identify the Pd(II) dimer complex [PdArBr(P(o-tolyl)3)]2, which was formed after the oxidative addition of ArBr to Pd0[P(o-tolyl)3].233 They proposed that transmetallation would occur on the monomer or dimer of the complex,233 however a later study by Driver and Hartwig showed that the reductive elimination step proceeds by a dissociative process and forms the three-coordinate species to give the coupled arylamine.234  The studies conducted by Buchwald et al. again recognized the importance of Migita 
et al.’s work and noted the lack of applicability of the route to the general synthesis of arylamines was probably due to the instability of aminostannanes.235 Buchwald 
et al.’s study aimed to extend the scope of Migita et al.’s work in order to apply the method to coupling a wider variety of amines, including primary and secondary alkyl and aryl amines. The group were able to demonstrate that this was possible by an in situ transamination reaction that could be applied more generally. The group also tested other PdCl2L2 catalysts (where L = (PPh3)2, DPPF or Ph2P(CH2)3PPh2) and determined that the original catalyst used by Migita et al. gave superior results. The study also showed that reactions of lithium amides with n-Bu3SnCl in ether, as was 
120  the conventional route to produce aminostannanes, was unsuccessful, possibly due to the production of LiCl or BuLi poisoning the active species. In order to avoid poisoning, in situ generation of aminostannanes was done by reacting an aminostannane derived from a volatile amine with a higher boiling amine in toluene with subsequent removal of the volatile amine by purging the vessel with argon.235   In 1995, Buchwald and Hartwig concurrently published methods for C-N bond formation that were tin free. Whilst tin-mediated methods were high yielding, they required long reaction times and removal of the tin-amide side products, which would pose a problem to the applicability of the methods to the large-scale preparation of arylamines for pharmaceutical purposes due to toxicity. Through the addition of a bulky base, the need for tin was eliminated. Buchwald et al. used a slight excess of sodium tert-butoxide (NaOtBu) alongside [PdCl2(P(o-tolyl)3)] and [Pd(dba)2]/2 P(o-tolyl)3 to couple primary and secondary amines with aryl bromides, followed by an aqueous workup and column chromatography producing pure arylamines.236 Hartwig et al. used lithium silylamide (LiN(SiMe3)2) as a base to successfully produce arylamines, though noted that slower reaction times were achieved with NaOtBu.237 The study also proposed that the mechanism proceeded by addition of the amine to a monophosphine complex after the break-down of the Pd(II) complex, leading to an enhancement of the amine acidity. This would then be followed by deprotonation of the bulky silyl amide base to form the amido complex, which would then rapidly undergo reductive elimination of the arylamine product.237 Scheme 7 shows the widely accepted Buchwald-Hartwig catalytic cycle.238   
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Scheme 42: Buchwald-Hartwig N-arylation proposed catalytic cycle.238  
3.2.4. Formation of (3R)-3-methyl-9-nitro-1,2,3,4-tetrahydro-5H-
[1]benzothieno[3,2-e][1,4]diazepin-5-one (115)  
 
Scheme 43: Formation of 115. Reagents and conditions: i) TFA (10% v/v in DCM), RT, NaOMe in MeOH, 50 °C, 2 h; ii) reflux, 2 h; iii) 0°C, HCl (1 M), 30 min 100%.  For the ring closing reaction to take place, first a general Boc deprotection was carried out by stirring 112 at room temperature overnight with 10% TFA in DCM, with reaction completion confirmed by TLC analysis. The volatile components were then carefully removed. The cyclization step was carried out under basic conditions, as per a procedure detailed by Khatana et al. for similar benzothieno-1,4-diazepin-
122  5-one compounds.239 The reaction mixture was stirred with NaOMe in MeOH and heated to 50 °C for 2 h, then heated to reflux for 2 h. The crude mixture was then poured into iced water and neutralized using 1 M HCl aqueous solution. The product (115) was isolated by vacuum filtration as a red powder in quantitative yield (Scheme 43).  
3.2.5. Formation of (3R)-9-amino-3-methyl-1,2,3,4-tetrahydro-5H-
[1]benzothieno[3,2-e][1,4]diazepin-5-one (116)  
 
Scheme 44: Formation of 116. Reagents and conditions: i) DBU, Mo(CO)6, EtOH, irradiated at 150 °C, 30 min, 92%.   The procedure employed for this step was originally developed by Spencer et al. for the reduction of poly-functionalised nitroaromatic compounds using microwave irradiation, molybdenum hexacarbonyl (Mo(CO)6) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in ethanol.240,241 The reaction is thought to proceed by the formation of metal nitrenes, which are formed when the nitro group is deoxygenated, resulting in the loss of carbon dioxide (CO2) via metal carbonyl mediated carbonylation, leading to the formation of the primary amine by protonolysis of the nitrogen.242 DBU is added as a non-nucleophilic base as it is known to facilitate CO liberation from Mo(CO)6.243  The conversion of nitrobenzothiophene 115 to amine 116 was carried out with one equivalent of Mo(CO)6 and three equivalents of DBU in EtOH in a sealed vessel irradiated at 150 °C at 30 minutes. Amine 116 was purified by flash column chromatography to give the isolated product in high yield (92%, see Scheme 44).    
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3.2.6. Formation of (R)-10-methyl-3-(6-methylpyridin-3-yl)-9-10-11-12-
tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoline-8-one. PF-
3644022 (33) The final step in the total synthesis of PF-3644022 (33) was investigated by previous members of the group with limited success. One of the avenues explored was based on work published by Wang et al. who developed a route to fused quinoline systems via a Doebner type multicomponent reaction (MCR).244–248 A Doebner MCR would usually be carried out using an aniline, a functionalized aldehyde and pyruvic acid, the product of which (a 2-substituted-quinoline-4-carboxylate) can be decarboxylated to give a 2-substituted quinoline.249,250 Instead, Wang et al. used an alkyl aldehyde, butyl vinyl ether (n-BVE) and molecular iodine (10 mol%) as a mild Lewis acid catalyst.251 The proposal was that an alkyl aldehyde should be in equilibrium with the enol form; the enol would immediately react with an I2-activated Schiff base, followed by an intramolecular Friedel-Crafts cyclization, with subsequent dehydration and oxidation producing an aromatized benzo[f]quinoline (Scheme 45). 
 
Scheme 45: Wang et al.’s proposed mechanism for I2-catalysed reaction of a Schiff base and alkyl aldehyde towards benzo[f]quinoline derivatives.251  It was therefore proposed that this system could be adapted for the final step in the synthesis of PF-3644022 (33), using amine 116, 6-methylpyridine-3-carboxaldehyde, n-BVE and a Lewis acid in a one-pot system. A trial system was 
124  developed and investigated by Lorna Brigham, a summer student in the research group. ii  Brigham’s test reaction involved using pyridine-3-carboxaldehyde and aniline (117) to promote cyclization and to test the scope of Wang et al.’s published methods.   
 
Scheme 46: Brigham’s trial multi-component quinoline synthesis. Reagents and conditions: i) pyridine-3-carboxaldehyde, solvent; ii) n-BVE, Lewis acid, Δ, 20 h, or MW 100 °C, 1 h.  Brigham found that a much higher quantity of molecular iodine was required for the reaction to proceed (50 mol%) and produce quinoline 119. Different Lewis acids were also tested but ultimately I2 produced the best results. It was also found that a pre-stir of aniline and aldehyde for 1 h at room temperature was required to first form the Schiff base before the addition of the Lewis acid. This minimized the formation of side products, which otherwise hampered purification techniques. Microwave irradiation also reduced the extent of side product formation.   The project was then handed over to Dr. Dwyer who conducted a solvent screening, leading to a change from Wang et al.’s procedure, which used THF, to MeCN which was found to be the optimum solvent. The modified method was applied to the final step in PF-3644022 (33) synthesis (Scheme 47).214 
                                                        ii Experiments and analysis of results completed by Lorna Brigham, M.C. Bagley, University of Sussex, 2015, unpublished. 
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Scheme 47: Final step in PF-3644022 (33) synthesis. Reagents and conditions: i) MeCN, RT, 1 h; ii) n-BVE, I2 (50 mol%), MW 100 °C, 3 h, 6%.214  
3.2.6.1. Formation of 6-methylpyridin-3-carboxaldehyde (120) The final step in the synthesis towards PF-3644022 (33) required the formation of 6-methylpyridin-3-carboxaldehyde (120). Initially, Dr. Dwyer had tried to oxidize 
121 using Dess-Martin periodinane (DMP) as this is usually a mild and highly efficient method of oxidation; however, on this occasion long reaction times resulted in poor yields. Therefore, Swern oxidation conditions were employed whereby oxalyl chloride was reacted with DMSO in dry DCM at −78 °C, followed by the dropwise addition of 121 and then the addition of NEt3 as base to form the sulfur ylide and facilitate the oxidation. Purification by flash chromatography gave aldehyde 120 in high yield (75%) (Scheme 48).  
 
Scheme 48: Formation of 120. Reagents and conditions: i) (COCl)2, DMSO, NEt3, CH2Cl2, −78 °C, 75%.  
3.2.6.2. A new method for the final step in the synthesis of PF-3644022 (33) Since previous efforts in the Bagley group to carry out the final step in the synthesis of PF-3644022 had only resulted in low yields (6%), the requirement for further investigation was obvious. Since test reactions carried out by Brigham and Bagley had shown promising results it was decided that a new type of Lewis acid catalyst may help improve the yield, since so far only iodine and SnCl2·H2O had been investigated. A new Lewis acid catalyst had been developed at the University of 
126  Sussex by Kostakis et al. This Zn/4f coordination cluster (CC) had been successfully employed in Friedel-Crafts reactions and in the Petasis borono-Mannich multicomponent reaction,252–254 with the full scope of its capabilities yet to be investigated. Therefore, it was of great interest to both the Bagley group and the Kostakis group to apply the catalyst to the Doebner-type MCR of the final step in our synthesis.  
3.2.6.2.1. Isoskeletal tetranuclear Zn/4f coordination cluster as a new catalyst The Kostakis group at the University of Sussex developed an isoskeletal tetranuclear Zn/4f coordination cluster (CC) that had been proven to be a highly efficient catalyst in Friedel-Crafts alkylation of indoles and nitrostyrenes, as well as in the Petasis borono-Mannich multicomponent reaction.252–254 Only a few recent examples of polynuclear CCs, which are made up of organic ligands, transition metals (3d) and/or lanthanides (4f), have been reported as useful catalysts.255–257 However, catalysts that contain zinc or lanthanides have been extensively used in Friedel-Craft reactions.258,259 Having had previous success with a series of isoskeletal CCs catalyzing domino reactions at room temperature,255,260 and with the knowledge that lanthanide and zinc/Schiff base compounds had been used as catalysts in reactions involving indole derivatives with aldehydes and ketones,261,262 the Kostakis group set out to synthesize and test a novel isoskeletal tetranuclear Zn/4f (CC) in the Friedel-Crafts reaction (Scheme 49).  
 
Scheme 49: Friedel-Crafts acylation tested by Kostakis group with novel catalyst.252  The catalyst the group designed is bimetallic, containing zinc and yttrium, and has a rigid, defective, dicubane topology, which remains intact in organic solvents—a feature which allows both metal centers to coordinate to substrates and promote coupling reactions efficiently due to the proximity of the metal centers to one another.252 During a solvent screen it was also found that the catalyst’s mode of 
127  action was homogeneous, because reactions in low polarity solvents yielded no conversion of substrates to products.  
Friedel-Crafts reactions Friedel-Crafts reactions have become some of the most important organic chemistry reactions. They are carbon-carbon bond forming reactions that involve the introduction of an alkyl or acyl group onto an aromatic substrate by treating the substrate with an alkyl halide or alkene for alkylation, or an acyl halide or anhydride for acylation, in the presence of a Lewis acid.   To test the scope of the new catalyst, the Kostakis group chose to synthesize bisindolylmethane via the nucleophilic addition of benzaldehyde to indole. Bisindolylmethane derivatives have shown great promise as pharmacophores; however, the existing catalytic systems and metal salts employed for their synthesis are expensive, and require toxic reagents, high temperatures and high catalytic loadings, and in the case of silver salts, they suffer from photosensitivity.263–266 Therefore there is a need to improve their synthetic process. The indole ring system is a class of heterocyclic subunit found extensively in nature and as such has extensive biological activity, which has been of great interest to the drug development community in the development of scaffolds.267,268    The conditions of the reaction were optimized and found that the optimum reaction time was 12 h and the ideal solvent system was ethanol-water (2:1), though DMF, acetonitrile or ethanol could also be used though with lower yields. The low yields when ethanol had been used indicated that water was needed to promote the reaction.252 At a 2.5 mol% loading, the reactants were converted to the desired product in quantitative yields, and at 1 mol% the product was obtained at a slightly lower yield of 96%, which was still a vast improvement on existing systems.262,264,265 The reaction conditions were then tested further with a variety of aldehydes and substituted indoles, which were reported as achieving excellent yields.252 However, when the reaction conditions were tried using ketones instead of aldehydes, even with longer reaction times and higher temperatures, there was no product formation. Further tests were carried out, reacting indoles with an aliphatic 
128  aldehyde instead of an aromatic aldehyde, which resulted in low yields even after 72 h. The optimized conditions were then applied to the reaction of substituted indoles with benzaldehyde, which had varying success; 2-methyl-indole gave a quantitative yield in only 2 h, but swapping the -CH3 group for the electron withdrawing -CF3 group resulted in only a 16% yield, and reactions with indole-3-acetic acid and N-methylindole resulted in no product formation. This lack of reactivity was postulated by Kostakis et al. to be due to the carboxylic acid group of indole-3-acetic acid being in competition with benzaldehyde to coordinate to the Y centre and that the nitrogen atom, blocked by a -CH3 group in N-methylindole, needed to coordinate to the catalyst in order for the reaction to proceed.  The mechanism proposed by the Kostakis group is shown in Scheme 50. First, the nitrogen atom of the indole coordinates to the Zn(II) centre and the oxygen atom of the aldehyde coordinates to the Y centre. This leads to the indole being deprotonated, leaving a negative charge at C-3 promoting the formation of a benzaldehyde-indole hemiaminal. Another indole is then alkylated and finally a proton exchange leads to the release of the bis-adduct.   
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Scheme 50: Mechanism of Friedel-Crafts alkylation proposed by Kostakis et al.252   The catalyst was also proven to be highly efficient for the conversion of trans‐β‐nitrostyrene and indole to an indolylnitroalkane, with the product being obtained in a 94% yield after 24 h at room temperature using ethanol as a solvent (Scheme 
51).254  
 
Scheme 51: Conversion of trans‐β‐nitrostyrene and indole to an indolylnitroalkane.254 Reagents and conditions: i) EtOH, 24 h, RT, Zn2Y2L4 (1 mol%), 94%. 
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Petasis borono-Mannich multicomponent reaction The Petasis borono-Mannich reaction is a multicomponent reaction (MCR) that involves amines, aldehydes and boronic acids269 to prepare amines and their 
derivatives such as α-amino acids, heterocycles and alkylaminophenols via a Mannich-type condensation.270 MCRs are incredibly useful in organic synthesis as they involve simple starting materials that can be converted into products in fewer steps and in shorter time periods; however, most existing methods still suffer from requiring high catalyst loads, high temperatures and long reaction times.271–281   
 
Scheme 52: Trial reaction carried out by Kostakis et al. to test the scope of the Zn2Y2L4 catalyst.253 Reagents and conditions: i) DME, RT, 12–16 h, Zn2Y2L4  (1 mol%).  A trial reaction was carried out by Kostakis et al. and conditions optimized for the reaction of salicylic aldehyde, indoline and phenylboronic acid (1:1:1) (Scheme 
52).253 The ideal solvent was found to be DME, and catalyst loading was trialled at 1 mol% because of the previous success of this loading in the Friedel-Crafts reaction,252,254 and when carried out at room temperature the reaction resulted in a yield of 74% after 12-16 h.253  
3.2.6.2.2. Results of the application of Zn/4f coordination cluster as a new 
catalyst for the final step in the synthesis of PF-3644022 (33) The catalyst provided for testing by the Kostakis group has the general formula Zn2Y2L4, where L = C21H25NO3 (Figure 72). 
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Figure 72: Simplified structure of Zn2Y2L4 catalyst.  There are two different ways that the ligands coordinate to the metal centres, which is illustrated in Figure 73.  
 
Figure 73: Coordination points of the ligands to the metal centres; two ligands coordinate as per the structure shown on the left with the other two ligands coordinating to the metal centres as per the structure shown on the right.  For the final reaction step the same conditions were employed for testing the new catalyst as were developed by Wang et al. and modified by Dr. Dwyer.251 Since previous publications by Kostakis et al. had reported high catalyst efficiency at quantities as low as 1 mol%,252–254 it was decided that the test reactions would be completed at 1 and 10 mol% catalyst loading. Using the catalyst in 50 mol%, as per the previous attempts using molecular iodine, was deemed inappropriate as the purpose of this investigation was to ascertain whether the catalyst would work in catalytic amounts not stoichiometric, as well as increase the yield from 6%.   
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Scheme 53: Final step in PF-3644022 synthesis. Reagents and conditions: i) MeCN, RT, 1 h; ii) n-BVE (10 mol%), Zn2Y2(C21H25NO3)4 (1 mol%/10 mol%), MW 100 °C, 3 h.  Reactions were run in MeCN at room temperature for 1 h before adding n-BVE and the catalyst, and then the reaction vessels were placed in a microwave reactor for 3 h at 100 °C. TLC analysis showed that there were several species present. Purification by flash chromatography could not cleanly separate the product from the side products formed. Mass spectrometry suggested that the product had been formed; however, the product was not clearly discernible from 1H NMR spectroscopic analysis with the broad peaks indicating that zinc from the catalyst could still be present in the crude product (Figure 74).   
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Figure 74: Analysis of 33. A: Mass spectrum showing mass of 33. B: NMR showing no discernible peaks consistent with the presence of product 33, with broadened peaks suggesting presence of Zn.  Also, the catalyst was not recovered after any of the reactions. From the reaction containing 10 mol% catalyst, a crude yield of 63% was achieved, whilst the reaction containing 1 mol% catalyst had a crude yield of 10%. Because the analysis carried out on the crude products was inconclusive, it is unknown how much, if any, of the 
B 
A 
134  yield was actually the desired product, PF-3644022. Analytical data of both crude products was identical.   A TLC plate indicated the presence of multiple side products which were formed during the reaction, though, despite the mass spectrum, it cannot be assumed that PF-3644022 was one of the products. It could also be possible that the catalyst was not reformed at the end of the reaction and the ligands were present in the crude product, though there appears to be no mass ion peak for the ligand (339.43), the metal complex (308.57) or the catalyst (1717.46).    
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3.3. Future perspectives As has been discussed, the catalyst Zn2Y2L4 has not been fully investigated for its applicability to the Doebner-type MCR described in this chapter. If it is assumed that the product PF-3644022 was made during the reactions described above, then it can also be assumed that those reaction conditions are not optimal for the catalyst. Whilst the reaction conditions that were set by previous group members were adhered to for the sake of a fair comparison of results, these were different conditions to those deemed as optimal when the catalyst had been used previously during the Friedel-Crafts or Petasis borono-Mannich reactions. For instance, solvent screens carried out by Kostakis et al. found that EtOH produced the best results for Friedel-Crafts reactions and DME produced the best results for the Petasis borono-Mannich reaction.   The method of heating could also play a role. For this study microwave-assisted dielectric heating was used but the Kostakis group studies all relied upon conventional heating. Perhaps the catalyst is not suited to microwave irradiation and so conventional heating methods should be tested.  The Kostakis group have also developed several other isoskeletal coordination cluster catalysts, all of which have the formula Zn2Ln2, where Ln=Y, Sm, Eu, Gd, Dy, Tb or Yb. Whilst it may not be possible to test all of these catalysts, some have shown quite promising results (yields >90%) at low catalyst loadings (2.5 and 1 mol%).  It may also be beneficial to investigate other Lewis acids, because investigations by the Bagley group have been somewhat limited.   Also, the Skraup method used by Anderson et al., and suggested by Dr. Dwyer in her doctoral thesis, has yet to be examined. This would require forming the unsubstituted quinoline 99, followed by functionalizing the pyridine ring to the N-oxide 100, which would then be chlorinated to form 101. From there a Suzuki coupling of 101 with 2-methylpyridinyl-5-boronic acid would result in formation of PF-3644022 (Scheme 19).  
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Scheme 54: Alternative route to PF-3644022 proposed by Dr. Dwyer.214 Reagents and conditions: i) glycerol, H2SO4, B(OH)3, Ac2O, Fe2(SO4)3;282 ii) Boc2O, DMAP, NEt3 then mCPBA; iii) (COCl)2, DMF, then HCl; (iv) 2-methylpyridinyl-5-boronic acid, Pd(PPh3)4, Na2CO3, 80 °C.163      
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3.4. Conclusion The results from testing the new catalyst Zn2Y2L4 were unfortunately inconclusive. Though there was a small amount of evidence to support the hypothesis that the product, PF-3644022, was formed during the reaction (mass spectrometry) it was not possible to determine with confidence that this was in fact the case by spectroscopic methods. The amount of product obtained from the reactions containing 10 mol% and 1 mol% catalyst were 19 mg and 3 mg, respectively, making further purification attempts almost impossible. Due to time constraints, it was not possible to carry out the synthetic route again in order to further investigate the catalyst.  Though the results are inconclusive at this time, exploring different catalysts has opened up new collaborations and there is great scope for further work to be explored with this chemistry.    
138  
Chapter 4 – Conclusions  Chapter 2 of this thesis saw the formation of several novel BODIPY compounds (Figure 75).  
 
Figure 75: BODIPY fluorophores synthesized during this project.  To finish the library of BODIPY fluorophores it would be necessary to complete the formation of 85 (Scheme 55). 
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Scheme 55: Proposed reaction scheme for the formation of 85. Reagents and conditions: i) LiOH, THF-H2O (1:1), 72 h, RT.  Once 85 has been made it would be necessary to test its properties in a cell line, thus 
proving whether or not logP is a factor in the structure’s ability to preferentially enter apoptotic cells. If it was found that 85 did not specifically target apoptotic cells then it would be necessary to instead focus work on developing the radiolabelled 
“drug-like” molecule, since the fluorophore development was only meant to provide a model and evidence on how the radiolabelled molecule might behave.   The development of 90 was also attempted in this thesis, though not realized. It is thought that this could be achieved using a procedure developed by Bissember and Banwell (Scheme 56).206   
Scheme 56: Proposed scheme for the formation of 90. Reagents and conditions: i) Under argon, potassium tert-butoxide, THF, RT, overnight, purification by trituration with boiling hexane; ii) acetyl 
140  chloride, NaI, irradiation at 80 °C for 3 h in a pressure-rated glass vial using a CEM Discover 
microwave synthesiser; iii) LiOH·H2O in water, THF, RT, overnight, acidify with HCl.  It would be necessary to establish a good procedure for the development of 90 before the project can be handed to a collaborator proficient in handling radioactive material for the insertion of iodine-131. It would also be prudent to develop a library of small molecules, perhaps by further investigating the development of 90 in a trial and error process of finding the most stable combination of structures, rings and solubilizing groups to adjust for the clogP. Whilst it may be possible to still observe the structures behaviour under a fluorescence microscope (mono- and dialkylpyridines display a weak fluorescence at about 300 nm207), the limitations of on-site equipment would make it necessary to outsource this part of the project.  
 Chapter 3 of this thesis set out to investigate the catalyst Zn2Y2(C21H25NO3)4 for its applicability to the Doebner-type MCR that would lead to the formation of PF-3644022 (33).   
 
Scheme 57: Final step in PF-3644022 synthesis. Reagents and conditions: i) MeCN, RT, 1 h; ii) n-BVE (10 mol%), Zn2Y2(C21H25NO3)4 (1 mol%), MW 100 °C, 3 h.  It was not conclusively proven that PF-3644022 (33) was in fact made during the reactions described in Scheme 57 but it has been assumed that these reaction conditions were not optimum for this catalyst. Whilst the reaction conditions that were set by previous group members were adhered to for the sake of a fair comparison of results, none of the optimum reaction conditions used during the employment of the catalyst during the Friedel-Crafts or Petasis borono-Mannich reactions were retained. Solvent screens carried out by Kostakis et al. found that 
141  EtOH produced the best results for Friedel-Crafts reactions and DME produced the best results for the Petasis borono-Mannich reaction and it would sensible to involve a solvent screen during a full test of this catalyst.  The Kostakis group also reported on several other isoskeletal coordination cluster catalysts they had developed, all of which have the formula Zn2Ln2, where Ln is Y, Sm, Eu, Gd, Dy, Tb and Yb. Whilst it may not be possible to test all of these catalysts, some have shown quite promising results (yields >90%) at low catalyst loadings (2.5 and 1 mol%) and may find application in the formation of quinoline synthesis.  A method suggested by Dr. Dwyer in her doctoral thesis has yet to be examined – the Skraup reaction would mimic methods developed by Anderson et al.163 This would require forming the unsubstituted quinoline, followed by functionalizing the pyridine ring to the N-oxide which would then be chlorinated. From there a Suzuki coupling would result in PF-3644022 (Scheme 58).  
 
Scheme 58: Alternative route to PF-3644022 proposed by Dr. Dwyer214 Reagents and conditions: i) glycerol, H2SO4, B(OH)3, Ac2O, Fe2(SO4)3;282 ii) Boc2O, DMAP, NEt3 then mCPBA; iii) (COCl)2, DMF, then HCl; (iv) 2-methylpyridinyl-5-boronic acid, Pd(PPh3)4, Na2CO3, 80 °C.163    
142  
Chapter 5 – Experimental  All procedures were completed in air unless otherwise stated. Commercially available reagents were used throughout without purification unless otherwise stated, with solvents dried by standard procedures. Analytical thin layer chromatography was carried out using aluminium-backed plates coated with Merck TLC Silicagel 60 F254. Plates were visualised under UV light (at 254 and/or 360 nm), and/or with ninhydrin and potassium permanganate solutions. Microwave-assisted reactions were carried out using a CEM DiscoverTM, CEM Explorer at the given 
temperature using the instrument’s in-built IR temperature measuring device, by varying the irradiation power (initial power given in parentheses). Column chromatography was carried out on a Biotage Isolera Prime flash purification system. SCX-2 ion exchange chromatography was carried out using Biotage Isolute  SPE SCX-2 flash columns. Fully characterised compounds were chromatographically homogeneous. Melting points were determined using a Stanford Research Systems Optimelt and are uncorrected. IR spectra were recorded in the range 4000-600 cm-1 using a Perkin Trans FT-IR Spectrum. NMR spectra were recorded using a Varian VNMRS instrument operating at 600, 500 or 400 MHz. J values were recorded in Hz and multiplicities were expressed in the usual conventions. ESI mass spectra were obtained using a Bruker Daltonics Apex III, with ESI source Apollo ESI, using methanol as the spray solvent. For EI mass spectra a Fissons VG Autospec instrument was used at 70 eV and were captured by Dr. Alla K. Abdul-Sada of the University of Sussex Mass Spectroscopy Centre.    
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Chapter 2 
3,3'-disulfanediylbis(2-(5-(dimethylamino)naphthalene-1-
sulfonamido)propanoic acid) (26) 
 Chemical formula: C30H34N4O8S4 Mr: 706.87   According to a procedure developed by Shirvan et al.126 L-cystine (96 mg, 0.4 mmol) and potassium carbonate (221 mg, 1.6 mmol) was dissolved in a solution of water and acetone (50/50). Dansyl chloride (270 mg, 1 mmol) was added and the mixture stirred for 1.5 h at RT. After this time, the acetone was removed under reduced pressure and the remaining solution acidified to pH 3 with citric acid (2 M). The solid was filtered under vacuum and dried in air to give the title compound (280 mg, 99%) as a pale yellow solid, mp. 133.6 – 134.2 °C (Found (ES+): 707.1338. C30H35N4O8S4 [MH] requires 707.1332); IR (neat) νmax/cm-1 3681.8, 3569.8, 3074.4, 1720.7, 1574.7, 1452.9, 1323.9, 1144.5, 923.9, 785.4, 626.2, 587.5, 576.5; 1H NMR (500 MHz, DMSO-d6) δH/ppm 12.81 (s, 2H, NH), 8.53 (d, 2H,  J = 8.5), 8.43 (d, 2H, J = 8.4), 8.25 (d, 2H, J = 8.2) 8.10 (d, 2H, J = 8.0), 7.52 (m, 4H), 7.23 (d, 2H, J = 7.2), 3.85 (m, 2H), 2.82 (s, 12H, 4CH3), 2.77 (m, 2H); 13C NMR (126 MHz, DMSO-d6) δC/ppm: 171.5, 151.7, 136.7, 129.9, 129.6, 129.5, 128.7, 128.1, 123.7, 119.9, 115.4, 55.3, 45.5. One quaternary carbon not visible.   
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General Procedure for BODIPY Synthesis  Following a procedure developed by Jiao et al.283 under inert atmosphere, bromo-acyl chloride (1 equiv.) in THF (1 mL) was added dropwise to a mixture of freshly distilled pyrrole (10 equiv.) in 1,2-dichloroethane (100 mL). NEt3 (5 equiv.) was added followed by BF3.Et2O, the mixture was heated to 50 °C and left to stir overnight. Reaction mixture was concentrated under reduced pressure and diluted with DCM. Organic layer washed with water, dried over Na2SO4 and solvent removed. Purification by flash chromatography.   
10-(5-bromopentyl)-2,8-diethyl-5,5-difluoro-1,3,7,9-tetramethyl-5H-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide (69)        Chemical formula: C22H32BBrF2N2 Mr: 453.21  Purified by flash chromatography on SiO2 (dry load), gradient eluting from hexane to hexane/ethyl acetate (80:20) to give the title compound (243.19 mg, 54%) as red crystals, mp. 150.5 – 151.3 °C; (Found (ESI+): 475.1695 C10H10ClNO4Na [MNa] requires 475.1702) 1H NMR (500 MHz, CDCl3) δ 3.44 (t, J = 6.6 Hz, 2H, 13-CH2), 3.02 
– 2.99 (m, 2H, 9-CH2), 2.49 (s, 6H, 19/21-CH3), 2.40 (q, J = 7.6 Hz, 4H, 14/16-CH2), 2.33 (s, 6H, 18/20-CH3), 1.96 – 1.91 (m, 2H, 12-CH2), 1.69 – 1.64 (m, 4H, 10/11-CH2), 1.05 (t, J = 7.6 Hz, 6H, 15/17-CH3); 13C NMR (126 MHz, CDCl3) δ 152.2 (α-C), 144.2 (meso-C), 135.5 (7α-C), 132.6 (β-C), 130.8 (1-C), 33.4 (CH2), 32.3 (CH2), 30.8 (CH2), 28.5 (CH2), 28.3 (C), 17.2 (CH2CH3), 14.8 (CH2CH3), 13.4 (CH3), 12.4 (CH3); m/z (EI) 452 (M•, 87%), 454 (83), 408 (100), 500 (66), 287 (87), 393 (47).   
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10-(3-bromopropyl)-2,8-diethyl-5,5-difluoro-1,3,7,9-tetramethyl-5H-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide (76)  
  Chemical formula: C20H28BBrF2N2 Mr: 425.16  Purified by flash chromatography on SiO2 (dry load), gradient eluting from hexane to hexane/ethyl acetate (80:20) to give the title compound (286 mg, 34%) as a red solid, mp. 203.4 – 205.1°C; 1H NMR (500 MHz, CDCl3) δ 3.81 (t, J = 6.0 Hz, 2H, 11-CH2), 3.14 – 3.06 (m, 2H, 9-CH2), 2.50 (s, 6H, 17/19-CH3), 2.39 (t, J = 7.6 Hz, 4H, 12/14-CH2), 2.34 (s, 6H, 16/18-CH3), 1.90 – 1.87 (m, 2H, 10-CH2), 1.04 (t, J = 7.6 Hz, 6H, 13/15-CH3). 13C NMR (126 MHz, CDCl3) δ 152.2 (α-C), 144.3 (meso-C), 135.7 (7α-
C), 132.6 (β-C), 130.9 (1C), 62.6 (CH2), 34.4 (CH2), 25.0 (CH2), 17.2 (CH2CH3), 14.8 (CH2CH3), 13.4 (CH3), 12.4 (CH3); m/z (EI) 312 (M•, 21%), 313 (17), 311 (5), 232 (100), 231 (97), 94 (91) 211 (61), 206 (52), 203 (49) 69 (51).  
10-(5-bromopentyl)-5,5-difluoro-5H-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-4-ium-5-uide (58)        Chemical formula: C14H16BBrF2N2 Mr: 341.00 
146  Purified by flash chromatography on SiO2 (dry load), gradient eluting from hexane to hexane/ethyl acetate (90:10) to give the title compound (256.5 mg, 43% mixed products. Yield of 58 9%) as a red sticky solid, (Found (ES+): 341.0624 C14H16BBrF2N2 [MH] requires 341.0631); 1H NMR (500 MHz, CDCl3) δ 7.06 – 7.04 (m, 2H, 3/5-CH), 6.94 – 6.92 (m, 2H, 1/7-CH), 6.28 (dt, J = 4.3, 2.5 Hz, 2H, 2/6-CH), 3.42 (t, J = 6.7 Hz, 2H, 13-CH2), 2.80 (d, J = 7.4 Hz, 2H, 9-CH2), 2.39 (s, 2H, 12-CH2), 1.93 – 1.86 (m, 2H, 10-CH2), 1.51 (dt, J = 8.8, 3.8 Hz, 2H, 11-CH2); 13C NMR (126 MHz, CDCl3) δ 190.8 (α-C), 178.3 (meso-C), 131.8 (7α-C), 124.8 (β-C), 116.5 (1-C), 110.7 (CH2), 37.6 (CH2), 33.6 (CH2), 32.3 (CH2), 27.6 (CH2).  
10-(3-bromopropyl)-5,5-difluoro-5H-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-4-ium-5-uide (60)  
 Chemical formula: C12H12BBrF2N2 Mr: 312.95  Purified by flash chromatography on SiO2 (dry load), gradient eluting from hexane to hexane/ethyl acetate (90:10) to give the title compound (197 mg, 18%) as a dark orange sticky solid; (Found (ESI+): 312.0215 C12H12BBrF2N2 [MH] requires 312.0239); 1H NMR (500 MHz, CDCl3) δ 7.04 (m, 4H, 1,3,5,7-CH), 6.30 (m, 2H, 2/6-CH), 2.45 (m, 2H, 11-CH2), 1.19 (m, 2H, 9-CH2), 0.96 (m, 2H, 10-CH2); 13C NMR (126 MHz, CDCl3) δ 190.5 (α-C), 132.7 (meso-C), 124.3 (7α-C), 116.04 (β-C), 110.77 (1-C), 27.81 (CH2), 17.11 (CH2), 10.70 (CH2).      
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10-(bromomethyl)-5,5-difluoro-5H-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-4-ium-5-uide (62)  
 Chemical formula: C10H8BBrF2N2 Mr: 284.90  Purified by flash chromatography on SiO2 (dry load), gradient eluting from hexane to hexane/ethyl acetate (90:10) to give the title compound (150 mg, 15%) as a dark orange solid, mp 115.8 – 118.9 °C; 1H NMR (500 MHz, CDCl3) δ 7.85 (s, 2H, 3/5-CH), 7.31 (d, J = 4.2 Hz, 2H, 1/7-CH), 6.57 – 6.52 (m, 2H, 2/6-CH), 2.64 (s, 2H, 9-CH2); 13C NMR (126 MHz, CDCl3) δ 143.6 (α-C), 128.2 (meso-C), 118.1 (7α-C), 91.7 (β-C), 88.4 (1-C), 16.3 (CH2).  
10-(bromomethyl)-5,5-difluoro-3-(1H-pyrrol-2-yl)-5H-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-4-ium-5-uide (63) 
 
 Chemical formula: C14H11BBrF2N3 Mr: 349.97  Purified by flash chromatography on SiO2 (dry load), gradient eluting from hexane to hexane/ethyl acetate (90:10) to give the title compound (130 mg, 11%) as a purple solid, mp 124.6 – 130.9 °C; 1H NMR (500 MHz, CDCl3) δ 10.48 (s, 1H, NH), 7.60 (s, 1H, 3-CH), 7.34 (d, J = 4.7 Hz, 1H, 9-CH), 7.16 (d, J = 3.5 Hz, 1H, 10-CH), 7.03-
148  6.99 (m, 2H, 1/7-CH), 6.91 (d, J = 4.7 Hz, 1H, 11-CH), 6.49 – 6.44 (m, 1H, 6-CH), 6.40-6.36 (m, 1H, 2-CH), 2.54 (s, 2H, 12-CH2).  
10-(Bromomethyl)-5,5-difluoro-3,7-dimethyl-5H-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-4-ium-5-uide (83) 
 
 Chemical formula: C12H12BBrF2N2 Mr: 312.95  Purified by flash chromatography on SiO2 (dry load), gradient eluting from hexane to hexane/ethyl acetate (60:40) to give the title compound (125 mg, 20%) as a dark red solid, mp. 175.3 – 177.2 °C; 1H NMR (500 MHz, CDCl3) δ 7.17 – 7.10 (m,  2H, 2/6-CH), 6.33 – 6.26 (m, 2H, 1/7-CH), 4.61 (s, 2H, 9-CH2), 2.61 (s, 6H, 10/11-CH3); 13C NMR (126 MHz, CDCl3) δ 159.4 (α-C), 135.7 (meso-C), 134.2 (7α-C), 127.2 (β-C), 120.1 (1-C), 37.7 (CH2), 15.2 (CH3); .m/z (EI) 312 (M•, 70%), 268 (92), 233 (100), 213 (93).   
General Procedure for Attachment of Methylated Meldrum’s Acid to BODIPY Under an inert atmosphere, methylated Meldrum’s acid (1 equiv.) and potassium carbonate (1 equiv.) was dissolved in DMF. To this was added a solution of BODIPY (1 equiv.) and KI (1 equiv.) dissolved in DMF. The mixture was heated to 50 °C and stirred for 48 h. Mixture was washed with water and extracted with EtOAc. Organic extracts were combined and washed with brine, dried over Na2SO4 and solvent removed in vacuo. Purified by recrystallization from hexane.    
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2,8-diethyl-5,5-difluoro-1,3,7,9-tetramethyl-10-(5-(2,2,5-trimethyl-4,6-
dioxo-1,3-dioxan-5-yl)pentyl)-5H-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-
4-ium-5-uide (75) 
 
       Chemical formula: C29H41BF2N2O4 Mr: 530.45  (310.5 mg, 59%) as a red solid, mp. 187.4 – 189.2°C ; (Found (ES+): 553.3017  C29H41BF2N2O4Na [MH] requires 553.3020); 1H NMR (500 MHz, CDCl3) δ 2.97 – 2.92 (m, 2H, 13-CH2), 2.49 (s, 6H, 22/24-CH3), 2.42 – 2.36 (m, 4H, 17/19-CH2), 2.31 (d, J = 6.6 Hz, 6H, 15/16-CH3), 2.06 – 2.03 (m, 2H, 12-CH2), 1.73 (s, 6H, 21/23-CH3), 1.63 (s, 3H, 14-CH3), 1.59 – 1.57 (m, 2H, 9-CH2), 1.50 – 1.41 (m, 2H, 10-CH2), 1.34 – 1.24 (m, 2H, 11-CH2), 1.04 (t, J = 7.5 Hz, 6H, 18/20-CH3); m/z (EI+): 530 (M⁺, 69), 428  (100), 413 (20), 287 (26).   
5,5-difluoro-3,7-dimethyl-10-((2,2,5-trimethyl-4,6-dioxo-1,3-dioxan-5-
yl)methyl)-5H-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide (84) 
 
 Chemical formula: C19H21BF2N2O4 
150  Mr: 390.19 
 (20 mg, 17%) as a dark red solid, mp. 210.2 – 213.0 °C; 1H NMR (500 MHz, CDCl3) δ 7.10 (d, J = 4.1 Hz, 2H, 2/6-CH2), 6.26 (d, J = 4.1 Hz, 2H, 1/7-CH2), 2.60 (s, 6H, 13/14-CH3), 2.48 (s, 3H, 10-CH3), 1.59 (s, 2H), 1.46 – 1.23 (m, 6H, 11/12-CH3).  
 
General Procedure for Ring Opening Meldrum’s Acid BODIPY (1 equiv.) and LiOH (4 equiv.) dissolved in THF-H2O (1:1) mixture and stirred for 72 h at r.t. Mixture concentrated under reduced pressure and residue dissolved in water and extracted with ether. Aqueous layer acidified to pH 2 with HCl (1 M) and extracted with EtOAc. Organic layers were combined and dried over Na2SO4 and solvent removed. Residue dissolved in basic water, washed with ether and reacidified to pH 2 and extracted with EtOAc.  
10-(6,6-dicarboxyheptyl)-2,8-diethyl-5,5-difluoro-1,3,7,9-tetramethyl-5H-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide (73)         Chemical formula: C26H37BF2N2O4 Mr: 490.39  to give the title compound (49.04 mg, 25%) as a red solid, mp. 150.1-152.2 °C (Found (ESI+): 513.2722 C26H37BF2N2O4Na [MH] requires 513.2707); 1H NMR (500 MHz, DMSO-d6) δ 12.59 (s, 2H, OHOH), 3.01 – 2.95 (m, 2H, 13-CH2), 2.41 – 2.37 (m, 10H, overlapping 15/17-CH2 and 20/22-CH3), 2.33 (s, 6H, 19/21-CH3), 1.76 – 1.70 (m, 2H, 9-CH2), 1.57 – 1.54 (m, 2H, 12-CH2), 1.51 – 1.46 (m, 2H, 10-CH2), 1.31 – 1.26 (m, 2H, 11-CH2), 1.25 (s, 3H, 14-CH3), 1.00 (t, J = 7.5 Hz, 6H, 16/18-CH3).  
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Dimethyl 2-((6-chloropyridin-3-yl)methyl)-2-methylmalonate (88) 
 
 Chemical formula: C12H14ClNO4 Mr: 271.70  According to a procedure developed by Zhu et al.205 under argon, potassium tert-butoxide (450 mg) in THF (10 mL) was added dropwise to dimethyl malonate (0.6 mL) and stirred at RT for 10 min. 3-Chloromethyl-6-chloropyridine (650 mg) was added and the mixture stirred overnight at RT. The mixture was then poured into water (40 mL) and extracted with diethyl ether (3 x 20 mL). The organic extracts were combined, washed with brine (1 x 30 mL) and dried over MgSO4, filtered and the solvent was removed in vacuo and the residue triturated with boiling hexane. Hexane was decanted from the insoluble oil, the extracts combined and solvent removed en vacuo to give the title compound (448.1 mg, 41%) as a white solid, mp. 84.1 – 86.0°C (Found (ES+): 272.0690 [MNa] requires 294.0504); 1H NMR (500 MHz, CDCl3) δH/ppm 8.16 (s, 1H, CH), 7.46 – 7.44 (m, 1H, CH), 7.25 – 7.23 (m, 1H, CH), 3.73 (d, J = 1.3 Hz, 6H, CH3), 3.19 (s, 2H, CH2), 1.37 (s, 3H, CH3); 13C NMR (126 MHz, CDCl3) 
δ 171.82, 151.12, 149.45, 140.54, 130.83, 124.58, 54.71, 37.93, 20.04. 
 
2-((6-Chloropyridin-3-yl)methyl)-2-methylmalonic acid (89) 
 
 Chemical formula: C10H10ClNO4 Mr: 243.64  According to a procedure developed by Zhu et al.205 lithium hydroxide monohydrate (220 mg) in water (2 mL) was added to 2-[(6-chloropyridine-3-yl)methyl]-2-methyl 
152  malonate (400 mg) in THF (3 mL) and the mixture was stirred overnight at RT. Mixture was poured into water (15 mL) and pH adjusted to <2 with HCl. Mixture extracted with diethyl ether, organic extracts combined, washed with water and dried over MgSO4, filtered and solvent removed in vacuo to give the title compound ( 310.3 mg, 85%) as a white solid, mp. 82.7 – 84.0°C (Found (ESI+): 244.0368 C10H10ClNO4 [MH] requires 244.0371); 1H NMR (500 MHz, DMSO-d6) δ 13.00 (s, 2H), 8.18 (s, 1H), 7.64- 7.62 (m, 1H), 7.44 – 7.41 (m, 1H), 3.06 (s, 2H), 1.14 (s, 3H).); 13C NMR (126 MHz, DMSO-d6) δ 165.27, 142.45, 133.25, 124.14, 115.53, 110.50, 46.07, 
29.09, 10.82; m/z (EI+): 245 (M•+, 19), 234 (56), 128 (40), 126 (100). 
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Chapter 3 
Methyl 3-Aminobenzo[b]thiophene-2-carboxylate (107) 
    Chemical formula: C10H9NO2S Mr: 207.25 
 
Method A A solution of 2-fluorobenzonitrile (0.16 mL, 1.5 mmol), DMSO (0.75 mL), methyl thioglycolate (0.135 mL, 1.5 mmol) and triethylamine (0.63 mL, 4.5 mmol) was irradiated in a pressure-rated glass tube (10 mL) for 15 min at 130 °C using a CEM discover microwave synthesiser. The reaction mixture was cooled in a stream of compressed air then poured into ice water and stirred for 5 min. The solid was vacuum filtered, washed with water until the filtrate was colourless and dried in air to give the title compound (203 mg, 65%) as a purple solid.  
Method B A solution of 2-iodobenzonitrile (34.0 mg, 1.5 mmol), DMSO (0.75 mL), methyl thioglycolate (0.135 mL, 1.5 mmol) and triethylamine (0.63 mL, 4.5 mmol) was irradiated in a pressure-rated glass tube (10 mL) for 15 min at 130 °C using a CEM discover microwave synthesiser. The reaction mixture was cooled in a stream of compressed air then poured into ice water and stirred for 5 min. The solid was vacuum filtered, washed with water until the filtrate was colourless and dried in air to give the title compound (148 mg, 47%) as a purple solid. 
 
Method C A solution of 2-bromobenzonitrile (27.0 mg, 1.5 mmol), DMSO (0.75 mL), methyl thioglycolate (0.135 mL, 1.5 mmol) and triethylamine (0.63 mL, 4.5 mmol) was irradiated in a pressure-rated glass tube (10 mL) for 15 min at 130 °C using a CEM discover microwave synthesiser. The reaction mixture was cooled in a stream of compressed air then poured into ice water and stirred for 5 min. The solid was 
154  vacuum filtered, washed with water until the filtrate was colourless and dried in air to give the title compound (72 mg, 23%) as a purple solid.  
Analysis mp 107.6–107.8 °C (MeOH–H2O) (lit.284 mp 110–111) (Found [ES+]: 208.0434. C10H10NO2S [MH] requires 208.0432); IR (neat) νmax/cm-1 3434 (N-H), 3337 (N-H), 1659 (C=O), 1520, 1289 (C-O), 1257, 1127, 1064, 756, 738; 1H NMR (500 MHz, DMSO-d6) δH/ppm 8.13 (1H, d, J = 8.1 Hz, 4-CH), 7.82 (1H, d, J = 8.1 Hz, 7-CH), 7.50 (1H, m, 6-CH), 7.39 (1H, m, 5-CH), 7.15 (2H, bs, NH2), 3.78 (3H, s, Me); 13C NMR (101 MHz, DMSO-d6) δC/ppm 164.8 (C=O), 149.8 (3-C), 138.8 (7α-C), 131.4 (3α-C), 128.5 (6-CH), 123.8 (5-CH), 123.1 (4-CH), 123.1 (7-CH), 94.4 (2-C), 51.2 (Me); m/z (EI) 207 (M•+, 93%), 176 (30), 175 (100), 147 (34), 146 (37).  
Methyl 3-Aminothieno[2,3-b]pyridine-2-carboxylate (108) 
    Chemical formula: C9H8N2O2S Mr: 208.24  
Method A 2-chloro-3-pyridinecarbonitrile (34.64 mg, 0.25 mmol), DMSO (1 mL), methyl thioglycolate (0.22 mL, 0.25 mmol) and triethylamine (0.10 mL, 0.75 mmol) was irradiated in a pressure-rated glass tube (10 mL) for 15 min at 130 °C using a CEM discover microwave synthesiser. The reaction mixture was cooled in a stream of compressed air then poured into ice water and stirred for 5 min. The solid was vacuum filtered, washed with water until the filtrate was colourless and dried in air to give the title compound (36 mg, 69%) as a yellow solid.  
Method B 2-fluoro-3-pyridinecarbonitrile (30.5 mg, 0.25 mmol), DMSO (1 mL), methyl thioglycolate (0.22 mL, 0.25 mmol) and triethylamine (0.10 mL, 0.75 mmol) was 
155  irradiated in a pressure-rated glass tube (10 mL) for 15 min at 130 °C using a CEM discover microwave synthesiser. The reaction mixture was cooled in a stream of compressed air then poured into ice water and stirred for 5 min. The solid was vacuum filtered, washed with water until the filtrate was colourless and dried in air to give the title compound (34 mg, 66%) as a yellow solid. 
 
Method C 2-bromo-3-pyridinecarbonitrile (45.8 mg, 0.25 mmol), DMSO (1 mL), methyl thioglycolate (0.22 mL, 0.25 mmol) and triethylamine (0.10 mL, 0.75 mmol) was irradiated in a pressure-rated glass tube (10 mL) for 15 min at 130 °C using a CEM discover microwave synthesiser. The reaction mixture was cooled in a stream of compressed air then poured into ice water and stirred for 5 min. The solid was vacuum filtered, washed with water until the filtrate was colourless and dried in air to give the title compound (27 mg, 51%) as a yellow solid. 
 
Analysis mp 191 °C (dec.) (lit.285 mp 194–196 °C) (Found [ES+]: 209.0380. C9H9N2O2S [MH] requires 209.0385); IR (neat) νmax/cm-1 3417 (N-H), 3314, 3202, 2943, 1679 (C=O), 1291 (C-O), 1127 (C-O), 755 (C-H), 738 (C-H), 712 (C-H); 1H NMR (500 MHz, DMSO-
d6) δH/ppm 8.68 (1H, dd, J = 4.6, 1.6 Hz, 6-CH), 8.54 (1H, dd, J = 8.1, 1.6 Hz, 4-CH), 7.46 (1H, dd, J = 8.1, 4.6 Hz, 5-CH), 7.30 (2H, bs, NH2), 3.80 (3H, s, Me); 13C NMR (101 MHz, DMSO-d6) δC/ppm 164.7 (C=O), 159.7 (7α-C), 150.7 (6-CH), 147.7 (3-C), 131.4 (4-CH), 125.5 (3α-C), 119.4 (5-CH), 93.2 (2-C), 51.4 (Me); m/z (EI) 208 (M•+, 100%), 177 (28), 176 (93), 148 (60).   
Methyl 5-nitrobenzo[b]thiophene-2-carboxylate (105)  
  Chemical Formula: C10H7NO4S Mr: 237.23 
156  A mixture of 2-chloro-5-nitrobenzaldehyde (1.50 g, 8.0 mmol), methyl thioglycolate (0.90 mL, 10 mmol) and K2CO3 (1.34 g, 9.6 mmol) in DMF (9.0 mL) was irradiated at 90 °C for 15 min in a pressure-rated glass vial (35 mL) using a CEM Discover microwave synthesizer. After cooling in a flow of compressed air, the mixture was poured into water and the solid filtered off under reduced pressure. Solid was washed with water and dried in air to give the title compound (1.5 g, 79%) as an off-white solid, mp 214.3-216.1 °C (lit286 211-212); 1H NMR (500 MHz, CDCl3) δH/ppm 8.79 (d, J = 2.2 Hz, 1H), 8.31 (dd, J = 8.9, 2.2 Hz, 1H), 8.19 (d, J = 0.9 Hz, 1H), 8.00 (dt, J = 8.9, 0.8 Hz, 1H), 3.99 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 162.4, 147.5, 146.1, 
138.5, 137.4, 130.8, 123.7, 121.3, 121.1, 53.1. (Me); m/z (EI+): 237 (M•+, 100), 206 (75), 160 (41).  
5-Nitrobenzo[b]thiophene-2-carboxylic acid (106)  
  Chemical Formula: C9H5NO4S Mr: 223.21  A mixture of methyl 5-nitrobenzo[b]thiophene-2-carboxylate (1.0 g, 4.2 mmol), aqueous NaOH solution (1M; 12.5 mL) and MeOH (17.5 mL) was irradiated at 100 °C for 3 min in a pressure-rated glass vial (35 mL) using a CEM Discover microwave synthesizer. After cooling in a flow of compressed air, the reaction mixture was poured into water and acidified with 1M HCl. The solid was filtered under reduced pressure, washed with water and dried in air to give the title compound ( 889 g, 95%) as an off-white powder, mp 241.8 - 243.2 °C, (lit.287 239-241); 1H NMR (500 MHz, Methanol-d4) δ 8.84 (d, J = 2.2 Hz, 1H), 8.26 (dd, J = 9.0, 2.3 Hz, 1H), 8.20 (s, 1H), 8.11 (d, J = 9.0 Hz, 1H); 13C NMR (126 MHz, CD3OD) δ 164.7, 148.8, 147.3, 140.1, 139.79, 131.9, 124.9, 122.2, 121.7, 49.5, 49.3, 49.2, 49.0, 48.8, 48.7, 48.5; m/z (EI+): 
223 (M•+, 100), 177 (29), 89 (27).   
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3-Bromo-5-nitrobenzo[b]thiophene-2-carboxylic acid (109)  
  Chemical Formula: C9H4BrNO4S Mr: 302.10  According to a modified procedure,225 to a mixture of 5-nitrobenzo[b]thiophene-2-carboxylic acid (500 mg, 2.25 mmol) and anhydrous NaOAc (565 mg, 6.5 mmol) in glacial AcOH (14 mL), bromine (0.7 mL, 13.5 mmol) was added dropwise under an inert atmosphere. The solution was refluxed at 55 °C for 27 h. The solution was allowed to cool to RT then poured into iced water and the solid isolated by vacuum filtration and dried in air to give the title compound (591 mg, 87%) as an off white solid, mp 308.4 – 310.5 °C (lit.215 307-309); 1H NMR (500 MHz, Methanol-d4) δ 8.79 (d, J = 2.2 Hz, 1H), 8.36 (dd, J = 8.9, 2.2 Hz, 1H), 8.18 (d, J = 8.9 Hz, 1H).; m/z (EI+): 
303 (MBr •⁺, 100), 301 (M79Br •+, 94), 273 (18), 257 (30), 223 (26).  
Methyl 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylate (110)  
  Chemical Formula: C10H6BrNO4S Mr: 316.13  
From 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylic acid  According to a modified procedure,225,288 iodomethane (0.2 mL, 3.22 mmol) was added to a solution of 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylic acid (500 mg, 1.66 mmol) and K2CO3 (575 mg, 4.15 mmol) in DMF (7.5 mL) and the solution stirred for 3 h at RT. The solution was quenched with NH4Cl (sat.aq.), poured into 
158  water and filtered under reduced pressure. Solid washed on filter paper with water and air dried to give the title compound  (485 mg, 92%) as an off-white powder, mp 210.2-212.3 °C (lit.215 211-212); 1H NMR (500 MHz, CDCl3) δ 8.88 (d, J = 2.1 Hz, 1H), 8.37 (dd, J = 9.0, 2.1 Hz, 1H), 7.99 (d, J = 8.9 Hz, 1H), 4.01 (s, 3H).); 13C NMR (126 MHz, CDCl3) δ 161.1, 146.6, 144.8, 139.0, 131.1, 123.9, 122.3, 121.5, 115.8, 77.4, 77.4, 77.2, 76.9, 53.2; m/z (EI+): 317 (M81Br •⁺, 100), 286 (67), 284 (65).  
(R)-Methyl 3-((2-((tert-butoxycarbonyl)amino)propyl)amino)-5-
nitrobenzo[b]thiophene-2-carboxylate (112)   
  Chemical Formula: C18H23N3O6S Mr: 409.46  According to a modified procedure,226 under argon, tert-butyl([2R]-1-aminopropan-2-yl)carbamate (131 mg, 0.75 mmol) was added to a mixture of methyl 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylate (200 mg, 0.6 mmol), Cs2CO3 (261 mg, 0.8 mmol), (±)-BINAP (37 mg, 0.06 mmol) and Pd(OAc)2 (1.8 mg, 8.0 µmol) in dry toluene (4 mL). Mixture irradiated at 150 °C for 75 min in a pressure rated glass vial (10 mL) using a CEM Discover microwave synthesizer by moderating the initial power (200 W). After cooling in a flow of compressed air, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 x 30 mL). The organic extracts were combined, washed with brine, dried over Na2SO4, filtered and the solvent removed in vacuo. Purification by flash chromatography on SiO2, gradient eluting with pet. Ether 40/60 to diethyl ether (50:50) to give the title compound (160 mg, 65%) as a red solid, mp 179.3-181.5 °C, (Found [ESI+]: 432.1207 C18H24N3O6SNa [MNa] requires 432.1200); 1H NMR (500 MHz, DMSO-d6) δ 3.81 (s, 3H), 3.78 – 3.71 (m, 1H), 3.56 (dt, J = 13.7, 7.3 Hz, 1H), 1.31 (s, 9H), 1.11 (d, J = 6.6 
159  Hz, 3H), 8.97 (d, J = 2.1 Hz, 1H), 8.30 (dd, J = 8.9, 2.0 Hz, 1H), 8.17 (d, J = 9.0 Hz, 1H), 7.58 (s, 1H), 6.91 (d, J = 8.1 Hz, 1H); 13C NMR (126 MHz, DMSO-d6) δ 163.7, 154.6, 150.2, 146.7, 144.4, 135.4, 124.8, 121.7, 120.6, 117.3, 87.8, 51.8, 50.6, 46.3, 40.1, 40.2, 28.1, 18.4.   
(3R)-3-Methyl-9-nitro-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-
e][1,4]diazepin-5-one (115)  
  Chemical Formula: C12H11N3O3S Mr: 277.30  According to a modified procedure,239,289 a solution of (R)-methyl 3-((2-((tert-butoxycarbonyl)amino)propyl)amino)-5-nirtobenzo[b]thiophene-2-carboxylate (100 mg, 0.24 mmol) in TFA (10% v/v in DCM) (2 mL) stirred at RT until salt formation confirmed by TLC (Rf 0.3; MeOH-DCM [10:90]), then volatiles removed in 
vacuo. Residue dissolved in a solution of NaOMe (25 wt. % in MeOH; 0.3 mL, 1.5 mmol) in MeOH (2 mL) then heated to 50 °C for 2 h, then heated to reflux for 2 h. The mixture was allowed to cool to RT then cooled in an ice bath and neutralized by addition of HCl (1M) and stirred for 30 min at 0 °C. Solid isolated by vacuum filtration, washed on the filter paper with water and allowed to air dry to give the 
title compound (65 mg, 98%) as a red powder, mp 330.8-343.1 (dec.); 1H NMR (500 MHz, DMSO-d6) δ 9.04 (d, J = 2.2 Hz, 1H), 8.22 (dd, J = 8.8, 2.2 Hz, 1H), 8.05 (d, 1H), 8.00 (d, J = 4.6 Hz, 1H), 3.64 – 3.57 (m, 1H), 3.38 (d, J = 4.3 Hz, 2H), 1.16 (d, J = 6.7 Hz, 3H), 13C NMR (126 MHz, DMSO-d6) δ 164.2, 145.4, 144.3, 141.8, 132.9, 123.9, 120.9, 118.6, 108.6, 50.7, 47.6, 18.6; m/z (EI+): 277 (M, 100), 262 (M-CH3, 26), 234 (31), 206 (26).   
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(3R)-9-Amino-3-methyl-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-
e][1,4]diaepin-5-one (116)  
  Chemical Formula: C12H13N3OS Mr: 247.32  According to a modified procedure,240 in a pressure-rated glass vial (10 mL), DBU (0.1 mL, 0.7 mmol) was added to a solution of (3R)-3-mehtyl-9-nitro-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one (60 mg, 0.22 mmol) and Mo(CO)6 (58 mg, 0.22) in ethanol (3 mL). The mixture was irradiated at 150 °C for 30 min using a CEM Discover microwave synthesizer by moderating the initial power (300 W). After cooling in a flow of compressed air the volatiles were removed in vacuo. Purification by flash chromatography on SiO2 gradient eluting with DCM to MeOH-DCM (10:90) to give the title compound (51 mg, 94%) as a brown solid, mp 150.8-161.1 °C (dec.) (Found [ESI+]: 248.0860. C12H14N3OS [MH] requires 248.0852); 1H NMR (500 MHz, DMSO-d6) δ 7.60 (d, J = 4.5 Hz, 1H), 7.37 (d, J = 8.5 Hz, 1H), 7.14 (t, J = 4.4 Hz, 1H), 6.98 (d, J = 2.1 Hz, 1H), 6.79 (dt, J = 8.5, 1.7 Hz, 1H), 5.04 (s, 2H), 3.53 (q, J = 6.1 Hz, 1H), 3.31 (d, J = 4.7 Hz, 2H), 1.13 (d, J = 6.7 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 164.8, 145.4, 141.2, 134.1, 126.7, 122.7, 117.1, 106.6, 104.9, 50.9, 47.7, 18.6.  
tert-Butyl ([2R]-1-aminopropan-2-yl)carbamate (111)  
  Chemical Formula: C8H18N2O2 Mr: 174.24 
161  According to modified procedures,290,291 at  0 °C EDCI.HCl (1.16 g, 6.0 mmol) was added to a solution of Boc-D-Ala-OH (1.0 g, 5.3 mmol) and HOBt.H2O (0.8 g, 6.0 mmol) in CH2Cl2 (40 mL). The solution was allowed to warm to RT and stirred for 30 min then cooled back down to 0 °C for aqueous NH3 solution (18.1 M; 1.2 mL) to be added drop-wise and stirred for 30 min whilst being allowed to warm to RT. Resulting solids were removed by filtration under reduced pressure and the filtrate was washed with water (2 x 20 mL) and brine (3 x 30 mL), dried over MgSO4, filtered and evaporated in vacuo. Under Ar at 0 °C a solution of BH3•SMe2 in THF (2 M; 27 mL, 54 mmol) was added portion-wise to a solution of (R)-tert-butyl-(1-amino-1-oxopropan-2-yl)carbamate (1 g, 5.4 mmol) in dry THF (18 mL). The reaction mixture was stirred for 18 h once it had been allowed to warm to RT. The reaction mixture was concentrated in vacuo and the residue treated with MeOH (3 x 20 mL), stirring and concentrating to dryness in vacuo. Purification by SCX-2 ion exchange chromatography, gradient eluting with MeOH to 2 M NH3 in MeOH, gave the title compound (0.75 g, 81%) as a colourless oil, (Rf 0.3; MeOH-CH2Cl2 [10:90]); (Found [ESI+]: 174.1598. C8H18N2O2 [MH] requires 174.1601); 1H NMR (500 MHz, CDCl3) δ 4.77 (d, J = 8.4 Hz, 1H), 3.64 – 3.55 (m, 1H), 2.69 (dd, J = 13.0, 4.9 Hz, 1H), 2.58 (dd, J = 13.0, 6.5 Hz, 1H), 1.39 (s, 9H), 1.07 (d, J = 6.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 155.9, 79.3, 77.4, 76.9, 48.7, 47.5, 28.5, 18.6; m/z (EI+): 174 (M•, 12), 173 (67), 86 (93), 58 (100). 
 
6-Methylpyridine-3-carboxaldehyde (120) 
 
 
 Chemical Formula: C7H7NO Mr: 121.14  Under argon at -78 °C, DMSO (1 mL) in dry DCM (7 mL) was added dropwise over a period of 20 min to a solution of COCl2 (3.5 mL, 7 mmol) in dry DCM (12 mL) and the mixture stirred for 20 min. Over a period of 20 min (6-Methylpyridin-3-yl)methanol 
162  (400 mg, 3.25 mmol) in dry DCM (3 mL) was added dropwise to the mixture. Triethylamine (5 mL, 36 mmol) was added dropwise over a period of 10 min and the solution stirred while being allowed to warm to RT for 30 min. The solution was poured into water (30 mL), extracted with DCM (2 x 30 mL), the organic extracts combined, dried over Na2SO4, filtered and the solvent removed in vacuo. Purification by flash chromatography on SiO2, gradient eluting from ethyl acetate/hexane (50:50) to ethyl acetate/hexane (70:30) to give the title compound  (295 mg, 75%) as a brown oil, 1H NMR (500 MHz, CDCl3) δ 10.06 (s, 1H), 8.94 (d, J = 2.1 Hz, 1H), 8.06 (dd, J = 8.1, 2.1 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 2.66 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 190.7 (CHO), 165.1, 152.2, 136.0, 129.4, 123.9, 25.2 (Me); m/z (EI+): 121 
(M•+, 72), 120 (52), 92 (100). Data matches literature values.292,293     
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Appendix  
Neuron cultures (plated on an astrocyte feeder layer) Note the following: 
• All solution volumes are enough for 24 wells of cells plated in 24 well plates (8 wells each in 3 plates – see step I)  
• Astrocytes will be required as a feeder layer for neurons. Therefore, on the initial dissection plate astrocytes only. It will take approx. 14 days for a T25 to become confluent. Once astrocytes are plated on coverslips (step II), neurons can be prepared 
• Pregnant rats are delivered fortnightly on a Tuesday, along with a litter of P1 pups. The pregnant rat will deliver her pups the following Monday, normally around midday. Thus, dissections can only be carried out on a Monday, Tuesday, or at the latest early Weds (for rats delivered on Tuesday only). Bear this in mind when planning out the procedure 
• Make up fresh media every week and HBSS on the day of dissection.   
Media/Reagents required (prepare just before use) Stock concentrations given in brackets  
20 μg/ml Poly-D-lysine (Sigma/cat no.) 
• 125 μl PDL (4 mg/ml – dissolved in sterile water and stored at -20 C in 5ml tubes) 
• 24 ml sterile water       Astrocyte media Hippocampal (neuron) media   BME (1X)  43 ml 45.5 ml Glucose (45 %) 440 μl  440 μl FCS 5 ml 1 ml Na-pyruvate (100 mM) 500 μl  500 μl HEPES (1 M, pH 7.35) 500 μl  500 μl Pen/Strep (100X)  500 μl  500 μl 
180  B27 (50X)  -  1 ml Glutamax (100X) -  500 μl  Hanks Balanced salt solution (HBSS) (for dissection) 
• 1.5 ml HBSS (containing calcium and magnesium) (10X) 
• 150 μl HEPES (1 M, pH 7.35) 
• 13.5 ml H2O  HEPES buffer solution (100X/1 M)  
• Make up from powder and pH to 7.3 with NaOH  Ara-C (Company/cat. No.) 
• 13 μl Ara-C (stock conc.5mM) 
• 7.5 ml hippocampal media (from above)  
Procedure I. Preparation of PDL coated plates (day 0 - Wed)   1. Add around 0.5 ml sterile water to the outer 16 wells in a sterile 24 well plate (helps prevent evaporation of media) 2. Sterilise coverslips in IMS, take out and allow to dry then place in the middle 8 wells using sterilised tweezers 3. Add 1 ml PDL to each of the 8 wells. Make sure no coverslips are floating, if they are gently push down with tweezers 4. Incubate overnight at 37C (if you forget, you can incubate for around 4h before plating astrocytes)  II. Plating astrocytes on PDL coated coverslips (day 1 - Thurs)  1. Aspirate PDL from coverslip. Add ~1 ml sterile water to wash and aspirate. Allow to dry while preparing astrocytes 2. Astrocytes should be confluent in a T25. Wash with sterile 1x PBS 
181  3. Trypsinise with 1 ml trypsin (the entire aliquot) and leave at RT until detached. Check the cells are shrunken on the microscope and gently return to hood. Aspirate residual trypsin then add 2 ml of astrocyte media, bash flask, check cells are dislodged and transfer to 15ml tube. Triturate (~30times)  4. Add 200-300 ul cell suspension (perhaps even less ~150 if you want to have just astro islands, which is better for imaging) to 17.3-17.2 ml astrocyte media (17.5 ml needed). Add 0.7 ml of diluted cell suspension to each well.  5. Label plates with todays date and the date on the flask that contained the astrocytes. Ensure no coverslips are floating. Return the remaining cell suspension to T25 and add 5-6ml of astro media. Label the flask with the date when it was used.   III. Dissection (day 6 - Tues)  
Bench preparation  1. Turn on the water bath to 37C (always on in our lab) and warm hippocampal and astrocyte media  2. Bring plenty of ice in ice bucket and keep the following on ice: Petri dish, sterile Pasteur pipette, 15 ml sterile polypropylene tube with ice cold HBSS and dissection kit 3. Clean the work bench and dissecting microscope thoroughly with Dettol 4. Take out all the instruments from sterile container, wipe with Dettol and let them air dry completely before use 5. Add most but not all (leave around 2 ml) ice cold and sterile dissection medium (HBSS) in petri dish and leave on ice  
Protocol 1. Keep animal covered during transport from room 4.04 to prep room (4.34) 2. Kill the P0-P1 rats by cervical dislocation using a blunt instrument and remove the head 3. Dissect the skull cap with forceps and scissors cutting above the ear towards the nose through the eye on both sides. Holding down the nose, gently peel 
182  back the skull. Remove the brain at the olfactory bulb and ensure it is detached all the way round before gently scooping out with a spatula and place in the petri dish containing ice cold HBSS. Keep petri dish on ice. The tissue must be always kept submerged in the dissection medium. (Alternatively, to open up the skull, cut the skin with the scalpel through the middle. Cut the skull through the middle and make diagonal cuts with the curved scissors more or less at the level of olfactory bulbs. Remove two halves of the skull will the forceps.)  4. Cut the brain in half and move to the microscope. Dissect out the hippocampus by firstly making a horizontal cut along the bottom, then up along the curved edge and finally rolling out the hippocampus. Ensure most of the cortex and all meninges and patches of blood vessels are removed (BE TIMELY). Once clean, using the Pasteur pipette move the hippocampus to the 15 ml tube containing the remaining HBSS and keep on ice. Repeat for other side of the brain. 5. Clean work area and tools thoroughly 6. In the hood, gently remove HBSS with a sterile transfer pipet, leaving hippocampi at the bottom of the tube 7. Gently add 2 ml hippocampal medium. Remove and repeat x3 to wash. On the 4th addition, leave the media in the tube. Transfer the contents of this tube to a fresh tube to ensure no traces of HBSS remain 8. Dissociate the cortices thoroughly by gently triturating up and down with a 1 ml pipette until no lumps remain. Avoid making any bubbles 9. Count the total number of cells: Put 10 µl of cell suspension in an eppendorf. In another eppendorf add 2.5 ul trypan blue to 7.5 ul media then add this 10 ul to the 10 ul of cells, mix them well, leave for 30 seconds to ensure deads cells pick up the trypan and load 10 ul onto a Neubauer chamber slide. Count number of live (white) cells in each corner square (each comprised of 16 smaller squares).  10. Work out the average number per corner square and calculate total number of cells per ml using the formula (avg. no. cells in one corner square x 2 (dilution factor) x 10,000 (volume conversion factor)).  
183  11. Work out how much cell suspension to add per well in the 24 well plate if plating 40,000 cells/well in a total volume of 0.7 ml made up with hippocampal media.   For example, if plating 25 wells (8 wells in 3 plates + 1 extra) will need a total of 1,000,000 cells. If you have e.g. 700,000 cells/ml then you need 1.43 ml of cell suspension and 16.07 ml of hippocampal media (0.7 x 25 = 17.5 ml less 1.43 = 16.07 ml).   Remove the media already on the cells (the astro media) Add 0.7 ml of this diluted cell suspension to each well onto the astrocyte feeder layer. The no. of cells plated may change depending on application and density required. Plate the remaining cells in a T25 in astrocyte media (400-500 ul per flask + 6 ml media)  IV. Ara-C (day 8 - Thurs) 1. Remove 200 μl media and replace with 300 μl hippocampal media containing ara-c to curb glial cell proliferation  Neurons will mature in 12-14 days from plating. Check your cells after about a week. They will still be quite young, but you should clearly see established neuronal networks. Monitor the colour of the media, do partial exchange (200-300ul) if media appears quite yellowish.   
26 April 2016 ML10 experiment Cells: Neurons from the hippocampus of a 1-day old rat, cultured in media on a layer of astrocytes.  Treated with staurosporine (1 uM or 0.5 uM) for 5 hours to induce apoptosis – lower concentration was intended to slow down the process to capture early events.  Final concentration of ML10 = 50 uM Incubation time = 30 min 
184  Positive control was Kinetic Apoptosis kit from Abcam – marks apoptotic cells, similar to Annexin (green)   Green brightness setting in FIJI 10/200, ML10 10/100 Two examples of each are shown 10x dry objective  
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Microwave-assisted synthesis of 3-aminobenzo[b]-
thiophene scaﬀolds for the preparation of kinase
inhibitors†
Mark C. Bagley,*a Jessica E. Dwyer,a Maria D. Beltran Molina,b Alexander W. Rand,a
Hayley L. Randa and Nicholas C. O. Tomkinsonb
Microwave irradiation of 2-halobenzonitriles and methyl thioglycolate in the presence of triethylamine in
DMSO at 130 °C provides rapid access to 3-aminobenzo[b]thiophenes in 58–96% yield. This transform-
ation has been applied in the synthesis of the thieno[2,3-b]pyridine core motif of LIMK1 inhibitors, the
benzo[4,5]thieno[3,2-e][1,4]diazepin-5(2H)-one scaﬀold of MK2 inhibitors and a benzo[4,5]thieno[3,2-d]-
pyrimidin-4-one inhibitor of the PIM kinases.
Introduction
Benzothiophenes are naturally-occurring heterocycles, found
in petroleum deposits in their simplest form but also discov-
ered recently as a motif in more complex glycosides isolated
from the roots of E. grijissii.1 Benzothiophenes are important
components of organic semiconductors due to their potential
for elongated and highly delocalised electronic structures.2,3
Substituted benzothiophenes have also found application in
drug discovery as highly-privileged structures and valuable
building blocks in medicinal chemistry, being incorporated
into tubulin polymerisation inhibitors,4,5 acetyl-CoA carboxy-
lase inhibitors,6 antidepressants,7 and as estrogen receptor
modulators.8,9 Benzothiophenes are present in a number of
clinical agents, including Raloxifene,10 a selective estrogen
receptor modulator, Zileuton,11 an inhibitor of 5-lipoxygenase
and leukotriene biosynthesis used for the treatment of
asthma, and the antifungal agent Sertaconazole, which inhi-
bits the synthesis of ergosterol.12
Scaﬀolds based upon 2- or 3-aminobenzo[b]thiophenes
have enormous potential for further derivatization and have
shown great promise in fragment-based drug discovery and in
hit identification or lead development, including approaches
towards antimitotic agents5,13 and in the development of
inhibitors of kinase targets, such as the LIMK protein family,14
PIM-kinases15 and MAPK-2 kinase (MK2) (Fig. 1).16,17 A
number of 3-aminothieno[2,3-b]pyridine-2-carboxamide hits,
such as 1, were identified from high throughput screening
(HTS) as inhibitors of LIMK1, leading to the development of
tricyclic derivatives such as 2a and the benzothieno[3,2-d]pyri-
Fig. 1 Aminobenzothiophene scaﬀolds in drug discovery.
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c5ob00819k
aDepartment of Chemistry, School of Life Sciences, University of Sussex, Falmer,
Brighton, East Sussex, BN1 9QJ, UK. E-mail: m.c.bagley@sussex.ac.uk
bWestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde,
Glasgow, G1 1XL, UK
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midine 2b as a LIMK1 inhibitor lead candidate, to disrupt
actin polymerisation and thus prevent the metastatic potential
of tumour cells where LIMK is over-expressed.14
Benzothienopyrimidinones have been investigated as PIM
kinase inhibitors.15 The PIM kinases (PIM1, PIM2 and PIM3)
have been implicated in tumourigenesis and simultaneous tar-
geting of all three isoforms has presented itself as a promising
approach in cancer therapy, with PIM triple knockout mice
found to be viable and fertile.18 The benzothiophene scaﬀold
was again identified from an initial HTS hit,15 leading to the
development of a range of potent and selective benzo[b]thio-
phene-derived inhibitors such as 3 with nM activity (Ki values
of 2, 3 and 0.5 nM against PIM1, PIM2 and PIM3, respectively)
with oral bioavailability in mouse models.
Examples of aminobenzothiophene derivatives are also
found amongst inhibitors of the mitogen activated protein
kinase (MAPK) family of enzymes. These enzymes are essential
for inflammatory cell signalling events and contain historically
popular drug targets for inflammatory diseases, including
rheumatoid arthritis and Crohn’s disease because of their
involvement in the production of pro-inflammatory cyto-
kines,19 as well as being implicated in accelerated cellular
ageing in Werner syndrome (WS) via p38.20–23 MAPK-activated
protein kinase (MK2) is a rate-limiting kinase downstream of
p38 in the MAPK pathway and has been the subject of many
studies in recent years,24 as MK2 knock-out mice possess
normal healthy phenotypes whereas p38 knock-out mice are
lethal.25 The aminobenzo[b]thiophene derivative PF-3644022
shows excellent kinase selectivity for MK2, in vivo potency on a
nanomolar scale and projected ADME characteristics that
suggested it was suitable for oral human dosing.17,26,27 However,
PF-3644022 was found to result in hepatotoxicity in dogs27 and
so the analogue PF029 was developed and exhibited an improved
toxicological profile with no loss of cellular potency. This was
rationalized through installation of a metabolic shunt onto the
reactive diazepinone ring and extension of the biaryl ring section
to increase the compound’s cationic character, thus reducing its
molecular aﬃnity for transporter proteins.
As part of our interest in the synthesis of MAPK inhibitors
for the study of cellular ageing in Werner syndrome,20,28–33 the
benzothiophene scaﬀold, and its selectivity and cellular activity
profile for MK2 exemplified by PF-3644022, made it an attractive
target for synthesis. We have shown that treating young WS cell
cultures with p38 MAPK inhibitors can bring about a complete
reversal of the ageing phenotype, giving increased replicative
life-span, growth rates comparable to normal young cells and a
reduction in levels of F-actin stress fibres.20,23 These findings
suggested that WS could be amenable to therapeutic interven-
tion, but with high toxicity and poor kinase selectivity exhibited
in vivo by many p38 inhibitors,34–36 an inhibitor scaﬀold that
targeted the downstream kinase MK2 would oﬀer a promising
alternative target.20,37
With such a range of biological properties, there is a conti-
nuing interest in the search for new methods to access substi-
tuted benzothiophenes.38 One approach, with the potential to
incorporate diversity into a target library, would be to employ
transition metal-mediated processes from the corresponding
3-halobenzo[b]thiophenes.39 However, methods for the syn-
thesis of 3-halobenzo[b]thiophenes are currently fairly limited.
In particular, routes can be problematic when using ring halo-
genation due to the low reactivity of the heteroaryl unit and its
functional group compatibility.40–43 The 5-endo-dig halocyclisa-
tion of ortho-alkynylaryl thiophenol derivatives oﬀers an
alternative approach,44–48 but this requires installation of an
alkyne by metal-catalyzed cross-coupling followed by cyclisa-
tion, mediated by a halogen-containing electrophile, so can
exhibit a number of inherent disadvantages.
Herein, we present an annulation-based method for the
rapid preparation of 3-halo and 3-amino-2-substituted benzo-
[b]thiophenes suitable for elaboration to a range of kinase
inhibitors.49 It employs microwave irradiation as a convenient
platform for fast reaction kinetics, and to improve reaction
eﬃciency, and avoids the need for metal-catalyzed processes to
establish the parent heterocycle. This method is shown to be
suitable to access the pharmacophore of a range of biologi-
cally-active scaﬀolds for application in medicinal chemistry
and drug discovery.
Results and discussion
The benzothiophene-containing chemotypes appearing in
recent drug discovery programmes (Fig. 1) feature, or could in
principle be derived from, electron-poor aminobenzothio-
phene intermediates or their 7-aza analogues (Scheme 1). For
Scheme 1 Benzothiophene precursors to kinase inhibitors.
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example, the PIM kinase inhibitor scaﬀold 4 has been
accessed from 5-bromobenzothiophene 5a, using the halogen
as a handle for library diversification in a late-stage Suzuki
coupling.15 Similarly, it could be hypothesized that inhibitors
of MK2 for study in WS cells, such as PF-3644022 (Fig. 1),
could be prepared from the same core motif 5, using 5-nitro-
benzothiophene 5b, rather than by the functionalization of
6-nitroquinoline as reported by Anderson et al.17 This
approach would enable the synthesis of a range of diverse
chemical tools from a single common template. The original
route to MK2 hit compound 6a, prior to the development of
PF-3644022,16 employed cinnamic acid 8a in reaction with
thionyl chloride in chlorobenzene at 120 °C to establish the
3-chlorobenzothiophene scaﬀold 7a (Scheme 1).50 Unfortu-
nately this route would be wholly inappropriate for the syn-
thesis of benzothiophene 7b for elaboration to the desired
intermediate 6b on route to PF-3644022, as altering the substi-
tuent-directing eﬀects to a nitro group results in poor yields
and inseparable mixtures of 7b and 7c in the benzothiophene
synthesis, as well as giving other side products, as reported by
Higa.51 Hence an alternative route had to be sought.
Our first approach towards scaﬀold 6b used an alternative
and established method to access 3-halobenzothiophenes by
halogenation of the corresponding benzothiophene.40 The
condensation of methyl thioglycolate with 2-chloro-5-nitrobenz-
aldehyde (9) under basic conditions gave methyl 5-nitrobenzo[b]-
thiophene-2-carboxylate (10) in high yield (Scheme 2). We have
shown in previous work how microwave dielectric heating can
be used to dramatically reduce reaction times in the synthesis
of inhibitor scaﬀolds.30,32,33,37,52 Given that elevated tempera-
ture has promoted this,53,54 and a closely-related process for
the synthesis of 2-acetylbenzothiophenes,55 we carried out this
transformation under microwave irradiation at 90 °C to give
the benzothiophene 10 in good yield, whilst shortening the
reaction time from 17 h to 15 min. Selective halogenation at
C-3 of 10 was facilitated in a convoluted sequence of reactions
via the carboxylic acid 11 to overcome poor heterocycle reactiv-
ity.40 Saponification, again conducted by microwave dielectric
heating, under basic conditions was complete in 3 min at
100 °C and gave the carboxylic acid 11 in excellent yield. Sub-
sequent heating with excess bromine and sodium acetate in
glacial acetic acid did give 3-bromobenzothiophene 13 in good
yield after esterification using methyl iodide on a number of
occasions. However, the bromination was found to be highly
variable and eﬀorts to develop an alternative process using
microwave heating were constantly frustrated56 and so a more
reliable and eﬃcient route was sought. The poor yield of this
bromination reaction is catalogued in a recent report.57
In an alternative approach, our success in the microwave-
assisted synthesis of 10 was adapted to incorporate an amino
group at C-3, amenable by diazotization chemistry to provide
eﬃcient access to 3-bromobenzothiophene 13. The cyclocon-
densation of methyl thioglycolate with 2-nitrobenzonitriles
under basic conditions has been established by Beck,58–60 and
adapted methods with halide displacement have also been
reported.61–64 By switching the base from NaOMe61 to Et3N63
and heating either 5-bromo-2-fluorobenzonitrile (14a) or
2-fluoro-5-nitrobenzonitrile (14b) and methyl thioglycolate
gave the corresponding 3-aminobenzothiophene 5a,b in very
high yield (Scheme 3), e.g. for 5b either at 100 °C in DMSO for
2 h using conductive heating (95% yield) or under microwave
irradiation at 130 °C for 11 min (94% yield), after simply
pouring the reaction mixture into ice-water and collecting the
product by filtration. Subsequent deaminative bromination60
of aminobenzo[b]thiophene 5b using tert-butyl nitrite in aceto-
nitrile in the presence of copper(II) bromide gave the target
bromobenzothiophene 13 in excellent yield by this much more
direct route.
The scope of this method was further explored by investi-
gating a number of substrates (Scheme 4, Table 1), suitable for
Scheme 2 Reagents and conditions: (i) K2CO3, DMF, RT, 17 h; (ii)
K2CO3, DMF, microwaves, 90 °C, 15 min; (iii) NaOH, MeOH–H2O, reﬂux,
3 h; (iv) NaOH, MeOH–H2O, microwaves, 100 °C, 3 min; (v) Br2, AcOH,
NaOAc, 55 °C, 48 h; (vi) MeI, K2CO3, DMF, RT, 3 h.
Scheme 3 Reagents and conditions: (i) Et3N, DMSO, 100 °C, 2 h; H2O;
(ii) Et3N, DMSO, microwaves, 130 °C, 11 min; H2O; (iii) tert-BuONO,
CuBr2, MeCN, 0 °C; RT, 2 h; HCl (aq.).
Scheme 4 Synthesis of benzothiophenes 5a–h and 7-aza–16.
Paper Organic & Biomolecular Chemistry
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elaboration to a range of benzothiophene-containing scaﬀolds
found in drug discovery (Fig. 1).
It was found that the process was most eﬃcient for highly
electron-poor precursors, such as 14a–d (entries 1–4), and was
generally most eﬀective with 2-fluorides, but could also accom-
modate bromides and iodides albeit with reduced eﬃciency
(Table 1, entries 8 and 9). In most cases a very simple work up
procedure was eﬀective, providing benzothiophenes 5a–h in
65–96% yield in reaction times varying between 11 and
35 min, depending upon substrate. The eﬃciency compared
well to other available methods (cf. Table 1, entry 7, with Beck
synthesis of 5g,58 52% yield after 20 h), and so this method
was adopted as the route of choice to access the benzothio-
phene scaﬀold. Furthermore, it was possible to apply the pro-
cedure to the synthesis of 7-azabenzothiophene 16 using
2-halonicotinonitriles 15a–c. Interestingly, the choice of
halogen as substrate did not cause much variation in the yield
of azabenzothiophene product 16 (entries 11–13), which rep-
resents the core heterocyclic motif of the 3-aminothieno[2,3-b]-
pyridine-2-carboxamide inhibitors14 of LIMK1.
Having developed this rapid microwave-assisted method to
prepare benzothiophenes, the 5-nitro analogue 13 was further
elaborated to the benzo[4,5]thieno[3,2-e][1,4]diazepin-5(2H)-
one MK2 inhibitor scaﬀold 6b. Buchwald–Hartwig coupling of
(R)-tert-butyl (1-aminopropan-2-yl)carbamate (17) and bromo-
benzothiophene 13 gave a good yield of the N-arylated product
18 under microwave irradiation at 150 °C after 75 min
(Scheme 5). Subsequent Boc-deprotection using TFA and lacta-
mization by treatment with NaOMe using a modified pro-
cedure of Boschelli65 under conductive heating gave the MK2
inhibitor scaﬀold 6b, bearing suitable functionality for further
elaboration, in essentially quantitative yield.
Finally, an application of our microwave-assisted method to
access a pre-functionalized benzothiophene 5i for direct trans-
formation to a benzo[4,5]thieno[3,2-d]pyrimidin-4-one scaﬀold
21 as a chemical tool for PIM kinase inhibition15,66 was investi-
gated. This inhibitor exhibits subnanomolar to single-digit
nanomolar Ki values against all three PIM kinases and has
been co-crystallised with PIM1, guiding subsequent SAR
studies. It was postulated that rather than introducing the
cyclopropylvinyl group by a late-stage Suzuki coupling, in
accordance with the original diversification study, this group
could be incorporated from the start in order to access 20
directly. To that end, 2-fluorobenzonitrile 14i was prepared by
the Pd-catalyzed Suzuki–Miyaura coupling of 5-bromo-2-fluoro-
benzonitrile (14a) and the corresponding boronate ester at
80 °C,15 and heated with methyl thioglycolate in the presence
Table 1 Scope of the microwave-assisted synthesis of 3-amino ben-
zothiophenes 5a–h (Y = NH2) and the 7-aza analogue 16
Entry Substrate R X Z
Time/
mina Product
Yieldb
(%)
1 14a 5-Br F CH 11 5a 96
2 14b 5-NO2 F CH 11 5b 94
3 14c 5-Cl F CH 11 5c 92
4 14d 4-CF3 F CH 18 5d (R = 6-CF3) 80
5 14e 4-NO2 F CH 35 5e (R = 6-NO2) 67
6c 14f 5-Ph F CH 15 5f 85
7 14g H F CH 15 5g 65
8 14g H Br CH 15 5g 23
9 14g H I CH 15 5g 47
10 14h 5-CF3 F CH 20 5h 88
11 15a H F N 15 16 66
12 15b H Cl N 15 16 69
13 15c H Br N 15 16 51
aHold time at the given temperature, as measured by the in-built IR
sensor, by modulation of the initial microwave power. b Isolated yield
of product 5 or 16 after reaction according to Scheme 4, cooling in a
stream of compressed air and pouring the reaction mixture into iced
water. c Product was isolated by aqueous work up, followed by
purification by column chromatography on silica gel.
Scheme 5 Reagents and conditions: (i) Pd(OAc)2 (5 mol%), Cs2CO3,
(±)-BINAP (13 mol%), PhMe, microwaves, 150 °C, 75 min; (ii) TFA, CH2Cl2,
RT, 4.5 h; (iii) NaOMe, MeOH, 50 °C, 2 h; reﬂux, 2 h; HCl (aq.).
Scheme 6 Reagents and conditions: (i) trans-2-cyclopropyl-
vinylboronic acid pinacol ester, Pd(Ph3)2Cl2 (10 mol%), 1 M Na2CO3,
DME/EtOH/H2O, 80 °C, 16 h; (ii) Et3N, DMSO, microwaves, 130 °C,
35 min; (iii) 2-chloroacetonitrile, HCl, dioxane, RT, 16 h; (iv) Me2NH,
EtOH, RT, 16 h; SCX column, MeOH/CH2Cl2; NH3, MeOH.
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of Et3N in DMSO at 130 °C for 35 min under microwave
irradiation to give the corresponding benzothiophene 5i in
reasonable yield after purification by column chromatography
(Scheme 6). The cyclopropylvinyl group was found to be com-
patible with the subsequent chemistry: reaction of 5i with
chloroacetonitrile in 4 N HCl in dioxane gave chloromethyl
derivative 19 which, on reaction with dimethylamine, under-
went further cyclization to give the thienopyrimidinone scaﬀold
20 after purification by immobilization on an acidic resin. Thus
the method delivered this known PIM kinase inhibitor by an
extremely rapid route, suitable for biological study.
Experimental
Materials and methods
Commercially available reagents were used without further
purification; solvents were dried by standard procedures. Light
petroleum refers to the fraction with bp 40–60 °C and ether
refers to diethyl ether. Unless otherwise stated, reactions were
performed under an atmosphere of air. Flash chromato-
graphy was carried out using Merck Kieselgel 60 H silica or
Matrex silica 60. Analytical thin layer chromatography was
carried out using aluminium-backed plates coated with Merck
Kieselgel 60 GF254 that were visualised under UV light (at 254
and/or 360 nm). Microwave irradiation experiments were per-
formed in a sealed Pyrex tube using a self-tunable CEM Discover,
CEM Explorer or Biotage Initiator 2.5 EXP EU focused monomo-
dal microwave synthesizer at the given temperature using the
instrument’s in-built IR temperature measuring device, by
varying the irradiation power (initial power given in parentheses).
Fully characterized compounds were chromatographically
homogeneous. Melting points were determined on a Kofler
hot stage apparatus or Stanford Research Systems Optimelt
and are uncorrected. Specific rotations were measured at the
indicated temperature (in °C) using a ADP440 polarimeter (Bel-
lingham + Stanley) at the sodium D line and are given in deg
cm−3 g−1 dm−1 with concentration c in 10−2 g cm−3. Infra-red
spectra were recorded in the range 4000–600 cm−1 on a Perkin-
Elmer 1600 series FTIR spectrometer using an ATR probe or a
Shimadzu IRAﬃnity-1 equipped with an ATR accessory and are
reported in cm−1. NMR spectra were recorded using a Varian
VNMRS instrument operating at 400 or 500 MHz or a Bruker
Avance III 400 MHz or Bruker Avance DRX 500 MHz for 1H
spectra and 100 or 126 MHz for 13C spectra; J values were
recorded in Hz and multiplicities were expressed by the usual
conventions. Low resolution mass spectra were determined
using a Waters Q-TOF Ultima using electrospray positive
ionization, A Waters LCT premier XE using atmospheric
pressure chemical ionization (APcI), an Agilent 6130 single
quadrupole with an APcI/electrospray dual source, a Fisons
Instrument VG Autospec using electron ionization at 70 eV
(low resolution) or a ThermoQuest Finnigan LCQ DUO electro-
spray, unless otherwise stated. TOFMS refers to time-of-flight
mass spectrometry, ES refers to electrospray ionization, CI refers
to chemical ionization (ammonia), FTMS refers to Fourier trans-
form mass spectrometry, NSI refers to nano-electrospray ioniza-
tion and EI refers to electron ionization. A number of high
resolution mass spectra were obtained courtesy of the EPSRC
Mass Spectrometry Service at University College of Wales,
Swansea, UK using the ionization methods specified.
Synthetic procedures
General procedure for synthesis of 3-aminobenzo[b]thio-
phenes 5 from benzonitriles 14. A mixture of the benzonitrile
14 (1.0 equiv.), methyl thioglycolate (1.05 equiv.) and triethyl-
amine (3.1 equiv.) in dry DMSO (2 M) was irradiated in a
Biotage Initiator 2.5 EXP EU or CEM Discover microwave
synthesizer at 130 °C for the time specified (hold time) by
modulating the initial microwave power. After cooling to room
temperature in a stream of compressed air, the reaction
mixture was poured into ice-water and the resulting solid col-
lected, washed with water and dried in vacuo to give the
desired product.
Methyl 3-amino-5-bromobenzo[b]thiophene-2-carboxylate
(5a). 5-Bromo-2-fluorobenzonitrile (14a) (0.50 g, 2.50 mmol),
methyl thioglycolate (0.22 mL, 2.60 mmol) and triethylamine
(1.10 mL, 7.75 mmol) were reacted according to the above
general procedure for 11 min to give the title compound
(700 mg, 96%) as a brown solid, mp 170–171 °C (Found [ES+]:
285.9535. C10H979BrNO2S [MH] requires 285.9532); IR (neat)
νmax/cm−1 3477 (N–H), 3363 (N–H), 2954 (C–H), 1681 (CvO);
1H NMR (400 MHz, d6-DMSO) δH/ppm 8.44 (1H, d, J = 1.9 Hz,
4-CH), 7.82 (1H, d, J = 8.6 Hz, 7-CH), 7.64 (1H, dd, J = 8.6, 1.9
Hz, 6-CH), 7.17 (2H, bs, NH2), 3.79 (3H, s, Me); 13C NMR
(101 MHz, d6-DMSO) δC/ppm 164.6 (C), 148.6 (C), 137.7 (C),
133.2 (C), 131.0 (C), 125.7 (CH), 125.2 (CH), 117.1 (CH), 96.1
(C), 51.4 (Me); m/z (ES) 286 (M[79Br]H+, 100%).
Methyl 3-amino-5-nitrobenzo[b]thiophene-2-carboxylate
(5b). 2-Fluoro-5-nitrobenzonitrile (14b) (0.50 g, 3.0 mmol),
methyl thioglycolate (0.30 mL, 3.3 mmol) and triethylamine
(1.3 mL, 9.3 mmol) were reacted according to the above general
procedure for 11 min to give the title compound (0.71 g, 94%) as an
orange solid, mp 243.4–244.1 °C (acetone) (lit.,67 mp 244–246 °C)
(Found [FTMS]: 253.0280. C10H9N2O4S [MH] requires 253.0278); IR
(neat) νmax/cm−1 3445 (N–H), 3342 (N–H), 1681 (CvO), 1572
(NO2), 1432 (C–C), 1328 (NO2), 1276 (C–O), 1093 (C–O); 1H NMR
(500 MHz, d6-DMSO) δH/ppm 9.24 (1H, d, J = 2 Hz, 4-CH), 8.29
(1H, dd, J = 9, 2 Hz, 6-CH), 8.12 (1H, d, J = 9 Hz, 7-CH), 7.47 (2H,
bs, NH2), 3.82 (3H, s, Me); 13C NMR (100 MHz, d6-DMSO) δC/ppm
164.2 (C), 149.6 (C), 144.9 (C), 144.5 (C), 131.4 (C), 124.3 (CH),
122.0 (CH), 119.4 (CH), 96.8 (C), 51.4 (Me); m/z (EI) 252 (M•+,
100%), 219 (72). 1H and 13C NMR spectroscopic analyses were in
good agreement with literature data.67
Methyl 3-amino-5-chlorobenzo[b]thiophene-2-carboxylate
(5c). 5-Chloro-2-fluorobenzonitrile (14c) (0.50 g, 3.2 mmol),
methyl thioglycolate (0.30 mL, 3.36 mmol) and triethylamine
(1.38 mL, 9.92 mmol) were reacted according to the above
general procedure for 11 min to give the title compound
(710 mg, 92%) as a colourless solid, mp 170–172 °C (Found
[ES+]: 242.0039. C10H935ClNO2S [MH] requires 242.0037); IR
(neat) νmax/cm−1 3477 (N–H), 3365 (N–H), 1681 (CvO), 1278
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(C–O); 1H NMR (500 MHz, d6-DMSO) δH/ppm 8.30 (1H, d, J =
2.1 Hz, 4-CH), 7.88 (1H, d, J = 8.6 Hz, 7-CH), 7.53 (1H, dd, J =
8.6, 2.1 Hz, 6-CH), 7.17 (2H, bs, NH2), 3.79 (3H, s, Me); 13C NMR
(126 MHz, d6-DMSO) δC/ppm 164.6 (C), 148.7 (C), 137.3 (C),
132.7 (C), 129.1 (C), 128.4 (CH), 125.0 (CH), 122.7 (CH), 96.2 (C),
51.4 (Me); m/z (ES) 242 (M[35Cl]H+, 100%). 1H NMR spectro-
scopic analyses were in good agreement with literature data.15
Methyl 3-amino-6-(trifluoromethyl)benzo[b]thiophene-2-car-
boxylate (5d). 2-Fluoro-4-(trifluoromethyl)benzonitrile (14d)
(0.50 g, 2.64 mmol), methyl thioglycolate (0.24 mL,
2.73 mmol) and triethylamine (1.14 mL, 8.20 mmol) were
reacted according to the above general procedure for 20 min
to give the title compound (580 mg, 80%) as a colourless
solid, mp 159–161 °C (Found [ES+]: 298.0120. C11H8F3NNaO2S
[MNa] requires 298.0124); IR (neat) νmax/cm−1 3471 (N–H),
3344 (N–H), 2964 (C–H), 1664 (CvO); 1H NMR (400 MHz,
d6-DMSO) δH/ppm 8.38–8.32 (2H, 5-CH and 7-CH), 7.72 (1H, d,
J = 8.7 Hz, 4-CH), 7.26 (2H, bs, NH2), 3.82 (3H, s, Me); 13C NMR
(126 MHz, d6-DMSO) δC/ppm 164.5 (C), 148.8 (C), 138.9 (C),
134.1 (C), 128.4 (q, 2JC–F = 31.8 Hz, C), 124.2 (q, 1JC–F = 272.7 Hz,
C), 124.1 (CH), 121.0–120.7 (m, CH), 120.3–120.0 (m, CH), 97.4
(C), 51.5 (Me); m/z (ES) 276 (MH+, 100%).
Methyl 3-amino-6-nitrobenzo[b]thiophene-2-carboxylate (5e).
2-Fluoro-4-nitrobenzonitrile (14e) (0.50 g, 3.00 mmol), methyl
thioglycolate (0.28 mL, 3.15 mmol) and triethylamine
(1.29 mL, 9.30 mmol) were reacted according to the above
general procedure for 35 min to give the title compound
(510 mg, 67%) as a colourless solid, mp 228–231 °C (lit.,58 mp
229–231 °C) (Found [ES+]: 275.0101. C10H8N2NaO4S [MNa]
requires 275.0097); IR (neat) νmax/cm−1 3489 (N–H), 3367 (N–
H), 1697 (CvO), 1624 (C–O); 1H NMR (400 MHz, d6-DMSO) δH/
ppm 8.90 (1H, d, J = 2.1 Hz, 7-CH), 8.37 (1H, d, J = 8.7 Hz,
4-CH), 8.19 (1H, dd, J = 8.7, 2.1 Hz, 5-CH), 7.30 (2H, bs, NH2),
3.83 (3H, s, Me); 13C NMR (101 MHz, d6-DMSO) δC/ppm 164.3
(C), 148.4 (C), 147.0 (C), 138.8 (C), 135.6 (C), 124.2 (CH), 119.8
(CH), 118.5 (CH), 99.8 (C), 51.7 (Me); m/z (ES) 253 (MH+, 20%),
252 (M•+, 100). 1H NMR spectroscopic analyses were in good
agreement with literature data.63
Methyl 3-amino-5-phenylbenzo[b]thiophene-2-carboxylate
(5f). 4-Fluoro-[1,1′-biphenyl]-3-carbonitrile (14f ) (0.30 g,
1.52 mmol), methyl thioglycolate (0.14 mL, 1.59 mmol) and
triethylamine (0.65 mL, 4.74 mmol) were reacted according to
a modified general procedure for 15 min. After cooling in
a stream of compressed air, EtOAc (25 mL) was added and the
solution was washed sequentially with water (3 × 25 mL) and
brine (3 × 25 mL), dried over MgSO4 and evaporated in vacuo.
Purification by flash chromatography on silica gel, eluting
with light petroleum–EtOAc (4 : 1), gave the title compound
(380 mg, 85%) as a colourless solid, mp 96–97 °C (Found [ES+]:
284.0741. C16H14NO2S [MH] requires 284.0740); IR (neat) νmax/
cm−1 3439 (N–H), 3338 (N–H), 2949 (C–H), 1658 (CvO); 1H
NMR (400 MHz, d6-DMSO) δH/ppm 8.54 (1H, s, 4-CH), 7.91
(1H, d, J = 8.5 Hz, 7-CH), 7.84 (1H, d, J = 8.5 Hz, 6-CH), 7.78
(2H, d, J = 7.5 Hz, 2′,6′-PhH), 7.51 (2H, app t, J = 7.5 Hz, 3′,5′-
PhH), 7.39 (1H, t, J = 7.5 Hz, 4′-PhH), 7.26 (2H, bs, NH2), 3.80
(3H, s, Me); 13C NMR (101 MHz, d6-DMSO) δC/ppm 164.8 (C),
149.9 (C), 139.6 (C), 138.0 (C), 136.2 (C), 132.2 (C), 129.0 (CH),
127.5 (CH), 127.2 (CH), 126.7 (CH), 123.6 (CH), 121.0 (CH),
95.0 (C), 51.2 (Me); m/z (ES) 284 (MH+, 100%).
Methyl 3-aminobenzo[b]thiophene-2-carboxylate (5g).
2-Fluorobenzonitrile (14g) (0.16 mL, 1.5 mmol), methyl thio-
glycolate (0.135 mL, 1.5 mmol) and triethylamine (0.63 mL,
4.5 mmol) were reacted according to the above general pro-
cedure for 15 min to give the title compound (203 mg, 65%) as
a purple solid, mp 107.6–107.8 °C (MeOH–H2O) (lit.,58 mp
110–111 °C) (Found [ES+]: 208.0434. C10H10NO2S [MH] requires
208.0432); IR (neat) νmax/cm−1 3434 (N–H), 3337 (N–H), 1659
(CvO), 1520, 1289 (C–O); 1H NMR (500 MHz, d6-DMSO)
δH/ppm 8.13 (1H, d, J = 8.1 Hz, 4-CH), 7.82 (1H, d, J = 8.1 Hz,
7-CH), 7.50 (1H, m, 6-CH), 7.39 (1H, m, 5-CH), 7.15 (2H, bs,
NH2), 3.78 (3H, s, Me); 13C NMR (101 MHz, d6-DMSO) δC/ppm
164.8 (CvO), 149.8 (3-C), 138.8 (7α-C), 131.4 (3α-C), 128.5
(6-CH), 123.8 (5-CH), 123.1 (4-CH), 123.1 (7-CH), 94.4 (2-C),
51.2 (Me); m/z (ES) 207 (M•+, 93%), 176 (30), 175 (100),
147 (34), 146 (37). NMR spectroscopic analyses were in good
agreement with literature data.59,68
Methyl 3-amino-5-(trifluoromethyl)benzo[b]thiophene-2-car-
boxylate (5h). 2-Fluoro-5-(trifluoromethyl)benzonitrile (14h)
(0.50 g, 2.6 mmol), methyl thioglycolate (0.24 mL, 2.73 mmol)
and triethylamine (1.14 mL, 8.20 mmol) were reacted accord-
ing to the above general procedure for 20 min to give the
title compound (640 mg, 88%) as a colourless solid, mp
140–141 °C (Found [ES+]: 298.0121. C11H8F3NNaO2S [MNa]
requires 298.0120); IR (neat) νmax/cm−1 3468 (N–H), 3335
(N–H), 1664 (CvO); 1H NMR (400 MHz, d6-DMSO) δH/ppm
8.67 (1H, bs, 4-CH), 8.09 (1H, d, J = 8.5 Hz, 7-CH), 7.79 (1H,
dd, J = 8.5, 1.5 Hz, 6-CH), 7.34 (2H, s, NH2), 3.82 (3H, s, Me);
13C NMR (101 MHz, d6-DMSO) δC/ppm 164.5 (C), 149.3 (C),
142.5 (C), 131.3 (C), 124.9 (q, 2JC–F = 32.7 Hz, C), 124.5 (q, 1JC–F
= 272.1 Hz, C), 124.4 (C–H), 124.1 (m, C–H), 120.7 (m, C–H),
96.2 (C), 51.4 (Me); m/z (ES) 276 (MH+, 100%).
Methyl (E)-3-amino-5-(2-cyclopropylvinyl)benzo[b]thiophene-
2-carboxylate (5i). (E)-5-(2-Cyclopropylvinyl)-2-fluorobenzoni-
trile (14i) (0.25 g, 1.33 mmol), methyl thioglycolate (0.12 mL,
1.39 mmol) and triethylamine (0.57 mL, 4.12 mmol) were
reacted according to a modified general procedure for
35 min. After cooling in a stream of compressed air, EtOAc
(25 mL) was added and the solution was washed sequentially
with water (3 × 25 mL) and brine (3 × 25 mL), dried over
MgSO4 and evaporated in vacuo. Purification by flash chrom-
atography on silica gel, eluting with light petroleum–EtOAc
(4 : 1), gave the title compound (210 mg, 58%) as a colourless
solid, mp 131–132 °C (Found [ES+]: 274.0899. C15H16NO2S [M]
requires 274.0896); IR (neat) νmax/cm−1 3481 (N–H), 3365 (N–
H), 1672 (CvO); 1H NMR (400 MHz, d6-DMSO) δH/ppm 8.12
(1H, d, J = 1.6 Hz, 4-CH), 7.71 (1H, d, J = 8.5 Hz, 7-CH), 7.50
(1H, dd, J = 8.5, 1.6 Hz, 6-CH), 7.12 (2H, bs, NH2), 6.53 (1H, d,
J = 15.8 Hz, CH), 5.93 (1H, dd, J = 15.8, 9.1 Hz, CH), 3.78
(3H, s, Me), 1.69–1.55 (1H, m, CH), 0.86–0.80 (2H, m,
CHH), 0.56–0.49 (2H, m, CHH); 13C NMR (101 MHz, d6-
DMSO) δC/ppm 164.8 (C), 149.7 (C), 136.9 (C), 135.2 (C), 133.7
(CH), 131.9 (C), 126.4 (CH), 126.4 (CH), 123.1 (CH), 119.4 (CH),
Organic & Biomolecular Chemistry Paper
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94.9 (C), 51.2 (Me), 14.4 (CH), 7.1 (CH2); m/z (ES) 274 (MH+,
100%).
(3R)-3-Methyl-9-nitro-1,2,3,4-tetrahydro-5H-[1]benzothieno-
[3,2-e][1,4]diazepin-5-one (6b). A solution of (R)-methyl 3-
((2-((tert-butoxycarbonyl)amino)propyl)amino)-5-nitrobenzo[b]-
thiophene-2-carboxylate (18) (0.30 g, 0.73 mmol) in TFA (10%
v/v in CH2Cl2) (5.7 mL, 7.3 mmol) was stirred at room tempera-
ture for 4.5 h. When salt formation was confirmed by TLC ana-
lysis [Rf 0.3 in MeOH–CH2Cl2 (1 : 9)] the mixture was
evaporated in vacuo. The residue was dissolved in a mixture of
MeOH (5 mL) and NaOMe (25 wt% in MeOH; 1 mL, 4.4 mmol)
and warmed to 50 °C for 2 h before heating at reflux for 2 h.
The reaction mixture was then allowed to cool to room tem-
perature, cooled in an ice bath, neutralized by the addition of
hydrochloric acid (1 M) and stirred at 0 °C for 30 min. The
resulting solid was isolated by filtration under reduced
pressure, washed with water and dried in air to give the title
compound (0.18 g, 100%) as a red powder, mp 337.4–342.4 °C
(dec.) (Found [ES+]: 278.0590. C12H1sN3O3S [MH] requires
278.0594); [α]24D +110.6 (c 0.04, MeOH); IR (neat) νmax/cm−1
3307 (N–H), 1598 (CvO), 1501 (NO2), 1438 (C–C), 1318 (NO2),
1102 (C–N), 736 (N–H); 1H NMR (500 MHz, d6-DMSO) δH/ppm
9.03 (1H, d, J = 2 Hz, 10-CH), 8.22 (1H, dd, J = 9, 2 Hz, 8-CH),
8.05 (1H, d, J = 9 Hz, 7-CH), 8.02 (1H, m, 1-NH), 7.95 (1H, d, J =
3 Hz, 4-NH), 3.60 (1H, m, 3-CH), 3.39 (2H, m, 2-CH2), 1.16 (3H,
d, J = 7 Hz, Me); 13C NMR (125 MHz, d6-DMSO) δC/ppm 164.2
(5-C), 145.3 (C), 144.2 (C), 141.8 (C), 132.9 (C), 123.8 (7-CH),
120.8 (8-CH), 118.6 (10-CH), 108.6 (C), 50.6 (2-CH2), 47.6 (3-CH),
18.6 (Me); m/z (ES) 277 (M•+, 87%), 262 (24), 234 (29), 206 (30).
Methyl 5-nitrobenzo[b]thiophene-2-carboxylate (10), pre-
pared under ambient conditions. Methyl thioglycolate
(0.48 mL, 5.4 mmol) and K2CO3 (0.89 g, 6.5 mmol) were added
sequentially to a solution of 2-chloro-5-nitrobenzaldehyde
(1.01 g, 5.4 mmol) in DMF (6.5 mL) and the mixture was
stirred at room temperature for 17 h. The reaction was then
quenched in ice-water and the resulting solid collected,
washed with water and dried in vacuo to give the title compound
(1.22 g, 95%) as an oﬀ-white solid, mp 213.3–217.6 °C (lit.,69
mp 213–215 °C) (Found [FTMS + p NSI]: 255.0435.
C10H11N2O4S [MNH4] requires 255.0434); IR (neat) νmax/cm−1
3093 (C–H), 1701 (CvO), 1528 (NO2), 1439 (C–C), 1342 (NO2),
1302 (C–O); 1H NMR (500 MHz, CDCl3) δH/ppm 8.80 (1H, d, J =
2 Hz, 4-CH), 8.32 (1H, dd, J = 9, 2 Hz, 6-CH), 8.20 (1H, s,
3-CH), 8.01 (1H, d, J = 9 Hz, 7-CH), 4.00 (3H, s, Me); 13C NMR
(125 MHz, CDCl3) δC/ppm 162.2 (C), 147.4 (C), 145.9 (C), 138.3
(C), 137.2 (C), 130.7 (3-CH), 123.6 (7-CH), 121.2 (9-CH), 120.9
(7-CH), 52.9 (Me); m/z (EI) 237 (M•+, 100%), 206 (63), 160 (25).
1H NMR spectroscopic analyses were in good agreement with
literature data.53,70
Methyl 5-nitrobenzo[b]thiophene-2-carboxylate (10), using
microwave-assisted conditions. A mixture of 2-chloro-5-nitro-
benzaldehyde (0.75 g, 4.0 mmol), methyl thioglycolate (0.45 mL,
5 mmol) and K2CO3 (0.67 g, 4.8 mmol) in DMF (4.5 mL) was
irradiated at 90 °C for 15 min (hold time) in a pressure-rated
glass tube (35 mL) using a CEM Discover microwave synthesizer
by moderating the initial power (100 W). After cooling in a flow
of compressed air, the reaction mixture was poured into water
and the resulting solid filtered under reduced pressure, washed
with water and dried in air to give the title compound (0.84 g,
88%) as an oﬀ-white solid, mp 216.8–218.5 °C (lit.,69 mp
213–215 °C), with identical spectroscopic properties.
5-Nitrobenzo[b]thiophene-2-carboxylic acid (11), using con-
ductive heating. A solution of aqueous NaOH (1 M; 5 mL,
5 mmol) was added to a solution of methyl 5-nitrobenzo[b]-
thiophene-2-carboxylate (10) (0.40 g, 1.7 mmol) in MeOH
(5.5 mL) and the mixture was heated at reflux for 3 h. After
cooling to room temperature, the solution was acidified with
1 M HCl (aq.) and the resulting solid filtered under reduced
pressure and dried in air to give the title compound (0.36 g,
95%) as an oﬀ-white powder, mp 241.4–242.7 °C (lit.,71 mp
239–241 °C) (Found [TOFMS]: 224.0020. C9H6NO4S [MH]
requires 224.0018); IR (neat) νmax/cm−1 2844 (br, O–H), 1670
(CvO), 1600 (C–C), 1511 (NO2), 1344 (NO2), 1313 (C–O); 1H
NMR (500 MHz, CD3OD) δH/ppm 8.87 (1H, d, J = 2 Hz, 4-CH),
8.30 (1H, dd, J = 9, 2 Hz, 6-CH), 8.24 (1H, s, 3-CH), 8.15 (1H, d,
J = 9 Hz, 7-CH); 13C NMR (125 MHz, CD3OD) δC/ppm 164.8 (C),
148.9 (5-C), 147.5 (C), 140.3 (C), 140.0 (C), 132.0 (3-CH), 125.1
(7-CH), 122.3 (4-CH), 121.9 (6-CH); m/z (EI) 223 (M•+, 100%),
195 (38), 149 (37). 1H NMR spectroscopic analyses were in
good agreement with literature data.53
5-Nitrobenzo[b]thiophene-2-carboxylic acid (11), using
microwave-assisted heating. A mixture of methyl 5-nitrobenzo-
[b]thiophene-2-carboxylate (10) (0.20 g, 0.84 mmol), aqueous
NaOH solution (1 M; 2.5 mL) and MeOH (3.5 mL) was irra-
diated at 100 °C for 3 min (hold time) in a pressure-rated glass
tube (10 mL) using a CEM Discover microwave synthesizer by
moderating the initial power (100 W). After cooling in a flow of
compressed air, the reaction mixture was diluted with water,
acidified with 1 M HCl and the resulting solid was filtered
under reduced pressure, washed with water and dried in air to
give the title compound (0.16 g, 94%) as an oﬀ-white powder,
mp 241.3–242.1 °C (lit.,71 mp 239–241 °C), with identical spec-
troscopic properties.
3-Bromo-5-nitrobenzo[b]thiophene-2-carboxylic acid (12).
According to a modified literature procedure,57 bromine
(1.4 mL, 27 mmol) was added portion-wise to a solution of
5-nitrobenzo[b]thiophene-2-carboxylic acid (11) (1.0 g,
4.5 mmol) and anhydrous sodium acetate (1.13 g, 13 mmol) in
glacial acetic acid (28 mL) under N2. A reflux condenser was
fitted and the solution heated at 55 °C for 27 h. After cooling
to room temperature, the solution was poured into ice-water
and the resulting solid isolated by vacuum filtration and dried
in air to give the title compound (1.02 g, 75%) as a yellow
powder, mp 309.5–316.8 °C (lit.,40 mp 307–309 °C) (Found
[TOF MS]: 301.9126. C9H579BrNO4S [MH] requires 301.9123);
IR (neat) νmax/cm−1 2961 (br, O–H), 1701 (CvO), 1600 (C–C),
1511 (NO2), 1347 (NO2), 1270 (C–O), 620 (C–Br); 1H NMR
(500 MHz, CD3OD) δH/ppm 8.83 (1H, d, J = 2 Hz, 4-CH), 8.39
(1H, dd, J = 9, 2 Hz, 6-CH), 8.21 (1H, d, J = 9 Hz, 7-CH); m/z (EI)
303 (M[81Br]•+, 98%), 301 (M[79Br]•+, 96), 293 (17), 291 (13).
Methyl 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylate
(13), from acid 12. According to a modified literature pro-
Paper Organic & Biomolecular Chemistry
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cedure,57 iodomethane (0.46 mL, 7.4 mmol) was added to a
solution of 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylic
acid (12) (1.12 g, 3.7 mmol) and K2CO3 (1.28 g, 9.2 mmol) in
DMF (15 mL). After stirring at room temperature for 3 h, the
reaction mixture was quenched with saturated aqueous NH4Cl
solution, poured into excess water and filtered under reduced
pressure. The collected solid was washed with water and dried
in air to give the title compound (1.09 g, 93%) as an oﬀ-white
powder, mp 211.5–212.5 °C (lit.,40 mp 211–212 °C) (Found
[TOF MS]: 315.9279. C10H779BrNO4S [MH] requires 315.9279);
IR (neat) νmax/cm−1 3101 (C–H), 1691 (CvO), 1600 (C–C), 1514
(NO2), 1347 (NO2), 1089 (C–O), 1052 (C–O), 617 (C–Br); 1H
NMR (500 MHz, CDCl3) δH/ppm 8.90 (1H, d, J = 2 Hz, 4-CH),
8.38 (1H, dd, J = 9, 2 Hz, 6-CH), 8.00 (1H, d, J = 9 Hz, 7-CH),
4.02 (3H, s, Me); 13C NMR (125 MHz, CDCl3) δc/ppm 161.0 (C),
146.5 (5-C), 144.6 (C), 138.9 (C), 131.0 (3α-C), 123.8 (7-CH),
122.2 (6-CH), 121.3 (4-CH), 115.6 (3-CH), 53.0 (Me); m/z (EI)
317 (M[81Br]•+, 100%), 315 (M[79Br]•+, 94), 286 (58), 284 (55).
Methyl 3-bromo-5-nitrobenzo[b]thiophene-2-carboxylate
(13), from 3-aminobenzothiophene 5b. Following the pro-
cedure of Iaroshenko et al.,60 CuBr2 (0.94 g, 4.2 mmol) was
added to a solution of tert-butyl nitrite (0.45 mL, 3.8 mmol) in
dry MeCN (11 mL) at 0 °C under argon. Methyl 3-amino-4-
nitrobenzo[b]thiophene-2-carboxylate (5b) (0.69 g, 2.7 mmol)
was then added portion-wise and the solution kept at 0 °C
until nitrogen evolution ceased. The reaction mixture was
allowed to warm to room temperature, stirred for 2 h and then
poured into dilute hydrochloric acid (10%; 25 mL). The
aqueous mixture was extracted with EtOAc (3 × 30 mL) and the
organic extracts were combined, dried (Na2SO4) and evapor-
ated in vacuo to give the title compound (0.86 g, 99%) as an
orange solid, mp 212.3–213.0 °C (acetone) (lit.,40 mp 211–212 °C),
with identical spectroscopic and spectrometric properties.
(E)-5-(2-Cyclopropylvinyl)-2-fluorobenzonitrile (14i). To a
solution containing 5-bromo-2-fluorobenzonitrile (14a) (3.0 g,
15.0 mmol), Pd(PPh3)2Cl2 (1.0 g, 1.5 mmol) and trans-2-cyclo-
propylvinylboronic acid pinacol ester (3.7 mL, 18 mmol) in
DME/EtOH/H2O (7 : 2 : 3) (50 mL) was added aqueous Na2CO3
solution (1 M; 27 mL). The resulting mixture was placed under
an atmosphere of nitrogen and heated at 80 °C for 16 h after
which time the reaction was cooled to room temperature and
filtered through Celite. Purification by flash column chromato-
graphy on silica gel, eluting with light petroleum–EtOAc (9 : 1),
gave the title compound (2.4 g, 86%) as a yellow oil (Found [ES+]:
188.0868. C12H11NF [MH] requires 188.0870); IR (neat) νmax/cm−1
3007 (C–H), 2496 (CN), 1672 (CvC); 1H NMR (400 MHz, CDCl3)
δH/ppm 7.53–7.46 (2H, m), 7.16–7.08 (1H, m), 6.39 (1H, d, J =
15.7 Hz), 5.71 (1H, dd, J = 15.7, 9.0 Hz), 1.65–1.53 (1H, m),
0.92–0.84 (2H, m), 0.59–0.52 (2H, m); 13C NMR (101 MHz,
CDCl3) δC/ppm 161.7 (d, J = 258.2 Hz), 137.9, 135.3 (d, J = 3.5 Hz),
131.8 (d, J = 7.9 Hz), 130.0, 124.2, 116.5 (d, J = 20.3 Hz), 101.5 (d,
J = 15.7 Hz), 77.2, 14.7, 7.6; m/z (ES) 188 (MH+, 100%).
Methyl 3-aminothieno[2,3-b]pyridine-2-carboxylate (16).
2-Chloro-3-pyridinecarbonitrile (15b) (35 mg, 0.25 mmol),
methyl thioglycolate (0.22 mL, 0.25 mmol) and triethylamine
(0.10 mL, 0.72 mmol) were reacted according to the above
general procedure for 15 min to give the title compound
(36 mg, 69%) as a yellow solid, mp 191 °C (dec.) (lit.,13 mp
194–196 °C) (Found [ES+]: 209.0380. C9H9N2O2S [MH] requires
209.0385); IR (neat) νmax/cm−1 3417 (N–H), 3314, 3202, 2943,
1679 (CvO), 1291 (C–O), 1127 (C–O); 1H NMR (500 MHz, d6-
DMSO) δH/ppm 8.68 (1H, dd, J = 4.6, 1.6 Hz, 6-CH), 8.54 (1H,
dd, J = 8.1, 1.6 Hz, 4-CH), 7.46 (1H, dd, J = 8.1, 4.6 Hz, 5-CH),
7.30 (2H, bs, NH2), 3.80 (3H, s, Me); 13C NMR (101 MHz,
d6-DMSO) δC/ppm 164.7 (CvO), 159.7 (7α-C), 150.7 (6-CH),
147.7 (3-C), 131.4 (4-CH), 125.5 (3α-C), 119.4 (5-CH), 93.2 (2-C),
51.4 (Me); m/z (EI) 208 (M•+, 100%), 177 (28), 176 (93), 148 (60).
1H NMR spectroscopic analyses were in good agreement with
literature data.13
tert-Butyl [(2R)-1-aminopropan-2-yl]carbamate (17). Accord-
ing to a modified literature procedure,72 a solution of Boc-D-
Ala-OH (0.50 g, 2.64 mmol) and HOBt·H2O (0.41 g, 3.0 mmol)
in CH2Cl2 (20 mL) was cooled to 0 °C and EDCI·HCl (0.58 g,
3.0 mmol) was added. The solution was allowed to warm to
room temperature and stirred for 30 min. The solution was
then cooled to 0 °C, aqueous NH3 (18.1 M; 0.6 mL) was added
drop-wise and the mixture was stirred at room temperature for
30 min. Any solid residue was removed by filtration and the fil-
trate was washed sequentially with water (20 mL) and brine
(2 × 20 mL), dried (MgSO4) and evaporated in vacuo. Purifi-
cation by flash column chromatography on SiO2, gradient
eluting with MeOH–CH2Cl2 (from 3–7% MeOH), gave Boc-D-
Ala-NH2 (0.37 g, 75%) as colourless crystals, mp
127.5–128.2 °C (lit.,73 mp 120–121 °C). According to a modi-
fied literature procedure,74 BH3·SMe2 (2 M in THF; 13.5 mL,
27 mmol) was added portion-wise to a solution Boc-D-Ala-NH2
(0.5 g, 2.7 mmol) in dry THF (9 mL) under N2 at 0 °C. The reac-
tion mixture was allowed to warm to room temperature, stirred
for 18 h, evaporated in vacuo and treated with MeOH (3 ×
15 mL), stirring and evaporating in vacuo each time. Purifi-
cation by ion exchange chromatography using an Isolute SPE
SCX-2 flash column, eluting first with MeOH and then with a
solution of NH3 in MeOH (2 M), gave the title compound
(0.39 g, 84%) as a colourless oil [Rf 0.3 in MeOH–CH2Cl2 (1 : 9)]
(Found [ES+]: 175.1443. C8H19N2O2 [MH] requires 175.1441);
[α]24D −5.7 (c 1.1, MeOH); IR (neat) νmax/cm−1 2973 (C–H), 1685
(CvO), 1521 (N–H), 1364 (CH3 deformation), 1247 (C–O), 1165
(C–N), 1045 (C–O), 872 (N–H); 1H NMR (500 MHz, CDCl3) δH/
ppm 4.78 (1H, m, NHBoc), 3.60 (1H, m, 2-CH), 2.70 (1H, m, 1-
CHH), 2.59 (1H, m, 1-CHH), 1.40 (9H, s, CMe3), 1.08 (3H, d, J =
7 Hz, 3-Me); 13C NMR (125 MHz, CDCl3) δC/ppm 155.7 (C),
79.1 (C), 48.6 (2-CH), 47.4 (4-CH2), 28.4 (CMe3), 18.5 (Me).
1H NMR spectroscopic analyses were in good agreement with
literature data.75
(R)-Methyl 3-((2-((tert-butoxycarbonyl)amino)propyl)amino)-
5-nitrobenzo[b]thiophene-2-carboxylate (18). According to a
modified literature procedure,76 (R)-tert-butyl (1-aminopropan-
2-yl)carbamate (17) (35 mg, 0.20 mmol) was added to a stirred
mixture of methyl 3-bromo-5-nitrobenzo[b]thiophene-2-carboxy-
late (13) (50 mg, 0.16 mmol), Cs2CO3 (73 mg, 0.22 mmol),
(±)-BINAP (13 mg, 0.02 mmol) and Pd(OAc)2 (2.0 mg, 8.0 μmol)
in dry toluene (1.0 mL) under N2 and the mixture was irra-
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diated at 150 °C for 75 min (hold time) in a pressure-rated
glass tube (10 mL) using a CEM Discover microwave synthesi-
zer by moderating the initial power (200 W). After cooling in a
flow of compressed air, the reaction mixture was partitioned
between water (20 mL) and EtOAc (30 mL). The aqueous layer
was further extracted with EtOAc (2 × 30 mL) and the organic
extracts were combined, washed with brine (30 mL), dried
(Na2SO4) and evaporated. Purification by flash column chrom-
atography on SiO2 (dry load), gradient eluting with light pet-
roleum to Et2O–light petroleum (1 : 1), gave the title compound
(50 mg, 76%) as a red solid, mp 182.9–184.0 °C (Found [ES+]:
410.1378. C18H24N3O6S [MH] requires 410.1380); [α]24D +55.3 (c
0.1, MeOH); IR (neat) νmax/cm−1 3355 (N–H), 2954 (C–H), 1672
(CvO), 1588 (NO2) 1508 (C–C), 1325 (NO2), 1230 (C–O), 1060
(C–N); 1H NMR (500 MHz, d6-DMSO) δH/ppm 8.94 (1H, m, 4-
CH), 8.27 (1H, d, J = 9 Hz, 6-CH), 8.15 (1H, d, J = 9 Hz, 7-CH),
7.54 (1H, m, 3-NH), 6.87 (1H, d, J = 6 Hz, 2′-NH), 3.81 (4H, m,
1′-CHH and OMe), 3.76 (1H, m, 2′-CH), 3.57 (1H, m, 1′-CHH),
1.32 (9H, s, CMe3), 1.12 (1H, d, J = 6 Hz, 3′-Me); 13C NMR
(125 MHz, d6-DMSO) δC/ppm 164.0 (C), 155.1 (C), 150.3 (3-C),
145.2 (C), 144.3 (C), 131.1 (3α-C), 124.7 (7-CH), 121.6 (6-CH),
120.5 (4-CH), 99.5 (2-C), 77.6 (CMe3), 51.7 (OMe), 50.5 (1′-CH2),
46.2 (2′-CH), 28.1 (CMe3), 18.3 (3′-Me); m/z (EI) 410 (MH+,
100%), 409 (M•+, 70).
Methyl 3-((1-amino-2-chloroethylidene)amino)-5-((E)-2-cyclo-
propylvinyl)benzo[b]thiophene-2-carboxylate hydrochloride (19).
Methyl (E)-3-amino-5-(2-cyclopropylvinyl)benzo[b]thiophene-
2-carboxylate (5i) (200 mg, 0.73 mmol) was suspended in a
solution of HCl in 1,4-dioxane (4 M; 3 mL) and chloro-
acetonitrile (91 μL, 1.43 mmol) was added drop-wise. The
reaction mixture was stirred at room temperature for 16 h
and the suspension was filtered under reduced pressure,
washed with light petroleum (60 mL) and dried in vacuo for
6 h to give the title compound (110 mg, 39%) as a colourless
solid, mp 195–197 °C (dec.) (Found [ES+]: 317.0512.
C16H1435ClN2OS [MH − MeOH] requires 317.0515); IR (neat)
νmax/cm−1 3332 (br, N–H), 3001 (C–H), 2675 (C–H), 1676
(CvO), 1620 (CvC); 1H NMR (400 MHz, CD3OD) δH/ppm 7.91
(1H, d, J = 8.6 Hz, 7-CH), 7.72 (1H, d, J = 1.5 Hz, 4-CH), 7.67
(1H, dd, J = 8.6, 1.5 Hz, 6-CH), 6.60 (1H, d, J = 15.8 Hz, CH),
5.96 (1H, dd, J = 15.8, 9.1 Hz, CH), 4.73 (2H, s, CH2), 3.94 (3H,
s, Me), 1.65–1.55 (1H, m, CH), 0.87–0.79 (2H, m, CHH),
0.59–0.48 (2H, m, CHH); 13C NMR (101 MHz, CD3OD) δC/ppm
166.3 (C), 162.4 (C), 138.9 (C), 138.3 (CH), 138.0 (C), 135.8 (C),
130.5 (C), 130.4 (C), 127.7 (CH), 127.3 (CH), 124.6 (CH), 119.6
(CH), 53.4 (Me), 40.1 (CH), 15.5 (CH), 7.8 (CH2, CH2); m/z (ES)
349 (M[35Cl]H+, 100%).
(E)-8-(2-Cyclopropylvinyl)-2-((dimethylamino)methyl)benzo-
[4,5]thieno[3,2-d]pyrimidin-4(3H)-one (20). Compound 19
(70 mg, 0.18 mmol) was added to a solution of dimethylamine
in ethanol (33%; 3 mL) and the reaction mixture was stirred at
room temperature for 16 h. The solvent was evaporated
in vacuo and the resulting colourless solid was dissolved in
MeOH–CH2Cl2 (1 : 1; 5 mL) and loaded onto an SCX cartridge
(1 g). The cartridge was flushed with MeOH (3 × 5 mL) and
then eluted with a solution of NH3 in MeOH (2 M; 8 mL) to
give the title compound as a colourless solid (55 mg, 94%), mp
202–203 °C (dec.) (Found [ES+]: 326.1324 C18H20N3OS [MH]
requires 326.1322); IR (neat) νmax/cm−1 2873 (br, C–H), 1672
(CvO), 1587 (CvC); 1H NMR (400 MHz, d6-DMSO) δH/ppm
12.41 (1H, bs, NH), 8.09 (1H, d, J = 1.5 Hz, 4-CH), 8.03 (1H, d,
J = 8.5 Hz, 7-CH), 7.69 (1H, dd, J = 8.5, 1.5 Hz, 6-CH), 6.68 (1H,
d, J = 15.8 Hz, CH), 6.01 (1H, dd, J = 15.8, 9.2 Hz, CH), 3.52
(2H, s, CH2), 2.29 (6H, s, Me), 1.66–1.56 (1H, m, CH), 0.85–0.78
(2H, m, CHH), 0.61–0.54 (2H, m, CHH); 13C NMR (101 MHz,
d6-DMSO) δC/ppm 158.5 (C), 157.2 (C), 152.7 (C), 138.3 (C),
136.2 (CH), 135.2 (CH), 134.6 (C), 126.5 (C), 126.2 (CH), 123.9
(CH), 122.0 (C), 119.7 (CH), 61.3 (CH2), 45.1 (Me, Me), 14.7
(CH), 7.2 (CH2, CH2); m/z (ES) 326 (MH+, 100%). 1H NMR spec-
troscopic analyses were in good agreement with literature data
for the corresponding HCl salt.15
Conclusions
This method for the microwave-assisted synthesis of 3-amino-
benzo[b]thiophenes is rapid, simple to carry out and generally
high yielding. It has been applied in the synthesis of a range
of functional benzothiophenes and their 7-aza analogues and
constitutes a very eﬃcient route to the corresponding 3-halo-
benzothiophenes using diazonium chemistry. Applications of
this process have been shown in the synthesis of the thieno-
[2,3-b]pyridine core motif of LIMK1 inhibitors using 2-halopyr-
idine-3-carbonitriles, the benzo[4,5]thieno[3,2-e][1,4]diazepin-
5(2H)-one scaﬀold of MK2 inhibitors with functionality suit-
able for subsequent modification using Buchwald–Hartwig
chemistry, and a benzo[4,5]thieno[3,2-d]pyrimidin-4-one target
as a chemical tool for inhibition of PIM kinases. In the case of
inhibitors of MK2, the use of this approach has been shown to
be superior to traditional bromination chemistry using the
parent benzothiophene heterocycle. Given the speed, eﬃciency
and reliability of these methods, and their ability to incorpor-
ate a wide range of functionality, these approaches are likely to
find application in providing chemical tools, rapidly, reliably
and eﬃciently, for advancing studies in chemical biology, as
well as to access targets in medicinal chemistry.
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